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vAbstract
Lactoferrin (Lf) is an iron binding protein produced in mammals. It
has antimicrobial and immunomodulatory properties.  Some bacteria that
regularly colonize mammalian hosts have adapted to living in high Lf
environments.  Helicobacter pylori, which inhabits the human gut, was
chosen as a model organism to investigate how bacteria may adapt to Lf.
H. pylori was able to use iron from fully saturated human Lf (hLf)
in various low iron media, achieving growth levels similar to the iron-
replete control. Partially saturated hLf decreased growth, yet both partially
saturated bovine Lf (bLf) and hLf were able to increase internalization of
bacteria into mammalian tissue culture cells.  A substantially larger
increase in internalization was seen when bacteria were supplemented with
hLf in low iron conditions, possibly mediated by iron-regulated cellular
receptors or bacterial lactoferrin binding proteins.
In eukaryotes, Lf is known to bind and facilitate internalization of
DNA into cells and sometimes the nucleus, and upregulate gene
expression. Here, one hundred bacterial genomes were surveyed for known
Lf binding sites as an indication that Lf had similar functions using
bacterial DNA.  While the frequency and location of Lf binding sites
suggest they occur at random, their presence in all genomes suggests that
Lf may be able to act as a vector for bacterial DNA, and facilitate the
movement of genes between species.
Lf is being widely considered for commercial and therapeutic uses,
with significant interest in producing it in genetically modified organisms
(GMO). Widespread production and use of Lf could increase the number
of bacteria that are adapted to it.  How Lf interacts with bacteria adapted to
it, and the ability of it to act as a DNA vector, may have relevance for
GMO risk assessment.
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Chapter 1
Introduction
Lactoferrin (Lf) is a multifunctional iron-binding protein produced
by mammals and found in glandular secretions such as milk, on mucosal
surfaces, and in neutrophils (Ling and Schryvers 2006).  In eukaryotic
cells, Lf is proposed to regulate aspects of the cell cycle, assist in iron-
uptake in the intestine, modulate the immune response to infection, and, in
some cases, directly activate gene expression as a transcription factor in the
nucleus (He and Furmanski 1995).  However, Lf also comes into contact
with pathogenic and commensal bacteria on mucosal surfaces and at sites
of infection, where it can interact with these bacteria in a number of ways.
It can inhibit bacterial growth by sequestering free iron in the extracellular
environment (Ward et al. 2005).  Lactoferrin can also exhibit protease
activity against bacterial virulence factors, abrogate invasion in a number
of species and increase bacterial membrane permeability (which can be
bactericidal) (Valenti and Antonini 2005).
Thus, with Lf’s many effects on bacteria and the immune system,
there is significant interest in using it as a therapeutic agent.  Biopharming
(engineering plants and animals to produce pharmaceuticals) has been
considered as a potential source of mass-produced, cost-effective Lf.
However, the use of genetically engineered organisms to produce Lf in
large quantities within the natural environment would expose a different
range of bacteria to Lf and the molecules to which it binds.  Therefore our
ability to assess the risks of undertakings such as biopharming first relies
on a solid understanding of Lf’s interactions with prokaryotes.
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1.1 The Ability of Lactoferrin to Affect Microbial
Growth
1.1.1 The Structure and Iron Binding Properties of Lactoferrin
Lactoferrin was first isolated from milk, and named for both its
source (lacto) and its ability to bind iron (ferrin).  It is constitutively
expressed at the highest levels in colostrum and milk, with lower levels
expressed in tears, nasal fluids, saliva, and secretions from pancreatic,
gastrointestinal, and reproductive tissues (Masson et al. 1966).  Lactoferrin
is also expressed in developing neutrophils and stored in secondary
granules at a concentration of 3 g per 106 cells (Masson et al. 1969).
Transcription of Lf is regulated by different environmental cues in
differing tissues.  These cues include growth factors, developmental cues,
retinoic acid, and, in the reproductive organs, estrogen (Teng 2006).
Lf is an 80 kDa glycoprotein, comprised of a single polypeptide
chain that folds into homologous N and C terminal lobes (Metz-Boutigue
et al.1984).  It is highly conserved across mammals, with an amino acid
sequence that puts it in the larger family of iron-binding proteins, which
includes transferrin (Tf) that is found in serum (Metze-Boutigue et al.
1984, Baker and Baker 2005). Lactoferrin is polycationic, with a
particularly cationic region in its N-terminal lobe that is responsible for its
ability to bind numerous substrates, including DNA, bacterial
lipopolysaccharide (LPS), and heparin (Valenti and Antonini 2005).
This highly cationic region, which is one of the features that
distinguish Lf from other members of the iron-binding protein family, can
be released through pepsin hydrolysis.  This results in the formation of an
Lf-derived peptide termed lactoferricin (Lfcin) that retains many of the
activities of the intact protein and in some cases displays an increased
potency (Bellamy et al. 1992, Gifford et al. 2005).  In solution, Lfcin
adopts a structure different from its conformation on the intact protein.  Its
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amphipathic structure is similar to that of other peptides that display
antimicrobial activity (Ward et al. 2005) and may account for the
considerable antimicrobial properties that Lfcin displays against Gram-
negative and Gram-positive bacteria, yeast, fungi, viruses, and protozoa
(Bellamy et al. 1992, Ward et al. 2005).   .
The two homologous lobes of Lf have conserved iron-binding sites
that can reversibly bind ferric iron at a very high affinity (K ~ 1022 M)
(Mazurier and Spik 1980, Baker and Baker 2005).  The binding of iron is
accompanied by a conformational change in the Lf protein to a more
closed structure, with the two domains of each lobe enclosing an iron ion
and effectively sequestering it away from the external environment (Baker
and Baker 2005).  Lactoferrin is capable of retaining bound iron in acidic
conditions as low as pH 3-4.  In contrast, transferrin releases iron at about
pH 5-6 (Mazurier and Spik 1980).
1.1.2 Inhibition of Bacterial Growth by Lactoferrin
Lactoferrin has a number of antimicrobial properties, well
documented both in vitro and in vivo, many of which are related to its
ability to bind iron (Singh et al. 2002, Ward et al. 2005).  Iron is an
essential element for almost all living organisms, acting as a cofactor for
the activity of numerous enzymes, and as a catalyst in electron transport.
One of the difficulties many organisms face in acquiring iron is that the
soluble form of iron, ferrous iron (Fe(II)), becomes oxidized to the
extremely insoluble ferric iron (Fe(III)) in the presence of oxygen.  Ferric
iron has a solubility of just 10-17 M at physiological pH, whereas bacteria
generally require iron at around 10-7 to 10-5 M to achieve maximal growth
(Andrews et al. 2003).
The situation can be particularly dire for bacteria that colonize
mammalian hosts, where most remaining free iron in serum and on
mucosal surfaces is chelated by the host iron-binding proteins Tf and Lf,
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respectively (Masson et al. 1966), making iron in the body a particularly
precious resource for bacteria (Raymond et al. 2003, Miethke and
Marahiel 2007).  Indeed, bacteriostasis (inhibition of bacterial growth) was
the first antimicrobial property described for Lf (Ward et al. 2005).  This is
because Lf exists primarily in the apo, non-iron bound state in the body
and is able to readily chelate any free iron on mucosal surfaces. This
property of Lf may also be part of the normal host resistance to biofilm
formation, which can require high concentrations of iron (Reid et al. 2008).
Iron sequestering by Lf on mucosal surfaces can inhibit formation of
Pseudomonas aeruginosa biofilms, even in concentrations too low to
affect growth rates (Singh et al. 2002).
However, not all of Lf’s anti-microbial activity is due to binding
iron.  Lactoferrin displays bactericidal activity that is irreversible with the
addition of iron, and thus distinct from its iron-sequestering, bacteriostatic
properties (Arnold et al. 1982).  The mechanism appears to be similar for
both Gram-positive and Gram-negative bacteria, and involves the
disruption of bacterial membranes.  In Gram-negative bacteria, the N-
terminal lobe of intact Lf is capable of inducing the release of
lipopolysaccharides (LPS) from the outer membrane.  This is done either
directly, through binding the lipid A part of LPS, or indirectly, by chelating
extracellular Ca2+ (Ellison et al. 1988, Appelmelk et al. 1994, Valenti and
Antonini 2005).  The release of LPS increases the permeability of the
membrane, and the susceptibility of the bacteria to osmotic shock,
lysozyme, and antibacterial molecules (Ellison et al.1988, Ward et al.
2005).
In Gram-positive bacteria, Lf probably acts by binding the lipid
matrix of the cell surface via electrostatic interactions. The non-polar
membrane interior becomes perturbed, leading to a similar increase in
membrane permeability (Valenti and Antonini 2005).  As the N-terminal
region of Lf appears to be central for its effect on bacterial membranes, it is
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not surprising that the N-terminal peptide Lfcin has a similar, if greatly
amplified, effect (Valenti and Antonini 2005).  In fact, along with
increasing membrane permeability, Lfcin may be able to actually cross
both the outer lipid layer and the cytoplasmic membrane of bacteria,
possibly then acting on intracellular targets (Gifford et al. 2005).
1.1.3 Bacterial use of Lactoferrin as an Iron Source
To survive in the low-iron host environment, pathogens engage a
wide array of methods for acquiring iron.  Among these, some bacteria can
scavenge iron from host proteins such as Tf, heme, and Lf.  A number of
bacteria reportedly use Lf as an iron source and human Lf-specific,
membrane-bound, Lf binding proteins (LBPs) have been reported in
Neisseria meningitidis, N. gonorrhoeae, Bordetella pertusis, Treponema
spp., Mycobacterium pneumonia, Moraxella bovis, M. catarrhalis, and
possibly one for bovine Lf (bLf) in Streptomyces uberis (Prinz et al. 1999,
Ling and Schryvers 2006).
LBPs from the Neisseriaceae family are the best characterized to
date, consisting of 2 distinct proteins, LbpA and LbpB.  These proteins are
expressed from an iron-repressible operon, such that LBPs are upregulated
when iron is scarce (Ling and Schryvers 2006).  Indeed, the binding of hLf
to cell surfaces increased 350-fold when the bacteria were grown in low
iron conditions (Schryvers and Morris 1988).  The Neisseriaceae LBPs are
specific to hLf, binding neither bovine Lf (bLf) nor the structurally related
human Tf (hTf), and bind regardless of the iron-saturation of the Lf
(Schryvers and Morris 1988, Prinz et al. 1999).
LbpA is homologous to TonB-dependent outer-membrane proteins,
with a C-terminal -barrel filled with an N-terminal plug domain (Prinz et
al. 1999, Ling and Schryvers 2006).  Most TonB systems are involved in
the uptake of macromolecules, particularly iron-siderophore complexes
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and vitamin B12 (Koebnik et al. 2005). In Moraxella and Neisseria sp., the
LbpA is shown to bind two regions within the C-terminus of hLf (Wong
and Schryvers 2003).  The exact role of the second LBP, LbpB, has yet to
be determined.   N. meningitidis LbpB-isogenic mutants are still able to
obtain iron from Lf (Bonnah and Schryvers 1998, Ling and Schryvers
2006). A possible model for LBPs and Lf interaction involves Lf binding
to LbpA and LbpB, causing a conformational change in Lf that results in
the release of iron and subsequent transport of the iron across the outer
membrane (Ling and Schryvers 2006).
1.2 The Ability of Lactoferrin to Affect Bacterial
Internalization
1.2.1 Known Affects of Lactoferrin on Bacterial Internalization
Lactoferrin is known to affect the ability of some facultative
intracellular bacteria to invade host cells.  Most often, Lf reduces the
frequency of internalization via mechanisms that include impeding
bacterial adherence to epithelial cells and degradation of bacterial protein
factors necessary for invasion (Valenti and Antonini 2005), although the
exact outcome differs by species and form of Lf used (Table 1.1, 1.2). The
majority of research to date has focused on the affect of bLf and the N-
terminal peptide Lfcin using tissue culture, but there is also evidence of Lf
inhibiting bacterial invasion in vivo (Ajello et al. 2002).
However, the effect of Lf is not always so clear.  For example,
invasion of the Caco-2 intestinal cell line by Listeria monocytogenes is
reportedly reduced in the presence of bLf, but no such reduction is found
with Listeria in THP-1 macrophages (Valenti et al. 1999, Longhi et al.
2004).  In contrast, bLfcin but not bLf limits internalization of Yersinia
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spp. and E. coli HB101 expressing the Yersinia InvA protein for
invasion, as well as L. monocytogenes (Di Biase et al. 2004, Longhi et al.
2004, Superti et al. 2005).
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Table 1.1: Effect of lactoferrin on internalization of facultative
intracellular organisms
EffectLf Type Amount
Tested
(mg/ml)
Bacterial Species Cell Type
-Lf +Lf
Source
Shigella flexneri
BS176,
Shigella flexneri
48 %
inhibition
1
Shigella
dysenteriae
48 %
inhibition
1
Human
Lactoferrin
0.33
Shigella sonnei
HeLa cells
64 %
inhibition
1
Willer
et al.
2004
Yersinia
enterocolitica
HEp-2 cells 87 %2 89 %2
Y.
psuedotuberculosis
HEp-2 cells 62 %2 60 %2
2
E. coli HB101
(with invA)
HEp-2 cells 40 %2 38 %2
Superti
et al.
2005
2 E. coli HB101
(with invA)
HeLa S3 34 %2 3.2 %2 Longhi
et al.
1993
1 Group A
Streptococci
HeLa S3 0.5 %2 (apo-Lf)
0.012 %2
(holo-Lf)
0.013 %2
2 Group A
Streptococci
HeLa S3 0.5 %2 0.002 %2
Ajello
et al.
2002
1 Listeria
monocytogenes
Caco-2
intestinal
cells
3.5 %2 0.3 %2 Valenti
et al.
1999
Bovine
Lactoferrin
0.13 Listeria
monocytogenes
THP-1
macrophages
4.4 %2 4.0 %2 Longhi
et al.
2004
0.5 Yersinia
enterocolitica
HEp-2 cells 79 %2 7 %2
0.5 Yersinia
psuedotuberculosis
HEp-2 cells 75 %2 6 %2
0.5 E. coli HB101
(with invA)
HEp-2 cells 73 %2 8 %2
Di
Biase
et al.
2004
Bovine
Lactoferricin
0.13 Listeria
monocytogenes
THP-1
macrophages
4.4 %2 0.7 %2 Longhi
et al.
2004
(1) Compared to internalization frequency in the non-Lf controls.
(2) Proportion of initial inoculum (as percent) recovered during gentamycin protection
assay, presumed to be intracellular.
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Table 1.2: Effect of lactoferrin on adhesion of facultative
intracellular microorganisms
EffectLf Type Amount
Tested
(mg/ml)
Bacterial Species Cell Type
-LF +LF
Source
Shigella flexneri
BS176, Shigella
flexneri
HeLa cells 56 %
inhibition1
Shigella
dysentereae
HeLa cells 71 %
inhibition1
Human
Lactoferrin
0.33
Shigella sonnei HeLa cells 51 %
inhibition1
Willer
et al.
2004
Yersinia
enterocolitica
HEp-2 3.3 % 3.0 %2
Y.
psuedotuberculosis
HEp-2 5.0 % 5.1 %2
2
E. coli HB101
(with invA)
HEp-2 3.8 % 3.7 %2
Superti
et al.
2005
2 E. coli HB101
(with invA)
HeLa S3 12 %2 1.3 %2 Longhi
et al.
1993
Bovine
Lactoferrin
0.13 Listeria
monocytogenes
THP-1
macrophages
no effect Longhi
et al.
2004
Yersinia
enterocolitica
HEp-2 cells (37˚C)3
2.9 %2
(28˚C)3
1.6 %2
(37˚C)3
28 %2
(28˚C)3
1.6 %2
0.5
Yersinia
psuedotuberculosis
(37˚C)3
5.1 %2
(28˚C)3
2.4 %2
(37˚C)3
42 %2
(28˚C)3
3 %2
Di
Biase
et al.
 2004
Bovine
Lactoferricin
0.13 Listeria
monocytogenes
THP-1
macrophages
1.6 %2 2.1 %2 Longhi
et al.
2004
(1) Compared to adhesion frequency in the non-Lf controls.
(2) Proportion of inoculum (as percent) recovered from cells during an adhesion assay.
(3) Infection was carried out at both 37˚C, when expression of invasion-mediating
proteins is low, and 28˚C when expression of invasion proteins is high.
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1.2.2 Mechanism of Lactoferrin-mediated Effects on Bacterial
Internalization
Many of these effects are seen at sub-inhibitory concentrations of
Lf, so that a decrease in internalization is not attributed to a decrease in
bacterial viability.  Lf is thought to affect bacterial internalization through a
number of different means that include binding to and blocking important
adhesion and invasion sites, degradation of proteins necessary for bacterial
adhesion and invasion and/or as an anti-microbial protein, by reducing
overall bacterial survival.
Lactoferrin has been shown to affect the adhesion of
microorganisms to both abiotic and cellular surfaces (Valenti and Antonini
2005).  Human Lf isolated from milk inhibited adhesion of three Shigella
species (S. flexneri, S. dysenteriae, and S. sonnei) to HeLa cells by 56-71
%, with a corresponding 50 % drop in invasion frequency (Willer et al.
2004).  Human Lf, hLfcin, bLf, and bLfcin bind Gram-negative and Gram-
positive bacterial surfaces, as well as elements of the host cell surfaces
such as glycosaminoglycans (GAGs) (Valenti and Antonini 2005),
potentially covering or masking bacterial receptors that act as binding sites
for facultative intracellular species and thereby reducing both the ability of
the bacteria to adhere and to invade (Isberg and Barnes 2001, Valenti et al.
2005).
This is illustrated by studies that show bovine Lfcin decreased
internalization of L. monocytogenes in TH1-macrophages, partially
attributed to competition between bLfcin and the listerial ActA surface
protein for cellular binding sites (Longhi et al. 2004).  Lactoferrin seems to
have a specific effect on InvA-mediated invasion, probably due to
subverting the interactions between InvA, GAGs, and eukaryotic cell
surface integrins necessary for InvA-mediated invasion.  Bovine Lfcin also
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reduces invasion in both Yersinia spp. and E. coli HB101 transfected
with the InvA gene (Longhi et al. 1993, Di Biase et al. 2004).
Lactoferrin can also directly degrade some proteins necessary for
pathogen infection via proteolysis.  Lactoferrin has been shown to degrade
or inactivate proteins that are required for host colonization by E. coli, S.
flexneri, and Haemophilus influenzae (Hendrixson et al. 2003, Ward et al.
2005).  With H. influenzae, this activity was blocked by serine protease
inhibitors, and subsequent studies have characterized a possible serine
protease catalytic domain in the N-terminal region of Lf.  The region is
capable of cleaving arginine-rich sequences in H. influenzae IgA1 protease
and Hap adhesins, surface proteins involved in avoiding host immune
response and attachment to cellular surfaces (Hendrixson et al. 2003).
This region is highly conserved across species, but high variability in the
level of protease activity in Lf makes it difficult to judge the relative
importance of proteolysis in Lf’s antimicrobial properties (Valenti and
Antonini 2005).  Lactoferrin reduces binding of Acintobacillus
actinomycetemcomitans to epithelial cells, probably by cleaving surface
Aae proteins, homologous to the E. coli Hap protein (Rose et al. 2003).
Studies of recombinant hLf (rhLf) and Shigella flexneri found a
reduction in internalization, but rhLf did not affect the adhesion or growth
of S. flexneri within the time limits of the experiment (Gomez et al. 2003).
While not affecting the host cell binding, the rhLf triggers the release and
degradation of IpaB and IpaC, proteins essential for inducing bacterial
uptake in epithelial cells.  Likewise, bLf seems to activate the secretion of
IpaB and IpaC from EIEC (Santapaola et al. 2004), even when bLf is
separated from the bacteria with a dialysis membrane.  Both Shigella spp.
and enteroinvasive E. coli (EIEC) secrete virulence factors via type III
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secretion systems and the low iron conditions induced by Lf may serve as a
signal to modulate the secretion of virulence proteins.
Lactoferrin’s effect on bacterial internalization seems to be
independent of its iron-binding functions, with little to no difference in the
effect of iron-saturated holo-Lf and iron-deficient apo-Lf when tested
(Valenti et al. 1999, Ajello et al. 2002).  Instead, sugar residues are
implicated in Lf’s effect on invasion efficiency.  The ability of hLf to
inhibit adhesion and invasion in Shigella spp. into HeLa cells is eliminated
when fucosylated residues on the Lf are modified by treatment with
sodium metaperiodate (Willer et al. 2004), a hypothesis supported by the
observation that rhLf does not have the same effect on adhesion of S.
flexneri to HeLa cells as hLf (Gomez et al. 2003, Willer et al. 2004).
1.2.3 Binding of Lactoferrin to Cell Surfaces
In some instances, the effect of Lf on invasive bacteria seems to be
mediated by its ability to bind the eukaryotic cell surfaces.  The binding of
Lf to outer-membrane receptors can have a potent effect on the cellular
immune response, altering the cell’s reaction to infection by invasive
bacteria and thus affecting the outcome of invasion. Lactoferrin is
immunostimulatory, changing expression of a number of important
cytokines in the presence of bacterial virulence factors (Prgomet et al.
2006), and has been shown to modulate apoptosis in epithelial cells during
infection with invasive species (Tsai et al. 1999, Valenti et al. 1999,
Superti et al. 2005). Furthermore, Lf’s ability to bind a wide range of
surface components allows it to mask binding sites necessary for
intracellular bacteria to invade.
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Specific receptors for hLf are widely distributed throughout
different tissues in the body, with individual cell types expressing specific
lactoferrin receptors (LfRs) with varying characteristics (Suzuki and
Lönnerdal, 2002).  The best characterized LfR was first identified in the
small intestine, and is known as the SI-LFR.  High levels of SI-LFR
mRNA expression are found in adult tissues, in the salivary gland, heart
tissue, skeletal muscle, the testes, the adrenal gland and the pancreas
(Suzuki et al. 2005).  Protein assays for LfRs in mice, based on the mouse
SI-LFR homologue, show expression in the digestive tract, nervous
system, stomach, reproductive system, and other tissues (Suzuki and
Lönnerdal 2004).  Among these tissue types Lf receptors appear to vary
structurally and functionally.  Some are believed to be related to iron
uptake, particularly in infants, while others may regulate inflammatory
response and cell maturation (Mikogami et al. 1995, Legrand 1997, Suzuki
et al. 2005).
While many tissues have specific LfRs, the majority of Lf that
binds cell-surfaces is believed to be interacting with negatively charged
proteoglycans and nucleolin, probably through Lf’s highly cationic region
(Legrand et al. 1997).  Lactoferrin can bind non-specifically to a number of
receptors on cell surfaces, including receptors for low-density lipoproteins,
lymphocytes, asialoglycoproteins as well as proteoglycans (Dhennin et al.
2000).  Proteoglycan binding may facilitate the interaction between Lf and
LfRs; similar to the role they play with fibroblast growth factor and its
receptor (Suzuki et al. 2005).  Though some nucleolin exists on cell
surfaces as receptors, the majority is found in the nucleus and mediates cell
proliferation, cell growth, cytokinesis, embryogenesis, and nucleogenesis
(Legrand et al. 2004).  Nucleolin may also play a role in Lf internalization,
as it can act as an intermediary in extracellular regulation of nuclear events,
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possibly even as a shuttle between the cell surface and nucleus (Legrand et
al. 2004).
The events following Lf binding to cell surfaces have not been
fully established, and seem to vary by cell type and function. In some
cases, Lf has also been reported to affect cell physiology via signal
transduction by simply binding surface receptors (Dhennin-Duthille et al.
2000).  Internalization of hLf has been shown in a number of cell lines
with immunofluorescence microscopy and appears to be nucleolin and
proteoglycan dependent (Legrand et al. 2004).  Lactoferrin internalization
may also be clathrin-mediated, with hLf-containing vesicles found to
contain markers associated with clathrin-dependent endocytosis (Legrand
et al. 2004, Lopez et al. 2008).  When internalization does occur, it appears
to do so from the apical membrane, with fluorescent-labeled Lf
internalized only from the apical side of Caco-2 cells, not the basolateral
side (Ashida et al. 2004, Mulligan et al. 2006).
1.3 The Ability of Lactoferrin to Interact with DNA
1.3.1 Nuclear Localization of Lactoferrin and DNA Binding
Once Lf binds epithelial cells, it can be translocated into the
cytoplasm.  Moreover a proportion of the internalized Lf also enters the
nucleus (Briggs et al. 1981, Fleet 1995, Penco et al. 2001, Haverson et al.
2002, Ashida et al. 2004, Legrand et al. 2004, Mariller et al. 2007, Lopez
et al. 2008).  Nuclear accumulation is rapid and directed by a nuclear
localization signal (NLS), believed to be a short stretch of arginine residues
in the N-terminus (Gly-Arg-Arg-Arg-Arg (GRRRR)) with similarity to the
NLS of ribosomal proteins and nuclear signals in a number of viruses
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(Penco et al. 2001).  This same region is essential for hLf interactions
with heparin, LPS, lysozyme, and DNA (van Berkel et al. 1997).
Lactoferrin binds to single stranded and double stranded DNA,
preferentially binding three major DNA consensus sequences known as
lactoferrin response elements (LFRE) (Fleet 1995).  These include LFRE1
(GGCACTT (G/A) C), LFRE2 (TAGA (A/G) GATCAA), and LFRE3
(ACTACAGTCTACA) (He and Furmanski 1995).   Studies have shown
that each of the three main LFREs is able stimulate transcription (Fleet
1995, He and Furmanski 1995, Son et al. 2002, Mariller et al. 2007).
Single base pair changes greatly reduce the amount of transcription
activation, and no activation is found when LFRE1 is scrambled to provide
a sequence of the same length and base composition, suggesting that the
interaction is specific (He and Furmanski 1995). Other LFREs have since
been identified, and most are similar to one these three.
Lactoferrin appears to have two binding sites that can interact with
DNA, both specifically and non-specifically.  On the N-terminus, the
amino acids Gly-Arg-Arg-Arg-Arg (GRRRRR) have been implicated, with
binding efficiency of Lf to DNA reduced by 66 % with removal of the first
three amino acids and by approximately 95 % with removal of all five N-
terminal amino acids (van Berkel et al. 1997).  The second binding site,
probably on the C-terminal lobe of Lf, has a much lower affinity to DNA,
binding LFREs with 1250-fold reduced affinity than the N-terminal region
(Kanyshkova, et al. 1999).  Computer modeling has suggested that the
groove between the C-terminal and N-terminal lobes could also interact
with DNA (Mariller et al. 2007).  DNA binding seems to occur slightly
more with apo-Lf than holo-Lf, though some studies have found the iron-
saturation of Lf to be unimportant (He and Furmanski 1995, van Berkel et
al. 1997, Kanyshkova et al. 1999).
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1.3.2 The Effect of Lactoferrin on Eukaryotic Gene Expression
As suggested by nuclear localization and DNA binding ability, Lf
has been shown to act on the expression of a number of genes, particularly
genes involved in host immune response and cell division.  However, it is
unclear if the effect of Lf is due to direct action on specific gene promoters
or occurring through some intermediary signaling.  Lactoferrin treatment
increases the tyrosine phosphorylation of numerous intracellular
polypeptides involved in signal transduction in cultured cells, suggesting
an intermediary role in modulating gene expression (Dhennin-Duthille et
al. 2000) but, despite many studies, there is still no general consensus on
how Lf affects gene expression.
A broad range of research has been done with Lf and the
expression of cytokines, signaling molecules involved in
immunomodulation. Lf is capable of binding unmethylated CpG
dinucleotides found in bacterial genomes and bacterial LPS, both potent
stimulators of host immune response that acts as a signal of bacterial
infection. The addition of Lf to CpG or LPS stimulated cells has been
shown to affect expression of both pro-inflammatory and anti-
inflammatory cytokines in different experimental approaches (Britigain et
al. 2001, Haverson et al. 2002, Son et al. 2002, Mulligan et al. 2006,
Prgomet et al. 2006). Lf can also affect expression of genes involved in
cell division and differentiation. Treatment with Lf arrested breast cancer
cells at the G1 and S transition in the cell cycle by changing the expression
and activity of a number of cell cycle progression regulators (Damiens et
al. 1998).
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Lf has been shown to affect expression of the KDR/Flk-1
receptor, which binds extracellular mitogens that induce angiogenesis
(Kim et al. 2006). As with most of the changes in protein expression
associated with Lf, it is unknown of the KDR/Flk-1 upregulation is due to
direct gene activation by Lf or is via other regulatory paths, such as MAP
kinase. In lymphocytes, Lf treatment induces a rapid and transient increase
in the activity of the mitogen activated protein (MAP) kinase, a key
regulatory enzyme involved in the differentiation and proliferation process
(Dhennin-Duthille et al. 2000).  Similarly, much of the affect of Lf on
cytokine expression in CpG and LPS stimulated cells is probably due to its
binding of extracellular CpG-ODN and LPS and thus interfere with how
they interact with cell receptors.
There are, however, two cases of Lf directly activating
transcription of genes. Five putative LFREs were identified in the 5’
flanking region of the gene for the human cytokine IL-1, occurring
between –3203 and –1043 of the gene (Son et al. 2002).  All are identical
or similar to the LFRE1 identified by He and Furmanski. Gel mobility shift
assays confirm that Lf binds to all five sites, although the combination of
sites sufficient for activation is unknown (Son et al. 2002). IL-1 affects the
expression of other proteins, and Lf’s effect on IL-1 is probably
responsible for some of the changes in expression seen in other proteins,
particularly granulocyte macrophage colony-stimulating factor and
possibly tracheal antimicrobial peptide (Penco et al. 1995, Velliyagounder
et al. 2003).
 In the second case, upregulation of a cytoplasmic isoform of Lf,
delta lactoferrin (Lf), has been shown to lead to cell cycle arrest in the S
phase (Mariller et al. 2007). Micro-array analysis shows that increased
levels of Lf doubles transcription of the gene Skp1, a protein involved in
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the regulation of protein degradation critical for normal G1- and S-phase
progression in the cell cycle (Mariller et al. 2007).
Two sequences similar to LFRE1 and LFRE2 were found within
the Skp1 promoter.  When placed before a luciferase gene construct, both
were able to drive expression in the presence of Lf (Mariller et al. 2007).
As the two sequences appear to act synergistically, there is some evidence
that Lf may bind both sequences as part of the same complex, perhaps with
both the N-terminal and C-terminal DNA binding domains (Mariller et al.
2007).  While normally cytoplasmic, Lf was shown to localize to the
nucleus, further supporting its role in skp1 transcription (Mariller et al.
2007).  While exogenous Lf can be endocytized and brought into the
human nucleus, it is possible that cyoplasmic forms of Lf are more likely
to directly activate genes, with external Lf liable to induce activation via
secondary messengers.
1.3.3 The Ability of Lactoferrin to act as a DNA Vector
Lactoferrin’s ability to bind DNA and be internalized into the
nucleus of cells makes it a potential DNA vector and it has already been
studied as prospective agent for gene therapy and drug delivery.
Lactoferrin has been used as a nuclear localizing agent for
polyethylenimine (PEI).  This agent is capable of binding and compacting
plasmid DNA and protecting it from nuclease degradation (Elfinger et al.
2007) however the use of PEI for DNA delivery is limited because of
macrophage clearance before it enters epithelial cells.  Fluorescence
labeled Lf was able to bind to a PEI-luciferase construct and bring it into
human bronchial cell lines (Elfinger et al. 2007). Expression of the
luciferase gene suggests it was translocated to the nucleus.
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Lactoferrin is also able to direct the internalization of stabilized
plasmid lipid particles (SPLPs), designed for in vivo delivery of plasmid
DNA, although failure to detect subsequent gene expression in an animal
model suggests further work needs to be done with Lf as a targeting agent
(Bartsch et al. 2005).  Another area of investigation is focusing on the use
of Lf as a nuclear localization factor for peptide-nucleic acids (PNA),
which have a peptide backbone but contain base pairs and can mimic DNA
sequences, giving them the potential to act as transcription factor decoys,
reducing transcription of homologous DNA sequences by attracting
transcription factors that would otherwise drive gene expression (Gambari
2004).  The N-terminal fragment of Lf containing the nuclear localization
signal is sufficient to deliver PNA to the nucleus (Penco 2001, Gambari
2004).
Some interesting work has been done that shows intact Lf directly
binding DNA and delivering it in vivo.  Lf was bound to two different
plasmids, and the plasmid-bound Lf was injected into the muscles of mice,
which were then monitored for gene expression (Sinogeeva et al. 2000).
Gene products from both plasmids were detected at the site of injection,
and one carrying the human dystrophin gene was found in the muscles of
other limbs, suggesting that the Lf had been able to broadly deliver the
human dystrophin gene (Sinogeeva et al. 2000).
20                                                     Chapter   1
The Use of Helicobacter pylori as a Model Organism to
Investigate Interactions between Lactoferrin and
Bacteria
We began with the hypothesis that bacteria that regularly colonize
host surfaces with large quantities of Lf would need to adapt to Lf’s
antimicrobial properties. Those that adapt might even exploit Lf
(Heinemann 2008).  This is interesting as it applies both to the microbial
ecology of the human body, and to issues of biosafety, with the potential
mass production of human Lf outside of the human body.  Helicobacter
pylori was chosen as a model organism because it lives in a high-Lf
environment and some research suggests it is able to use Lf as an iron-
source (Husson et al. 1995, Dhaenens et al. 1997, Velayudhan et al. 2000)
H. pylori is a spiral shaped, Gram-negative bacterium. Infection
with H. pylori leads to chronic gastritis in the host, and in some cases can
lead to the development of peptic ulcers and gastric cancer (Blaser 1998,
Huang et al. 1998, Rothenbacher and Hermann 2003).  This species has
colonized the human stomach for tens of thousands of years, and is highly
adapted to its environment (Falush et al. 2003, Blaser and Atherton 2004,
Kusters 2006). These adaptions include production of a stomach acid
neutralizing enzyme (urease), flagella to move through the mucous layer of
the stomach, and the virulence factors cytoxin associated gene A (CagA)
and vacuolating cytotoxin A (VacA) (Blaser and Atherton 2004, Bourzac
and Guilleman 2005, Kusters 2006). Production of CagA in particular is
associated with an increased risk of developing ulcers and gastric cancer
disease, and is used to distinguish between more pathogenic Type I strains
(cagA+) and Type II strains (cagA-) (Blaser and Atherton 2004, Kusters
2006).
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Some research has suggested that H. pylori has also evolved to
utilize hLf (Husson et al. 1993, Dhaenens et al. 1997), which is abundant
on the mucosal surface of the stomach.  There is a lack of confirmatory
studies on if and how H. pylori uses hLf as an iron-source, and how hLf
may be affecting other aspects of H. pylori’s biology.
1.4 The Ability of H. pylori to use Lactoferrin as an
Iron Source
1.4.1 Non-Lactoferrin Sources of Iron for H. pylori
H. pylori is thought to encounter immense variation in the source
and concentration of bioavailable iron.   The mucous layer of the stomach
epithelium is an Lf- rich environment, which can lead to iron scarcity
(Ling and Schryvers 2006).  Yet there is the potential for significant
influxes of iron released from food by peptic degradation, or acquired
directly from gastric epithelial cells as a result of the H. pylori-mediated
inflammatory response (van Vliet et al. 2002).  To further complicate the
situation, the exploitability of the iron itself depends on its oxidative state,
which is affected by changing pH in the stomach (vanVliet et al. 2002).
H. pylori has 13 genes encoding putative elements of iron-transport
and iron storage systems (Berg et al. 1997, Tomb et al. 1997, Alm et al.
1999).  Many of these genes are regulated by the ferric uptake regulator
Fur, a transcriptional repressor that generally acts to down regulate iron-
uptake systems when iron is abundant.  While Fur is best known for its role
in controlling iron uptake in bacteria, in H. pylori Fur also regulates
intracellular iron storage, modulates urease expression in response to
nickel and may play a role in the ability of H. pylori to survive the acidic
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environment of the stomach (Delany et al. 2001, Bijlsma et al. 2002, van
Vliet et al. 2002).
H. pylori also has homologues to membrane-bound, iron-transport
proteins that in other bacteria allow the uptake of free iron in the
environment. H. pylori can take up the more extracellularly rare Fe(II) via
Feo, a cytoplasmic-membrane-bound, iron permease found in many
bacteria (Velayudhan et al. 2000).  This system may be particularly
important in conditions of low-oxygen such as is found in the stomach,
where one would expect a higher ratio of Fe(II) to Fe(III) (Andrews et al.
2003).  Additionally, the genome of H. pylori encodes 3 homologues to the
FecA protein, which is a Fe(III)-dicitrate transporter although their role in
iron-uptake remains unclear (Berg et al. 1997, Velayudhan et al. 2000).
H. pylori may increase its ability to extract iron from the
environment by excreting iron-binding proteins, such as siderophores, or
obtaining iron directly off of host proteins, such as heme and Lf.
Siderophores are a group of highly divergent, high-affinity iron chelators
that are produced and excreted from organisms with the purpose of binding
extracellular Fe(III) in the environment that can then be brought back into
the cell (Meithke and  Maraheil 2007).  Most studies have reported no
siderophore production in H. pylori, and indeed in none of the gastric
Helicobacter species (Husson et al. 1993, Illingworth et al. 1993,
Dhaenens et al. 1999). The one report of H. pylori siderophore production
may instead be attributable to the extracellular ferric reductase activity
associated with the synthesis and excretion of riboflavin (Worst et al.
1998, vanVliet et al. 2002).
Many pathogenic bacteria have evolved the means to acquire iron
from heme, the most abundant source of iron in the body.  Heme and
hemoglobin must be released from red blood cells before extracellular
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pathogens have access to it, usually through the use of haemolysins and
proteases (Andrew et al. 2003).  H.  pylori has been reported to use heme
as an iron source in iron-limited media and when other iron-uptake systems
have been knocked out (Husson et al. 1993, Velayudhan et al. 2000) via
three high affinity, outer membrane heme binding proteins (Worst et al.
1995).
1.4.2 Human Lactoferrin as an Iron Source for H. pylori
The data on H. pylori’s use of lactoferrin as an iron source is
mixed.  Evidence that H. pylori has a putative LBP and can use hLf as an
iron-source is offset by at least one study that reports no use of hLf as well
as unrelated studies demonstrating that certain forms of Lf inhibit H. pylori
growth (Husson et al. 1993, Illingworth et al. 1993, Dhaenens et al. 1999,
Opekun et al. 1999).
H. pylori lives in a particularly high Lf environment, as infection
causes inflammation of the gut, which in turn increases the release of Lf.
Lactoferrin is among the genes upregulated in epithelial cells during H.
pylori infection and studies have found a positive correlation between the
degree of H. pylori induced gastric inflammation and the concentration of
Lf in the gastric mucosa (Wen et al. 2004, Choe et al. 2003).  One group
found that Lf expression in the stomach was highest when the patient had
both H. pylori infection and iron-deficiency anemia, which is widely
associated with H. pylori infection in adolescents (Choe et al. 2003).
These researchers hypothesized that H. pylori’s use of Lf-bound iron in the
stomach may be a contributing factor to the host’s inability to acquire
sufficient iron leading to subsequent anemia.
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Husson et al. found that partially iron-saturated hLf could support
full growth of H. pylori strain 43504 and 15 clinical isolates in iron-limited
media (Husson et al. 1993).  The bacteria were unable to grow when the
medium was supplemented with bLf or hTf.  This suggests that the
mechanism, similar to those described for other bacteria such as N.
meningitidis, is specific to host Lf (Husson et al. 1993).  Additionally, feoB
mutants unable to get Fe(II) from the environment were able to survive in
iron-limited conditions by using iron from human Lf and Tf (Velayudhan
et al. 2000).
Husson’s study also showed that H. pylori were unable to recover
growth when the Lf was separated from the bacteria with a dialysis bag,
indicating that H. pylori’s use of hLf may be dependent on cell-to-protein
contact (Husson et al. 1993).  A 70 kDa outer membrane protein of H.
pylori was later identified as a putative LBP, shown via affinity
chromatography to bind biotinylated-hLf (Dhaenens et al. 1997).  The
specificity of this putative LBP was examined via competitive binding
experiments, and Lf binding was shown to be uninhibited by horse Tf,
bovine Tf, and hTf (Dhaenens et al. 1997).  Partial inhibition was observed
with bLf but the bacteria were unable to use it for growth in iron-limited
conditions.  These findings suggest that the H. pylori LBP, which is only
expressed in iron-limited medium, may be involved in removing iron from
Lf (Dhaenens et al. 1997).  However, further characterization of the protein
has not occurred and the corresponding gene has yet to be identified.
1.4.3 Lactoferrin as a Therapeutic Against H. pylori
Some forms of Lf are under investigation for their ability to inhibit
H. pylori growth, particularly as possible adjuvants to antibiotic therapy.
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Lactoferrin is shown to work as a therapeutic against many
microorganisms (Arnold et al. 1980).  Some authors have reported that bLf
has a bacteriostatic effect on H. pylori in vitro, which the authors attribute
to iron sequestering (Dial et al. 1998).  This is consistent with earlier work
suggesting that H. pylori is unable to use iron from bLf for growth (Husson
et al. 1993, Dhaenens et al. 1997).  Bovine Lf has also been tested in vivo
as a potential therapeutic, but success has been mixed (Di Biase et al.
2006, Zullo et al. 2007).
More interesting, perhaps, is the use of rhLf as a potential
therapeutic agent.   Miehlke et al. found recombinant hLf (rhLf), reduced
the growth of 8 of 13 clinical isolates (Miehlke et al. 1996, Joshi et al.
2001).  Methodological issues have been raised with the study, though, and
work investigating rhLf’s potential to act a therapeutic have not found it
successful (Opekun et al. 1999, Guttner et al. 2003). The possible ability of
rhLf to impeded H. pylori growth is not necessarily inconsistent with the
ability of H. pylori to use hLf as an iron source.  It is possible that rhLf
could affect H. pylori differently than hLf, as it would be expected to have
differing patterns and types of post translational modifications, such as
glycosylation, depending on the species in which it is produced. Indeed
rhLf has been shown to have different impacts on the physiology of
Shigella spp. compared to hLf (Gomez et al. 2003).
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1.5 The Ability of H. pylori to be Internalized into
Epithelial Cells
1.5.1 Evidence for Internalization of H. pylori into Epithelial Cells
There is considerable controversy over whether H. pylori should be
considered a facultative intracellular microorganism (Peterson and
Krogfelt 2003, Dubois and Boren 2007).  The evidence we do have comes
mostly from in vitro studies with  cultured cell lines.  Taken together, these
studies suggest that H. pylori internalization occurs, and is an active, host-
cell mediated process with the bacteria surviving in vacuoles within
epithelial cells (Su et al. 1999, Amieva et al. 2002.  As such, there is a
growing body of in vitro evidence that suggests that H. pylori is invasive
under certain conditions, but whether this internalization is biologically
relevant remains unclear due to scarce evidence in vivo.
Recent work using immunohistochemistry and fluorescence in situ
hybridization provides evidence of intracellular H. pylori in the lamina
propria, within gastric epithelial cells, and immunocytes of patients with
gastric diseases (Ogata 1997, Oh et al. 2005, Dubois and Boren 2007,
Necchi et al. 2007).  Moreover, some of these bacteria were still able to
produce mRNA and antigens, suggesting they were viable (Necchi et al.
2007).  Yet, while internalization does seem to occur in vivo, it does so at
much lower frequencies than have been reported from in vitro studies and
some studies of clinical biopsies and primary cultures of human antral
gastric epithelial cells have failed to find evidence of internalization
(Peterson and Krogfelt 2003).  More often, the presence of intracellular
bacteria is confirmed but the frequency of invasion remains quite low.  Ko
et al. found intracellular bacteria in only 2 of 100 samples of gastric antral
biopsy specimens immuno-stained for H. pylori (Ko et al. 1999).  In
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another study, intracellular H. pylori was found in four out of eight
patients with either gastric ulcer or chronic gastritis, but only in 1 % of all
examined cells (Peterson and Krogfelt 2003).
In such instances where intracellular H. pylori are found in vivo,
the frequency of invasion seems to be higher in damaged epithelial cells
and around active ulcers.  In a study of 144 gastric biopsies using light and
differential interference contrast microscopy, 5.6 % of patients with minor
epithelial damage had internalized H. pylori, increasing to 100 % in
patients with severe epithelial damage (Chan 1992).  However, it remains
to be determined if the internalized bacteria were in some way responsible
for the increased tissue damage, suggesting a role for invasion in H. pylori
pathogenesis, or if they were simply more able to invade damaged tissue.
In vitro work using immortalized cancer cell lines has provided a
more robust pool of evidence. The proportion of infecting bacteria that are
engulfed by host cells during the widely used gentamycin (GM) protection
assay range across the literature from rare (less than 0.0019 %; Wilkinson
et al. 1998) to relatively frequent (15 %; Peterson et al. 2000), varying
according to H. pylori strain and cell type used (Table 1.3).  Generally,
frequencies seem to be higher for Type I strains of H. pylori, defined as
having the CagA pathogenicity island that plays an important role in H.
pylori pathogenesis (Kusters et al. 2006), than the Type II strains, which
lack it.  Among cell types, the highest frequencies of internalization have
been reported for the gastric adenocarcinoma cell lines AGS and Kato III,
with lower frequencies of internalization found in laryngeal
adenocarcinoma HEp-2 cell lines and no significant internalization found
in assays with cervical adenocarcincoma cell line HeLa (Rautelin et al.
1995, Peterson et al. 2001, Peterson and Krogfelt 2003).  This degree of
variation in reported invasion frequencies among strains and cell types
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suggests that both strain-specific and cell-specific factors may mediate the
internalization of H. pylori into cultured cell lines.
Table 1.3: Frequencies of H. pylori internalization into epithelial cell
lines using gentamycin protection assays
Strain Cell Type Internalization
Frequency1
Source
Type I
AF4 AGS ~ 0.006 % Peterson et al. 2001
G27 AGS ~ 0.055 % Peterson et al. 2001
G27 AGS             1.0 % Amieva et al. 2002
P119 AGS             1.5 % Su et al. 1999
A5 AGS             2.0 % Su et al. 1999
266952 AGS             2.5 % Kwok et al. 2002
AF4 AGS             15.0 % Peterson et al. 2000
Type II
51932 AGS            0.0005 % Peterson et al. 2001
M019 AGS             1.0 % Su et al. 1999
51934 AGS             8.0 % Peterson et al. 2000
Un-typed
Various
clinical
isolates
HEp-2            0.0006 %-
           0.0019 %
Wilkinson et al. 1998
1. Proportion of inoculum (as percent) that survived the gentamycin protection assay;
presumed to be intracellular.
2. Strain is +cagA, but gene product may not be functional.  Type is questionable.
1.5.2 Mechanism of Internalization by H. pylori
Most in vitro work suggests that H. pylori internalization is an
active, host-cell mediated process.  There is evidence that the process is
mediated by binding integrins, cell surface receptors that are well known to
promote bacterial internalization (Su et al. 1999, Scibelli et al. 2007).  H.
pylori internalization has also been associated with localized tyrosine
phosphatase signals and condensed actin filaments, suggesting signal-
induced uptake (Kwok et al. 2002).  Further evidence from HEp-2 cells
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supports this, with a 100-fold reduction in invasion in the presence of
ammonium chloride, which inhibits receptor-mediated endocytosis, and by
dansylcadaverine, which inhibits receptor clustering and internalization
(Peterson and Krogfelt 2003).
While there has been some contradictory evidence with non-gastric
cell lines, most studies utilizing AGS cells support the role of actin-
mediated processes in H. pylori internalization (Su et al. 1999, Peterson et
al. 2001, Amieva et al. 2002).  Similar processes are important for the
internalization of many invasive bacteria (Kwok et al. 2002).  Multiple
experiments, including some using video microscopy, have shown that
cytochalasin D, which abrogates actin polymerization, can reduce or
eliminate H. pylori invasion (Amieva et al. 2002, Peterson and Krogfelt
2003).  Using a scanning electron microscope, Kwok et al. found evidence
to support H. pylori entering AGS cells via zipper-like, receptor-mediated
endocytosis, similar to that described for Yersinia, Neisseria, Listeria and
Streptococcus spp. (Kwok et al. 2002).  The mechanism involves the host
cell membrane engulfing the bacteria at the site of attachment to such an
extent that the membrane zips up around the entire surface of the
bacterium.
1.5.3 Intracellular Survival of H. pylori
After internalization, endocytosed particles are generally targeted
to lysosomes, which contain hydrolytic enzymes and antimicrobial agents.
Facultative intracellular bacteria regularly subvert the host cell endocytotic
pathways to generate a safe intracellular niche.  They do so with a variety
of mechanisms, often escaping into the cytoplasm, avoiding fusion with
lysosomes, or neutralizing the bioactive components within lysosomes
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after fusion (Terebiznik et al. 2006).  Through live imaging and differential
interference contrast microscopy, H. pylori have been seen to survive
engulfment, with live, moving bacteria recorded in cellular vacuoles o up
to 8 hrs after infection (Amieva et al. 2002).  Significant numbers have
been recovered from GM protection assays as much as 48 hrs post-
infection (Terebiznik et al. 2006).  As there is little evidence of H. pylori
living free in the cell cytoplasm, it probably survives by bypassing or
surviving lysosomal fusion (Amieva et al. 2002, Peterson and Krogfelt
2003).
H. pylori-containing vacuoles possess markers of late endosomes,
which typically fuse with lysosomes, after 24 hrs of invasion (Terebiznik et
al. 2006).  Fluorescent probes loaded into lysosomes pre-infection were
also found in H. pylori containing vacuoles post-infection, further evidence
of lysosomal fusion (Terebiznik et al. 2006).  To survive this fusion, H.
pylori require a mechanism(s) to inactivate the bactericidal properties of
lysosomes because even though they reside in the stomach, H. pylori are
not acidophilic.  Reducing the acidity in lysosomes could be important for
their survival, though the evidence for them doing so is mixed (Amieva et
al. 2002, Terebiznik et al. 2006).  Neutralization of the toxic components
in lysosomes may also include inactivation of bactericidal Cathepsin D,
which appears to be less concentrated in H. pylori-containing vacuoles
(Terebiznik, et al. 2006).  Levels of Cathepsin D were lowest in vacuoles
containing strains of H. pylori with the gene for the vacuolating cytotoxin
VacA, which has been implicated in intracellular survival in a number of
studies.
Whereas all H. pylori strains possess the vacA gene, only 50 % of
strains express the VacA cytotoxin (Atherton, 1995).  VacA induces
extensive vacuolation in cultured cells in vitro, and has an important role in
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H. pylori pathogenesis (Kusters et al. 2006).  Moreover, the presence of
VacA seems to promote the generation of larger vacuolar compartments
within the cell and mediate fusion among H. pylori-containing vacuoles
(Terebiznik et al. 2006).  VacA isogenic mutants do not seem to differ in
their ability to adhere to or invade TC cells (Peterson et al. 2001, Amieva
et al. 2002), but tend to not survive as long within the host cell, which is
consistent with VacA’s ability to modulate the vacuolar environment.
Amieva et al. found evidence that VacA-negative, isogenic mutants
survived 13 hrs less than VacA-positive wild type (WT) strains, and
Peterson et al. found intracellular survival among VacA-negative mutants
to be about 7.5 % of the WT at 24 hrs post-infection (Peterson et al. 2001,
Amieva et al. 2002).  The effect was reversible with the addition of broth
culture filtrates and purified VacA toxin from the VacA positive strains
(Peterson et al. 2001, Terebiznik et al. 2006).
Whereas some facultative intracellular bacteria are able to replicate
within the host cells, the total number of live H. pylori recovered from in
vitro assays slowly decreases over time (Wilkonson et al. 1998, Peterson et
al. 2001).  There is evidence to suggest that this may relate to bacteria
being released back into the extracellular environment (Amieva et al.
2002).  The potential for H. pylori to recolonize the extracellular
environment has important implications for H. pylori pathogenesis.  H.
pylori is difficult to treat with antibiotics, with infection frequently
reoccurring after antibiotic therapy has ceased.  Invasion can be a way of
evading host defenses and antibiotics, with host cells serving as a reservoir
of bacteria for re-infection.  To counter-act this, most current treatment
regimens include the use of macrolides, which can concentrate
intracellularly (Pechere 2001).
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The majority of information we have from H. pylori internalization
comes from in vitro work, and the difference between the prevalence of H.
pylori internalization in in vivo and in vitro studies is notable. This
difference may be reconciled with future work that more precisely
replicates in vivo conditions in vitro (Peterson and Krogfelt 2003).  Also
further in vivo studies using H. pylori specific markers may corroborate in
vitro work on the mechanisms by which H. pylori invade and survive
inside epithelial cells. The question at this point is not so much whether H.
pylori has the ability to invade, but whether the in vitro observations hold
true in vivo, and whether invasion has any affect on pathogenesis or is just
incidental.
Objectives of Current Study
The aim of this study was to increase understanding of how Lf
interacts with bacteria, especially ones that regularly come into contact
with it, and to further our knowledge of the microbial ecology of the
human body.  To do this, we have chosen H. pylori as a model organism
While Lf impedes the growth of most bacteria, some human
pathogens are not inhibited by Lf and can even utilize Lf-bound iron for
growth.  H. pylori may be one of these species (Husson et al. 1993,
Velayudhan et al. 2000), potentially expressing an Lf binding protein
capable of specifically interacting with hLf (Dhaenens et al. 1997). Most
characterized LBPs in prokaryotes have been studied in relation to their
ability to use Lf as an iron source.  Yet many of these species have
redundant mechanisms for acquiring iron, and in some, LBPs do not
appear to play an important role in iron-acquisition (Ling and Schryvers
2006). Furthermore, Neisseriaceae LBPs bind Lf regardless of iron
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saturation, though binding does increase when iron is scarce (Ling and
Schryvers 2006).  LBPs fill a variety of functions in eukaryotes, and the
putative role of LBPs for iron-acquisition in bacteria does not preclude
additional, as yet unidentified, functions.
 For example, Lf has been shown to affect the internalization of a
number of facultative intracellular bacteria.  This is done either through
binding elements necessary for bacterial adhesion to epithelial cells, or by
degrading bacterial invasion factors (Valenti and Antonini 2005).  To date,
however, little work has been done on species that are adapted to high
levels of Lf and potentially express LBPs.  Lactoferrin may have little
effect on the invasion of these species, or, because hLf also binds and is
internalized into epithelial cells, these bacteria may able to invade at a
higher frequency by directly binding hLf bound to the cell surface.
It is also possible that Lf could be internalized into bacterial cells as
it is with eukaryotic cells, and thus come into contact with bacterial DNA.
Given that one of Lf’s many functions in human cells is its ability to act as
a transcription factor (Fleet 1995, He and Furmanski 1995), the possibility
exists that Lf may also be able to act as a transcription factor in
prokaryotes.  In vitro work has shown that Lf binds three distinct DNA
sequences known as Lf response elements (LFRE) with a high affinity and
specificity, and can increase expression of reporter genes with LFREs in
their promoter region (He and Furmanski 1995, Fleet 1995).  These
elements have also been found in the promoter of the two human genes
known to be directly activated by Lf (Son et al. 2002, Mariller et al. 2007).
A presence Lf binding sites in bacterial genomes would suggest possible
functional roles for Lf.
In addition, Lf’s ability to bind DNA makes it a potential DNA
vector for horizontal gene transfer, which is the movement of genes
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between species.  This is an especially important issue for genetically
modified organisms (GMOs), and the potential for transgenes to move into
other, non-GMO species is the focus around which much risk assessment
revolves.  Genes reportedly transfer between bacteria within human cells
(Ferguson et al. 2002).  Thus, by affecting invasion frequencies, Lf may
affect horizontal gene transfer between bacteria, and between bacteria and
human cells.
The aims of this study were:
• To confirm the ability of H. pylori to utilize Lf as an iron-source in
iron limited media (Chapter 2).
• To determine if Lf affects the generally low frequency of
internalization of H. pylori into gastric epithelial cells (Chapter 3).
• To search for the possible existence of Lf binding sites in a wide
array of bacteria. H. pylori was examined specifically to determine
if any LFREs occur in locations that suggest functional roles for Lf
(Chapter 4).
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Chapter 2:
The Ability of Helicobacter pylori to Utilize
Lactoferrin as an Iron-source when Iron is Limited.
2.1 Experimental Justification
Lactoferrin binds iron on mucosal surfaces of the body, limiting
the free iron available to bacteria.  Pathogenic bacteria have various means
to acquire iron in the host, and some are able to liberate iron from host
iron-binding proteins such as Lf.  H. pylori have been reported to use hLf
as an iron-source and express a 70 kDa lactoferrin binding protein (LBP)
(Husson et al. 1993, Dhaenens et al. 1997).  This use appears to be hLf-
specific, because bLf and even recombinant hLf (rhLf) are considered as
potential therapeutic agents against H. pylori (Miehlke et al. 1996, Opekun
et al. 1999, Di Biase et al. 2006, Zullo et al. 2007).  The ability of H.
pylori to use Lf has not been widely researched and the mechanism by
which it may do so remains unclear.
Here, the ability of type strains of H. pylori to use Lf as an iron-
source was tested.  A system similar to that of Husson et al. was used,
where H. pylori was grown in iron-limited medium supplemented with hLf
as a potential iron source (Husson et al. 1993).  Iron-limiting conditions
were created in this study by the addition of desferioxamine (DE), a potent
iron-chelator, to H. pylori growth medium.  The “iron-limited medium”
was then supplemented with Lf from human milk to see if growth
recovered.  Our hypothesis was that if H. pylori growth is not inhibited by
hLf, then hLf would not reduce growth in iron-replete or iron-limited
conditions; and if H. pylori could use hLf as an iron source, then the
addition of Lf to iron-limited medium should result in growth recovery.  H.
pylori can grow with FeCl3 as a sole iron-source, taking up Fe(III) via the
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FeoB iron-acquisition system and possibly other means (Velayudhan et al.
2000), and therefore FeCl3 was used as a positive control.
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2.2 Materials and Methods
2.2.1 Bacterial Strains and Culture Conditions
Three well-characterized H. pylori type strains were used for this
research: 60190 (cagA+ / vacA s1m1), Tx30a (cagA- / vacA s2m2), and the
mouse-adapted strain SS1 (cagA+/ vacA s2m2) (Cover et al. 1990,
Atherton et al. 1995, Lee et al. 1997).  Cultures were maintained on
Colombia blood agar plates (Fort Richard, NZ; see Appendix I), and grown
for assay in culture broth consisting of 2.8 % (w/v) Brucella Broth (BB;
BD) supplemented with 5 % fetal bovine serum (FBS; Gibco).  Cultures
were incubated at 37˚C in 10 % CO2.  Master stocks were stored at –70˚C
in glycerol storage medium.  Iron-replete medium was standard BB + 5 %
FBS (defined above), and iron-limited medium was BB + 5 % FBS
supplemented with 20 µM of the iron chelater desferoxamine mesylate
(DE) (Sigma) unless otherwise stated.
2.2.2 Bacterial Growth Assays
To assess the affect of Lf on the growth of H. pylori, bacteria were
grown in iron-replete or iron-limited broth culture, supplemented with
either FeCl3, ~25 % iron-saturated Lf from human milk (Biochemika) or
~85 % iron-saturated (holo) Lf (Biochemika) as potential iron sources.
Growth was measured as the optical density at 650nm (OD650) on a
SpectroMax190 spectrophotometer (MDS).
Before starting the bacterial growth assays, the minimal
concentration of DE capable of reducing growth was determined for each
of the three H. pylori strains used in this study.  Strain 60190 was used as a
standard, and all experiments were done in triplicate.  Strains SS1 and
Tx30a were tested to confirm they displayed a similar growth pattern in
differing concentrations of DE. These assays were carried out using iron-
replete medium (BB, 5 % FBS), supplemented with DE ranging from 10
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µM to 50 µM (final concentration).  Additionally, growth was also
measured for each concentration of DE in the presence of 10 µM FeCl3, to
determine the ability of iron supplementation to overcome the iron-
chelating effect of DE.
To determine if H. pylori can utilize Lf as an iron-source, bacteria
were grown in iron-limited medium supplemented with 0.5mg/ml  or 1
mg/ml of partially iron-saturated Lf (binding ~3 µM iron and ~6 µM iron
respectively), or 0.5 mg/ml of fully iron-saturated iron (binding ~10 µM
iron).  Controls included bacterial growth in iron-replete medium
(positive), iron-limited medium, and iron-limited medium supplemented
with 10 µM FeCl3.  Bacteria were also cultured in iron-replete medium in
the presence of hLF.
For all assays, 2 ml of each condition was prepared and aliquoted
into 3 wells (200µl each) of a 96 well plate (BD) for a no-bacteria,
absorbance control.  H. pylori were added to the remainder of each
condition (approximately 5 x106 bacteria per ml from an overnight broth
culture), which was then aliquoted into 5 test wells (200µl each).
Culture absorbance was measured (OD650) at 0, 18, 24, 42, 48, 66
and 72 hrs.  Between measurements, the 96-well plates were incubated on
a rotary shaker (120 rpm) at 37˚C in 10 % CO2.  Growth was calculated as
average OD650 of the wells with bacteria, minus the average OD650 of the
no-bacteria controls.  Growth in each condition was normalized to the iron-
replete positive control. Statistical significance between conditions was
determined with a Student t-test
2.2.3 SDS Page and Silver Staining
To detect phenotypic changes in H. pylori grown in iron-limiting
conditions, bacterial cell lysates were run on an SDS acrylamide gel and
proteins were silver-stained.  Bacteria were grown in iron-replete and iron-
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limited culture conditions, using both Brucella broth with 5 % FBS and
F12 medium (Ham) (+L-glutamine) with 10 % FBS and 1 % L-glutamine
(Invitrogen; made according to manufacturers instructions).  F12 medium
is used with AGS cells, and was included for reference with the invasion
assays in Chapter 3.
 Bacteria were grown overnight to an OD650 of 0.10 to 0.15, and
approximately 1x107 bacteria/ml were added to 4.5 ml of each medium.
The broth cultures were incubated for 4 hrs at 37˚C in 10 % CO2 with
constant rotation and growth was determined by a change in absorbance
over this time.  Bacteria were recovered from the medium by
centrifugation (5 min at 14,000 rpm) and washed twice in phosphate
buffered saline (PBS).  Bacterial pellets were stored at –20˚C prior to use.
Lysates were prepared by resuspending the washed bacterial pellets
in 1 ml PBS and sonicating on an OmniRupter 4000 sonicator (Omni
International) for four, 30 sec intervals.  The lysates were then centrifuged
(5 min, 14,000 rpm) to remove cellular debris.  The concentration of
protein in the supernatant (lysate) was determined using a modified Lowry
procedure (Markwell et al. 1998) with bovine serum albumin (BSA) used
to generate a standard curve.
The samples were run on 12.5 % acrylamide gels and visualized
using a dual silver stain (see Appendix I; Keenan et al. 1997).
Approximately 2 µg of protein from each condition, with an equal amount
of reducing buffer, was heated at 99oC for 5 mins before being loaded onto
the gel.  A prestained protein ladder (Fermentas) was used as a molecular
weight marker.  Gels were run for approximately an hr at 250 volts, 40
milli-amps and 15 watts.  The gel was fixed overnight in a solution of 50 %
ethanol and 10 % acetic acid in dH20.  The fixative was then removed, and
replaced with 5 % ethanol and 1 % acetic acid in dH20 and gently agitated
for 15 mins.  Periodic acid (0.7 %) was added during the last 10 mins.
This alters carbohydrate moieties so that they stain with silver and thus
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helps visualize bacterial LPS O chains (Keenan et al. 1997). Gels were
washed in dH20 (three 10 min washes) before staining with 0.1 % silver
nitrate for 30 min.  After a brief dH20 wash, the gel was developed in 3 %
sodium carbonate with 0.05 % formaldehyde until banding became
apparent.  Development was stopped with 1 % acetic acid.  Where
necessary, the gels were washed in Farmers Reducer (see Appendix I;
Heukoshoven and Dernick 1985) for 10-30 sec to reduce background
staining before being restained (as above).  The gel was imaged with a
FluorS Mutilmager imager (BioRad).
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2.3 Results
2.3.1 Determining the Minimal Inhibitory Concentration of DE
H. pylori was grown in iron-replete medium supplemented with
varying concentrations of the iron-chelator DE to find the minimal
inhibitory concentration (MIC) of iron chelator.  Growth was measured as
a function of optical density at 650 nm, and compared against the iron-
replete positive control.
Bacteria ceased to grow in most conditions after 72 hrs,
occasionally forming aggregates at the bottom of wells that sharply
increased optical density.  As such, overall levels of growth was compared
between conditions at 48 hrs.   Optical density measures total biomass, and
it is possible that growth rate is simply being reduced in some conditions,
such that growth levels could reach the iron-replete control in time.  Yet
many conditions reached stationary phase without achieving the same
levels of growth as the iron-replete control, suggesting the partial iron-
limitation is not just slowing growth rate but reducing total biomass of the
bacteria.
 H. pylori strain 60190 was used as a standard. Two other strains
(SS1 and Tx30a) were then tested to see if they exhibited similar patterns
to strain 60190.  Over a 72 hr period, DE was capable of slowing (10 µM
DE) or preventing ( ≥ 20 µM) growth of strain 60190 (Figure 2.1).
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Figure 2.1: Effect of increasing iron-limitation on the growth of H.
pylori strain 60190. Bacteria were grown in iron-replete medium (IR
Control) with increasing concentrations (10-50 µM) of iron-chelator DE.
(A) Growth over 72 hrs from one representative experiment. (B) Growth at
48 hrs relative to the positive control, mean of three independent
experiments ±SE.
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Strain 60190 was also grown in this same series of concentrations of DE
with the addition of 10 µM FeCl3 to determine if growth could be
recovered with the addition of iron.  Growth was recovered at
concentrations of ≤ 35 µM DE (Figure 2.2).
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Figure 2.2: Iron supplementation rescues growth of H. pylori strain
60190 in iron-limiting conditions. Bacteria were grown in iron-replete
medium (IR control) and iron-limited medium (with10-50 µM DE)
supplemented with 10 µM FeCl3 to determine if it was sufficient iron for
recovery of growth. (A) Growth over 72 hrs from one representative
experiment. (B) Growth at 48 hrs relative to the positive control, mean of
three independent experiments ±SE.
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Strains SS1 and Tx30a were grown in medium supplemented
with 10-50 µM DE, with and without 10 µM FeCl3.  Each experiment was
performed once to determine if a similar pattern of growth occurred across
strains (see Appendix II). At least partial growth inhibition was seen in all
strains with 20 µM DE and the addition of 10 µM FeCl3 reversed the
effect.  From this, iron-limited medium was defined as BB + 5 % FBS
supplemented with 20 µM DE, and used for all further growth assays.
2.3.2 Growth of H. pylori with 0.5 mg/ml of Partially Iron-Saturated
Human Lactoferrin
To see if hLf affected the growth of H. pylori, strains were grown
in both iron-replete and iron-limited media supplemented with hLf.
Growth of all H. pylori strains was measured in medium supplemented
with 0.5 mg/ml of Lf from human milk, about 25 % iron-saturated.  This is
equivalent to approximately 3 µM iron in solution.
Similar to previous results, growth in strain 60190 was significantly
reduced with the additional of 20 µM DE (p-value <0.001) and recovered
with the addition of FeCl3 (p-value <0.001).  The addition of 0.5 mg/ml
hLf to iron-replete and iron-limited conditions did not significantly change
the growth of strain 60190, although small decreases in absorbance when
compared to the iron-replete or iron-limited control were apparent,
suggesting some growth inhibition (Figure 2.3).
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Figure 2.3: Growth of strain 60190 with 0.5 mg/ml of partially iron-
saturated human lactoferrin. Bacteria were cultured in iron-replete (IR
control) and iron-limited (with 20 µM DE; IL control) media.  Media were
supplemented with ~25 % iron-saturated hLf or 10 µM FeCl3. (A) Growth
over 72 hrs from one representative experiment. (B) Growth of 48 hrs
relative to the positive control, mean of three independent experiments ±
SE. *, results are significantly different than iron-replete control.  **,
results are significantly different than the iron-limited control (p < 0.05 by
Student T-test).
     *                                         *
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     **
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Overall, strain SS1 grew poorly, only reaching to an OD650 of 0.20,
but growth relative to the control was similar across conditions to that
observed for strain 60190 (Figure 2.4). Again, growth was significantly
reduced with the additional of 20 µM DE (p-value <0.001) and recovered
with the addition of FeCl3 (p-value <0.001).  The addition of 0.5 mg/ml of
partially iron-saturated hLf to iron-replete conditions significantly reduced
total growth levels of strain SS1, to about 80 % of the control at 48 hrs (p-
value <0.001; Figure 2.4).  The addition of 0.5 mg/ml hLf to iron-limiting
conditions did not significantly reduce growth, though a small decrease in
total growth level was apparent.
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Figure 2.4: Growth of strain SS1 with 0.5 mg/ml of partially iron-
saturated human lactoferrin, with growth inhibition in iron-replete
conditions. Bacteria were grown in iron-replete (IR control) and iron-
limited (with 20 µM DE; IL control) media.  Media were supplemented
with ~25 % iron-saturated hLf or 10 µM FeCl3. (A) Growth over 72 hrs
from one representative experiment. (B) Growth at 48 hrs relative to the
positive control, mean of three independent experiments ± SE. *, results
are significantly different than iron-replete control. **, results are
significantly different than the iron-limited control (p < 0.05 by Student T-
test).
        **
 *
    *
      **
       *
      **
Chapter 2                                                            49
Growth of strain Tx30a was only partially inhibited in medium
with 20 µM DE, but was still significantly lower than the iron-replete
control (p-value <0.001).  Growth was recovered in iron-limited medium
with 10 µM FeCl3, but not up to the level of the iron-replete control (84
%).  The large increase in growth in the iron-replete control at 72 hrs was
due to clumping of non-viable bacteria at the bottom of each well.
No affect was seen with the addition of 0.5 mg/ml of partially iron-
saturated hLf to iron-replete medium. The addition of hLf to iron-limiting
conditions significantly reduced the growth level achieved by strain Tx30a
by over 70 % (p-value <0.001; Figure 2.5).  This may represent a strain-
specific difference in iron uptake or intracellular iron stores, as has been
reported elsewhere (Bland et al. 2004). Alternatively, the effect of adding
hLf may not have been as notable in strains 60190 and SS1 as growth in
iron-limiting conditions was already quite low.
From this, there is no evidence that any of these three strains of H.
pylori are using partially iron-saturated hLf as an iron-source.  The
presence of 0.5 mg/ml of hLf decreased growth levels of strains 60190 and
SS1 by about 20 %, although it was only significant for the latter (Table
2.1).  Growth levels of all strains was reduced in iron-limited media
supplemented with hLf.  This reduction could be due to an hLf chelation of
iron in the media.
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 Figure 2.5: Growth of strain Tx30a with 0.5 mg/ml of partially iron-
saturated human lactoferrin, with growth inhibition in iron-limiting
conditions. Bacteria were grown in iron-replete (IR control) and iron-
limited (with 20 µM DE; IL control) media.  Media were supplemented
with ~25 % iron-saturated hLf or 10 µM FeCl3. (A) Growth over 72 hrs
from one representative experiment. (B) Growth at 48 hrs relative to the
positive control, mean of three independent experiments ± SE. *, results
are significantly different than iron-replete control.  **, results are
significantly different than the iron-limited control (p < 0.05 by Student T-
test).
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Table 2.1: The effect of 0.5 mg/ml of partially iron-saturated human
lactoferrin on H. pylori growth1
Strain IR
medium2
IL
medium2
IR+hLF IL+hLF IL+FeCl33
60190 100 11  ± 4.7 82 ± 13 3.5 ± 1.7 106 ±  9.3
SS1 100 10 ± 7.5 82 ±  0.66 1.6 ±  0.33 92 ±  3.2
Tx30a 100 58 ± 18 102 ±  4.1 16 ± 15 84 ± 1.6
(1) Growth expressed as percentage of the iron-replete control (IR) over three
experiments, ±SE.
(2) Iron-replete medium is defined as BB with 5 % FBS.  Iron-limited medium (IL) is BB
with 5 %FBS and 20 µM DE.
(3) Iron-limited medium was supplemented with 10 µM FeCl3 to determine if growth
could be recovered with the addition of iron to the medium.
2.3.3 Growth of H. pylori strain 60190 with 1.0 mg/ml of Partially Iron-
Saturated Human Lactoferrin
To see if the addition of more hLf might have a measurable effect
on growth, H. pylori strain 60190 was cultured with 1.0 mg/ml of partially
iron-saturated hLf.  This concentration of hLf potentially increased both
the possible inhibitory effect of hLf, and the amount of iron (~6 µM iron)
that would be available if H. pylori were able to use hLf as an iron source.
As observed previously with strain 60190, growth was significantly
reduced with the addition of 20µM DE to the medium, and growth was
recovered with the addition of FeCl3 (Figure 2.6).  There was no significant
difference between growth in iron-limited medium with the addition of 1
mg/ml hLf.  If partially iron-saturated hLf is able to chelate remaining free
iron in the medium, increasing the concentration of hLf should result in an
equal or stronger inhibition of growth than seen with 0.5 mg/ml.  However,
growth in iron-limited medium was quite low, only 1% of the iron-replete
positive control, making additional inhibition from hLf difficult to detect.
Nevertheless, growth on iron-replete conditions was decreased by 30 %
with 1.0 mg/ml of partially iron-saturated hLf (Table 2.2).
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 Figure 2.6: Possible growth inhibition of strain 60190 with 1 mg/ml of
partially iron-saturated human lactoferrin. Bacteria were grown in iron-
replete (IR control) and iron-limited (with 20 µM DE; IL control) media.
Media were supplemented with ~25 % iron-saturated hLf or 10 µM FeCl3.
(A) Growth over 72 hrs from one representative experiment. (B) Growth at
48 hrs relative to the positive control, mean of three independent
experiments ± SE. *, results are significantly different than iron-replete
control.  **, results are significantly different than the iron-limited control
(p < 0.05 by Student T-test).
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Table 2.2: The effect of 1 mg/ml of partially iron-saturated human
lactoferrin on H. pylori growth1
Strain IR
medium2
IL
medium2
IR+hLF IL+hLF IL+FeCl33
60190 100 1 ± 0.017 72 ±  6.9 1 ±  0.058 86 ± 4.8
(1) Growth expressed as percentage of the iron-replete control (IR) over three
experiments, ±SE.
(2) Iron-replete medium is defined as BB with 5 % FBS.  Iron-limited medium (IL) is BB
with 5 %FBS and 20 µM DE.
(3) Iron-limited medium was supplemented with 10 µM FeCl3 to determine if growth
could be recovered with the addition of iron to the medium.
2.3.4 Growth of H. pylori strain 60190 with 0.5 mg/ml of Iron-Saturated
Human Lactoferrin
To see if the level of hLf iron saturation affects the ability of H.
pylori to use hLf, the growth of strain 60190 was tested with 0.5 mg/ml of
iron-saturated (holo) hLf (~85 % iron-saturated).  This brought the total Lf-
bound iron to 10 µM, the same as used in the FeCl3 controls.
Growth of strain 60190 was only partially reduced with the
addition of 20 µM DE to the medium, but the reduction was still
significant (p-value <0.001).  Growth was recovered with the addition of
10 µM FeCl3 (Figure 2.6).
Addition of holo-hLf to iron-limited medium resulted in
significantly increased growth when compared to the iron-limited control
(p-value<0.05).  In iron-replete medium, the addition of holo-hLf resulted
in a substantial increase in growth (p-value 0.062) (Table 2.3).
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Figure 2.7: Growth recovery of strain 60190 in iron-limiting
conditions with 0.5 mg/ml of fully iron-saturated human lactoferrin.
Bacteria were grown in iron-replete (IR control) and iron-limited (IL
control) media (with 20 µM DE; IL control).  Media were supplemented
with ~85 % iron-saturated hLf or 10 µM FeCl3. (A) Growth over 72 hrs
from one representative experiment. (B) Growth at 48 hrs relative to the
positive control, mean of three independent experiments ± SE. *, results
are significantly different than iron-replete control.  **, results are
significantly different than the iron-limited control (p < 0.05 by Student T-
test).
 *
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Table 2.3: The effect of 0.5 mg/ml of fully iron-saturated human
lactoferrin on H. pylori growth1
Strain IR
medium2
IL
medium2
IR+hLF IL+hLF IL+FeCl33
60190 100 34 ± 0.030 130 ± 4.7 120 ± 10 84 ± 3.5
(1) Growth expressed as percentage of the iron-replete control (IR) over three
experiments, ±SE.
(2) Iron-replete medium is defined as BB with 5 % FBS.  Iron-limited medium (IL) is BB
with 5 %FBS and 20 µM DE.
(3) Iron-limited medium was supplemented with 10 µM FeCl3 to determine if growth
could be recovered with the addition of iron to the medium.
2.3.5 Phenotypic Changes in H. pylori in Iron-limited Conditions
The ability of iron-limitation to induce changes in the phenotype of
H. pylori strain 60190 was examined. Bacteria were grown in iron-replete
and iron-limited media BB + 5 % FBS and F12 nutrient broth (+ 10 %
FBS) for 4 hrs.  Growth was measured at OD650 before and after incubation
for all conditions to see if there was a difference in growth between
conditions (Table 2.4).  The bacteria were lysed, and lysates were
examined using SDS-PAGE and silver staining.  Whereas there was little
evidence of growth inhibition, differences in bacterial phenotype were
observed after only 4 hrs in iron-limiting media.
Table 2.4: Growth of H. pylori over four hours in iron-replete and
iron-limited conditions
IR-BB1 IL-BB1 IR-F121 IL-F121
T0 0.059 0.060 0.060 0.053
T4 0.075 0.072 0.062 0.059
(1) Growth expressed as OD650 in iron replete (IR) and iron-limited (IL) BB + 5 % FBS
and F12 nutrient medium (+10 % FBS) at the start (T0) and after four hrs incubation (T4).
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Figure 2.8: Phenotypic changes in HP60190 grown in iron-limited
conditions.  Bacteria were grown for 4 hrs in iron-replete and iron-limited
media (with 20µM DE).  (A) iron-replete BB (B) iron limited BB (C) iron-
replete F12 nutrient medium (D) iron-limited F12 nutrient medium (M)
prestained protein ladder, in kDa. Bacterial lysates were visualized on 12.5
% acrylamide gel by SDS-PAGE and silver stained.
There is an apparent increase in protein, approximately 70 kDa, in
the iron-limiting-BB conditions.  There is an analogous, though less
evident, increase in the same band in the IL-F12 nutrient medium.
Comparing inter-lane staining, it appears that lane (D) may have been load
with slightly less protein (C), meaning that the increased density of the
staining of the 70 kDa band could be even higher than it first appears in
iron-limiting-F12 medium. These results suggest that even in the 4 hr time
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limit of the assay, some changes in bacterial phenotype are evident in
iron-limiting media.
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2.4 Discussion
Lactoferrin is an iron-binding protein, chelating free iron where it is
produced on mucosal surfaces in mammals. Human Lf on the mucosal
layer of the stomach is known to increase during H. pylori infection (Choe
et al. 2003, Wen et al. 2004). In the tens of thousands of years that H.
pylori has infected humans (Blaser 1998, Falush et al. 2003), it is likely
that this bacterium has developed some adaptations to living in a high Lf
environment.  Indeed, despite the presence of the usually bacteriostatic Lf,
H. pylori infections are highly persistent, rarely being cleared by the host
without additional therapeutics (Lee et al. 1993, Kusters et al. 2006).
Previous studies have suggested that H. pylori may be able to use iron
bound to hLf for growth, but the data is unclear and the possible
mechanism has yet to be determined.
To test the ability of H. pylori to use hLf, bacteria were grown in
iron-replete and iron-limited media supplemented with hLf.  First, the
minimal concentration of the iron-chelator DE capable of inhibiting growth
of strains 60190, SS1, and Tx30a was determined.  It was found that 20
µM DE was sufficient to completely prevent growth in 60190 and SS1 and
partially inhibit growth in Tx30a.  From this, iron-limited medium was
defined as the addition of 20 µM DE to iron-replete Brucella broth.  In all
cases, the addition of 10 µM FeCl3 to iron-limited medium resulted in
growth similar to the positive iron-replete control, suggesting the iron-
limitation created by DE can be overcome by supplementation with
additional iron sources.
2.4.1 Affect of Partially Iron-Saturated Human Lactoferrin on the
Growth of H. pylori
Growth of H. pylori was tested in iron-replete and iron-limiting
conditions with 0.5 and 1 mg/ml of partially iron-saturated hLf.  The
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addition of partially iron-saturated hLf to iron-replete conditions led to a
reduction of growth in strains 60190 and SS1, but not Tx30a.  A 20 %
decrease in the level of growth at 48 hrs was apparent with the addition of
0.5 mg/ml of hLf in strains 60190 and SS1, though only significant in the
latter.  When the amount of hLf was increased to 1 mg/ml, growth of strain
60190 was reduced by 30 % in iron-replete conditions.
Growth of all three strains was decreased in iron-limited medium
supplemented with partially iron-saturated hLf, possibly due to chelation of
remaining iron in the medium.  This decrease was only significant with
strain Tx30a.  Growth in iron-limited conditions was already low in strains
60190 and SS1, making it difficult to detect further inhibition with the
addition of hLf.  A similar issue arose with the addition of 1 mg/ml of
partially iron-saturated hLf, where growth in iron-limiting conditions was
as low as 1 % of the control.  Otherwise, were the decrease in growth due
to iron-chelation, additional hLf would be expected to exert an even larger
degree of inhibition.
Partially iron-saturated hLf appears to decrease growth in both
iron-replete and iron-limited conditions.  This could be due to hLf
chelating iron in the medium.  Human Lf has a range of antimicrobial
activities, and it is possible that hLf is affecting growth through a
mechanism unrelated to iron-content. This is unlikely, though, in light of
the increase in growth with fully iron-saturated hLf discussed below.
2.4.2 Affect of Fully Iron-Saturated Human Lactoferrin on the Growth of
H. pylori
The level of iron-saturation of hLf can affect its ability to chelate
additional iron from the medium, as well as increase the amount of Lf-
bound iron available for use.  Whereas partially iron-saturated hLf
decreased growth of strain 60190 in iron-replete medium, the addition of
0.5 mg/ml of holo-hLf led to a 30 % increase in growth.  This effect was
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notably increased in iron-limited medium, bringing growth up to the level
of the iron-replete control.
However, partially and fully iron-saturated hLf could be affecting
growth differently because of discrepancies in the total amount of Lf-
bound iron being added to the medium.  Only 3 - 6 µM of iron is present in
0.5-1.0 mg/ml of partially iron-saturated hLf, whereas 0.5 mg/ml of holo-
hLf translates to approximately 10 µM of iron under these culturing
volumes.  Iron-replete medium (Brucella broth with 5 % FBS) would be
expected to have 1.63 – 2.94 µM free iron (Worst et al. 1995).  If H. pylori
were able to access all Lf-bound iron, both partially and fully iron-
saturated Lf should be sufficient for growth.  However, the efficiency at
which the bacteria are able to utilize the various forms of iron probably
differs.
One preliminary trial was performed with 0.25 mg/ml of holo-hLf,
representing approximately 5 µM of iron in solution, and growth recovery
in iron-limiting conditions was not evident. It is possible then, that the
quantity of Lf-bound iron was insufficient for growth with the partially
iron-saturated hLf.
Iron deficiency does not, however, account for the decrease in
growth seen with partially iron-saturated hLf.  It may be that iron bound to
holo-hLf is more accessible to H. pylori.  Human serum, with 30 % iron-
saturated transferrin, is usually inhibitory to the growth of Candida
albicans, yet the fungus grows profusely in serum with 100 % saturated
transferrin (Bullen 2005).  Furthermore, the conformation of Lf changes as
it binds more iron, which could affect how it interacts with receptors.
Holo-Lf has a closed structure, with iron release dependent on
destabilization of the closed form either by receptor binding or a low pH
(Mazurier and Spik 1980, Baker 2005).  Whether or not levels of iron-
saturation affect the ability of H. pylori to use hLf would depend on the
mechanism by which it is obtaining the iron.
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2.4.3 Potential Mechanisms of Acquiring Iron from Human Lactoferrin
The mechanism by which H. pylori is able to access iron bound to
hLf is unknown. H. pylori is known to express a number of iron-regulated
outer membrane proteins (IROMPS) (Lee et al. 2009), some of which are
associated with uptake of iron from host iron-binding proteins (Dhaenens
et al. 1997, Worst et al. 1995).  Changes in the H. pylori phenotype was
observed within 4 hrs of iron-limitation, and some of these may be proteins
involved in the uptake of iron from hLf.
A number of other species have been shown to use Lf as an iron-
source, often with membrane bound, tonB-like lactoferrin binding proteins.
Expression of a lactoferrin binding protein has been suggested for H. pylori
as well (Dhaenens et al. 1997), but the gene for the putative H. pylori LBP
has not been identified.
H. pylori may also be able to acquire iron from Lf indirectly,
without the need of an LBP.  H. pylori has recently been described as
having a riboflavin-mediated system of iron acquisition (Worst et al.
1998).  Flavins are capable of reducing Fe(III) in iron-containing
complexes to Fe(II) (Worst et al. 1998, Andrews et al. 2003).  The more
soluble Fe(II) can then diffuse into the cell through porin channels in the
membrane.  Interestingly, a similar system was described in Listeria
monocytogenes, with a membrane-bound flavin reducatase increasing the
accessibility of free iron from several iron-binding proteins, including
siderophores, heme, transferrin, and lactoferrin (Deneer et al. 1995, Worst
et al. 1998).
2.4.4 How Lactoferrin may be Affecting Growth in vivo
All strains tested here showed a decrease in growth with partially
iron-saturated hLf and strain 60190 showed an increase in growth with
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fully iron-saturated hLf.  Most hLf in the body is not fully iron-saturated
(Bullen 2005) and the partially iron-saturated hLf used in this study, which
was isolated from human milk, has a similar level of iron-saturation as hLf
in vivo.  However, iron levels in the stomach are subject to large variations
(van Vliet et al. 2002) and saturation of Lf in the stomach could be
changing as well.  Differing degrees of iron-saturation may possibly
account for diverging reports on whether or not Lf is an affective
therapeutic for H. pylori in vivo.
It is interesting to note that the Miehlke et al. study showing rhLf
reduced H. pylori growth used rhLf that was 95 % iron-free (Miehlke et al.
1996).  As mentioned previously, rhLf may affect H. pylori differently than
hLf from human milk due to differing post-translational modifications, as
has been suggested elsewhere with Shigella spp. (Gomez et al. 2003).  It
may be, though, that iron-free Lf is able to exert a stronger effect against
bacterial growth, acting as larger sink for iron than similar amounts of
partially iron-saturated hLf isolated from human milk.
It would be interesting to see if the increase in growth seen with
fully iron-saturated hLf in strain 60190 was also seen with strains SS1 and
Tx30a.  Various studies showing an increase in H. pylori growth used
either partially or fully iron-saturated hLf, though with strains other than
used here (Husson et al. 1993, Velayudhan et al. 2000). Strain-specific
differences in H. pylori’s ability to use hLf could contribute to its
persistence in the host and possibly even virulence.  Some patients with H.
pylori-related, iron-deficient anemia are colonized with strains that produce
more IROMPs and are more efficient users of iron (Lee et al. 2009).
Chapter 3                                                             63
                                                                                  
Chapter 3
The Effect of Lactoferrin on the Frequency of
Internalization of Helicobacter pylori into Human
Epithelial Cells
3.1 Experimental Justification
Lactoferrin, particularly bovine Lf (bLf), has been shown to reduce
the invasion of epithelial cells by a number of pathogens (Ajello et al.
2002, Di Biase et al. 2004, Superti et al. 2005). To date, however, little is
known about how Lf affects internalization in species that are adapted to
high levels of human Lf (hLf) and potentially express Lf binding proteins
(LBP).
Previous work suggests that H. pylori has a low rate of
internalization into epithelial cells (Peterson and Krogfelt 2003), which
may be affected by interacting with hLf. Human Lf may decrease
internalization of H. pylori into human epithelial cells, as has been shown
with other species, or have no effect, as is possible if H. pylori adapts to LF
in the stomach.  It is also possible that hLf could increase the invasiveness
of H. pylori.  This hypothesis is supported by evidence of a putative H.
pylori LBP that has been described as hLf-specific (Dhaenens et al. 1997).
By directly binding hLf that is bound to the epithelial cell surface (Legrand
et al. 2004), H. pylori may be passively internalized.  This effect may be
different from that of bLf, which binds bacterial and cellular surfaces
(Valenti et al. 2005) but does not have a high affinity for hLf-specific
receptors (Dhaenens et al. 1997).
The commonly used gentamycin protection assay was used to
enumerate internalized H. pylori, and to then derive a frequency of
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internalization. In this assay, gastric adenocarcinoma (AGS) cells were
infected with bacteria for 4 hrs, washed, and then incubated for two hrs
with gentamycin to kill any extracellular bacteria.  Cells were lysed and
any bacteria recovered from the lysate were presumed to have been
intracellular because they were in this way protected from exposure to
gentamycin.  The internalization assay was performed under both iron-
replete (as a positive control) and iron-limiting conditions.  Iron-limited
medium was created by two methods: firstly by removing fetal bovine
serum (FBS), which contains iron, and secondly by adding the iron-
chelator desferoxamine mesylate (DE) to FBS-supplemented F12 medium.
 .   
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3.2 Materials and Methods
3.2.1 Bacterial Strains and Growth Conditions
Bacteria were grown and maintained as described in Chapter 2
(refer to page 31).  All assays were done with H. pylori strain 60190.
3.2.2 Cell culture
AGS cells (ATCC CRL-1739) were grown at 37˚C in F12 nutrient
medium.  Antibiotics and FBS were omitted to generate F12 nutrient
medium without antibiotics or serum respectively.  For assays, AGS cells
were grown in 24 well plates (BD), seeded with 1x 105 cells per well and
grown overnight to approximately 2 x 105 cells.
3.2.3. Determining Efficacy of Gentamycin
To determine if incubation with gentamycin can kill H. pylori, 100
µg/ml of gentamycin (Gibco) was added to F12 nutrient medium without
antibiotics.  Overnight cultures of bacteria were added to the medium and
incubated for two hrs at 37˚C in 10 % CO2 under constant rotation (120
rpm).  Samples of 200 µl were taken at 30 min intervals and plated on
Columbia blood agar plates.  The plates were incubated at 37˚C in 10 %
CO2 and H. pylori colony-forming units (CFUs) were quantified four days
later.
3.2.4 Determining Cell and Bacterial Viability in Medium Without FBS
The effect of medium without FBS on AGS cells and H. pylori
viability during the 4 hr period of the gentamycin protection assay was
determined. AGS cells (2 x 105) in 24 well plates were incubated with F12
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medium with and without the addition of 10 % FBS for 4 hrs at 37˚C. AGS
cells were examined under light microscopy for morphological signs of
stress.  Separately, H. pylori was recovered from an overnight broth by
centrifugation (10 min at 10,000 rpm), resuspended in F12 medium (with
and without FBS) and incubated for 4 hrs at 37˚C in 10 % CO2 with
rotation. The number of H. pylori in each condition was quantified via
serial dilutions on Colombia blood agar plates.
3.2.5 Determining Efficacy of Lysis Buffers
An assay was performed to determine if potential lysis buffers were
able to efficiently lyse AGS cells.  AGS cells (2 x 105), grown overnight in
a 24 well plate, were washed 3 times in PBS before the addition of 1 ml of
lysis buffer that included F12 medium without antibiotics (control), 0.5 %
saponin in PBS, 0.05 % saponin in PBS, 0.25 % sodium deoxycholate
(NaDoc; Difco) in H20 (w/v), 1 % Nonidet P40 (BDH Chemicals LTD; see
Appendix I) or H20 adjusted to pH 11 with NaOH.  Each well was
aspirated five times with a pipette.  Cells were examined for lysis at 5 min
intervals.
3.2.6 Lysis Buffer Viability Assay
An assay was performed to determine if H. pylori could survive
exposure to these lysis buffers.  H. pylori were grown overnight in broth
culture and 200 µl aliquots were centrifuged (10 min at 10,000 rpm) to
recover bacteria.  Each bacterial pellet was resuspended in 200 µl of lysis
buffer (see above) and left to sit at room temperature, with 10 µl samples
removed and cultured at 5, 10, and 20 min intervals.  A more precise
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quantification of bacterial viability was determined after 20 min of
incubation via serial dilutions on Colombia blood agar plates.
3.2.7 Gentamycin Protection Assay
A gentamycin protection assay was performed to determine if, and
at what frequency, H. pylori invades AGS cells.  To prepare the inoculum
for infecting the cultured cells, H. pylori were grown in broth culture
overnight to an OD650 between 0.10 and 0.15.  Aliquots of 0.5 ml of broth
culture were centrifuged (10 min at 10,000 rpm), and the bacterial pellets
were resuspended in antibiotic-free F12 medium with and without the
addition of 10 % FBS.  The number of bacteria in the inoculum was
quantified via serial dilutions on Columbia blood agar plates.
AGS cells grown overnight in 24 well plates (2 x 105) were washed
with PBS (three 500 µl washes) to remove antibiotics before infection with
bacteria.  Cells were infected with 50-80 µl of H. pylori inoculum, which
equated to approximately 5 x 106 bacteria, giving a multiplicity of infection
(MOI) of 25:1.  To determine the effect of Lf on internalization in FBS-
free, iron-limiting conditions, duplicate wells were supplemented with
1mg/ml of partially iron-saturated hLf.
In a separate experiment, internalization was tested in iron-replete
(F12 nutrient medium + 10 %FBS) and iron-limited medium (F12 nutrient
medium + 10 % FBS +  20 µM DE).  Media were similarly inoculated with
bacteria and added to washed AGS cells.  In this experiment, additional
wells were supplemented with 1 mg/ml of partially iron-saturated hLf,
denatured hLf, or partially iron-saturated bLf from bovine milk (Sigma).
The denatured hLf was prepared by heating hLf at 100˚C for five min.
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Experiments were carried out at 37ºC for 4 hrs, to allow
internalization to occur.  After infection, individual wells were washed
with the media used during the infection step.  The AGS cells were then
incubated with 100 µg of gentamycin for 2 hrs, using the same media
conditions, before being washed three times with F12 medium.  The final
wash, which was retained as a medium control, was supplemented with
100 µl of lysis buffer to show there were no remaining bacteria in solution
or in non-adherent cells.  One ml of 0.5 % saponin in PBS (lysis buffer)
was added to each well and aspirated five times before being left to sit for
10 min. The wells were aspirated again before collection of the AGS cell
lysate.
Bacteria in the lysate were quantified via serial dilutions on blood
agar plates, and the plates were incubated for 4 days at 37˚C in 10 % CO2.
For each condition, overall internalization frequency was calculated as
percent of the original inoculum recovered after incubation with
gentamycin.  For comparison across conditions, the number of intracellular
bacteria was normalized to the iron-replete control for that experiment.
Statistical significance between conditions was determined with a Student
t-test.
3.2.8 Adhesion Assay
AGS cells were grown overnight and inoculated with bacteria as in
the gentamycin protection assay, testing iron-limitation via DE.  Infection
was carried out at 37˚C for 4 hrs.
After infection, wells were washed three times with F12 medium.
Thereafter, 1 ml of 0.5 % saponin in PBS was added to each well, and the
wells were aspirated five times, allowed to sit 10 min, and aspirated again.
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Bacteria in the lysis buffer were quantified via serial dilutions on blood
agar plates, and the plates were incubated for 4 days at 37˚C in 10 % CO2.
Adhesion frequency was calculated as percent of the original inoculum
recovered after infection.  For comparison across conditions, the number of
intracellular bacteria was compared to the iron-replete control.  Statistical
significance was determined between conditions with a Student t-test.
3.2.9 Analysis of the Statistical Power of the Internalization and
Adhesion Assays
Statistical power is defined as the probability of rejecting the null
hypothesis when it is false and should be rejected (Roush and Tozer 2003).
If the difference between conditions are not statistically different, that
could suggest the actual effect size between conditions is smaller than the
measured effect size and more replicas are needed.
A power analysis was carried out using the free web program
G*Power3 (Erdfelder 1996) to determine the number of additional replicas
that would be needed to get statistically significant differences between
conditions, taking into account the variation seen in the initial data.  The
measured effect size between two conditions was determined using the
standard deviation and means from the initial data set for both the
internalization and adhesion assay using DE-mediated iron-limitation.
Effect size was calculated as below, where mu1 is the mean of population
1 and mu2 is the mean of population 2. Sigma is the standard deviation.    
d= [ mu1 - mu2 ]
                             sigma
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Because the sample sizes between conditions were the same, it is
possible to standardize sigma from the two standard deviations as shown
below, where sigma A2 is the standard deviation of population 1 and sigma
B2 is the standard deviation of population 2:
   
 sigma'=  √  ((  sigmaA2  +  sigmaB2)/2)
   
The effect size and number of replicas was then entered into a post-
hoc power analysis, which determines the power of a given set of data.  For
the internalization and adhesion assays, the calculated power was used in
an a-prior power analysis to determine how many more replicas would be
needed to detect other effect sizes at the p<0.05 level, given the degree of
variation seen in the original data set.
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3.3 Results
An initial set of experiments was performed to validate the
conditions used during the gentamycin protection assay.  Gentamycin was
tested for its ability to kill H. pylori.  The bacteria were incubated with 100
µg/ml of gentamycin for two hrs, with samples taken at To and thereafter at
30 min intervals.  No colony forming units (CFUs) were observed from
samples (including the initial sample) after four days of incubation on
Colombia blood agar plates.  This suggests that H. pylori is killed soon
after exposure to gentamycin in vitro and within the two-hr period of the
gentamycin protection assay.
The effect of removing FBS from the medium for 4 hrs was
examined separately in both AGS cells and H. pylori.  No morphological
differences in the cells after 4 hrs incubation was seen using light
microscopy, irrespective of the presence of 10 % FBS in the F12 medium.
Bacteria were quantified via serial dilution for both conditions.  Over two
experiments, the average recovery from medium with FBS was 1.9 x 107,
whereas the average recovery from medium without FBS was 9.2 x 106,
indicating a 62 % drop in the number of culturable bacteria when FBS was
removed from the medium over a 4 hr period.
The ability of various buffers to lyse AGS cells and their potential
toxicity to H. pylori was tested.  Lysis buffers, which included 0.5 %
saponin in PBS, 0.05 % saponin in PBS, 0.25 % NaDoc, 1 % Nonidet P40
and H20 adjusted to pH 11 with NaOH, were added to AGS cells and the
cells visually examined for lysis at 5 min intervals.  Treatment with Na-
DOC and Nonidet P40 resulted in almost complete lysis within 5 min
whereas treatment with 0.5 % saponin and pH-adjusted H20 resulted in
almost complete lysis within 10 min.  After 10 min, unlysed cells were still
evident in the 0.05 % saponin treatment.
72                                                     Chapter 3
To test potential toxicity of lysis buffers, H. pylori were suspended
in medium (F12 medium + 10 % FBS) or lysis buffer.  Samples were taken
over regular intervals and cultured on blood agar plates. Bacteria remained
viable for at least 20 mins in all lysis buffers except for 0.25 % NaDoc and
1 % Nonidet P40, which killed the bacteria within 5 min (Table 3.1).
Table 3.1: H. pylori viability after incubation with lysis buffers.
Incubation
Period
Medium
control
0.05 %
Saponin
0.5 %
Saponin
0.25 %
NaDoc
1 %
Nonidet
P40
pH-adjusted
H20
5 min lawn lawn lawn 01 01 lawn
10 min lawn lawn lawn1 01 01 lawn
20 min lawn lawn lawn1 01 01 lawn
(1) Small clear spots on the blood agar plates suggest some blood cell lysis.
To quantify bacterial survival, this assay was repeated once using
0.5 % saponin and H20 pH 11 lysis buffers and serial dilutions of the
bacteria were plated after 20 min of treatment (Table 3.2).  The 0.05 %
saponin buffer was not retested in this assay because of the observation
that it failed to effectively lyse AGS cells.  Treatment of H. pylori with 0.5
% saponin resulted in similar recoveries as the medium-only control
samples.  In contrast, there was a notable drop in viability after treatment
with pH-adjusted H20.  From this, the 0.5 % saponin was chosen for cell
lysis during the gentamycin protection assay.
Table 3.2: Quantification of H. pylori viability after incubation with
lysis buffers.
Lysis Buffer Bacterial Recovery1
Medium control 1.1 x107
pH-adjusted H20 1.0 x106
0.5 % Saponin 1.6 x107
(1) Results are from a single experiment calculated from CFUs at high dilution factors.
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3.3.1 Effect of Lactoferrin on Internalization in FBS-mediated Iron-
limiting Conditions
AGS cells are routinely cultured in F12 nutrient medium
supplemented with 10 % FBS, which contains iron. To create iron-limiting
conditions, cells were cultured in F12 medium without the addition of
FBS.  Partially saturated Lf from human milk was added to both iron-
replete and iron-limited media.  Briefly, AGS cells were incubated with H.
pylori for 4 hrs, washed, and incubated an additional 2 hrs with gentamycin
to kill any external bacteria.  The cells were then lysed and serial dilutions
of the lysate were plated on blood agar plates to determine the number of
viable bacteria, presumed to be intracellular.
There was a large degree of day-to-day variation in the frequency
of internalization. To mitigate this, the frequency of internalization was
normalized to the positive (iron-replete) control of each experiment (Table
3.3). The internalization frequency was also averaged across all
experiments for each condition to give an indication of the number of
bacteria entering AGS cells (Table 3.3). Because the frequency of
internalization was not normalized, these results do not necessarily
correspond to percent of control, instead being skewed in favor of
experiments with larger overall frequencies of internalization.  All
comparisons across conditions were done with the normalized data.
The frequency of internalization was low in all conditions, with
0.031 % to 0.66 % of the bacteria added to the AGS cells recovered during
the gentamycin protection assay (Table 3.3).  The number of intracellular
bacteria was found to be significantly higher when the assay was carried
out in iron-replete medium (p-value <0.001); the removal of FBS from the
medium reduced internalization almost 10-fold (Figure 3.1). This decrease
in internalization may be due to iron-limitation from removal of FBS, loss
of other nutrients found in FBS, and/or changes in bacterial viability, given
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that recovery of culturable bacteria from medium without FBS after 4 hrs
was reduced by 62 %.
The addition of hLf (1 mg/ml, partially iron-saturated) was
associated with an apparent reduction in H. pylori internalization of AGS
cells under iron-replete conditions, and increased internalization in iron-
limiting conditions.   However, these differences only reached statistical
significance at the 0.22 and 0.18 level.
Table 3.3: Effect of human lactoferrin on the internalization of H.
pylori into gastric epithelial cells, without FBS as an iron-source
Lf Medium1 % Internalization2 % of Positive
Control3
Control (none) Iron-replete 0.66 ± 0.61 100
none Iron-limiting 0.081 ± 0.076 10 ± 1.0
hLf4 Iron-replete 0.054 ± 0.020 56 ± 29
hLf Iron-limiting 0.031 ± 0.018 38 ± 33
(1) Iron-replete and iron-limited media defined as F12 nutrient medium with and without
10 % FBS, respectively.
(2) Mean internalization frequency, un-normalized. Calculated as the percent of inoculum
recovered from AGS cells during a gentamycin protection assay.  Mean of three
experiements ± SE.
(3) Percent of internalization normalized to the iron-replete positive control for each
experiment.  Mean of three experiments ± SE.
(4) Internalization measured in the presence of 1 mg/ml of partially iron-saturated human
lactoferrin..
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Figure 3.1: Reduction of H. pylori internalization into gastric epithelial
cells in medium without FBS, and possible mediating effects of human
lactoferrin. The ability of H. pylori 690190 to invade AGS gastric
epithelial cells was tested in iron-replete (with addition of 10 % FBS) and
iron-limiting (without FBS) F12 medium, with and without the addition of
1 mg/ml partially saturated hLf.  Internalization is expressed as percent of
positive control (iron-replete medium).  Results are the mean ±SE of three
individual experiments. *, results are statistically significantly different
from iron-replete control (p < 0.05 by Student T-test).
3.3.2 Effect of Lactoferrin on Internalization in DE-mediated Iron-
limiting Conditions
An alternative system of iron limitation was used in an attempt to
clarify the effect of Lf on internalization.  Here, 10 % FBS was routinely
added to the F12 medium and iron-limitation was created by the addition
of 20µM DE, thus avoiding any possible confounding factors involved in
removing FBS from the medium.  Partially iron-saturated bLf or hLf (1
mg/ml) was added to each condition.
As before, the frequency of internalization of H. pylori was found
to be low across the conditions tested, ranging from 0.045 % to 0.28 % of
the initial inoculum (Table 3.4).  Again, the unnormalized internalization
   *
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frequency was provided to show that the overall number of bacteria getting
into the AGS cells. For comparison across conditions, the number of
internalized bacteria in the different conditions was normalized to the iron-
replete control in each experiment (Table 3.4).
Table 3.4: Effect of bovine and human lactoferrin on the
internalization of H. pylori into epithelial cells under iron-limiting
conditions.
Lf Medium1 % Internalization 2 % of Positive
Control3
Control (none) Iron-replete 0.055 ± 0.017 100
none Iron-limited 0.010 ± 0.0037 27 ± 13
bLf4 Iron-replete 0.180 ± 0.098 280 ± 170
bLf Iron-limited 0.045 ± 0.018 91 ± 30
hLf4 Iron-replete 0.17 ± 0.056 240 ± 100
hLf Iron-limited 0.28 ± 0.14 480 ± 250
(1) Iron-limited and iron-replete media defined as F12 nutrient medium with 10 % FBS,
with and without 20 µM DE respectively
(2) Mean internalization frequency, un-normalized.  Calculated as the percent of inoculum
recovered from AGS cells during a gentamycin protection assay.  Mean of four
experiments ± SE.
(3) Percent of internalization normalized to the iron-replete positive control for each
experiment.  Mean of four experiments ± SE
(4) Internalization measured in the presence of 1 mg/ml of partially iron-saturated human
lactoferrin
The use of DE, which chelates free iron in the medium (Bland et al.
2004), was associated with a significant decrease in the frequency of
internalization of H. pylori into epithelial cells (p-value<0.001) (Figure
3.2).  Increased internalization of H. pylori was evident with the addition of
bLf and hLf to both iron-replete and iron-limiting conditions; this effect is
most notable with supplementation of iron-limiting conditions with hLf
(Figure 3.2).  The effect of adding Lf to iron-limited medium was only
significant to the p=0.064 (bLf) and p=0.085 (hLf) levels, which means the
null hypothesis that Lf has no affect on internalization in iron-limited
conditions cannot be rejected.
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Figure 3.2: Possible increase of H. pylori internalization into gastric
epithelial cells with the addition of lactoferrin. The ability of H. pylori
690190 to invade AGS gastric epithelial cells was tested in iron-replete and
iron-limiting (with 20 µM DE) F12 medium, with and without the addition
of 1 mg/ml partially saturated bLf or hLf.  Internalization is expressed as
percent of positive control (iron-replete medium).  Results are the mean
±SE of three individual experiments.  *, results are statistically significant
from iron-replete control (p < 0.05 by Student T-test).
3.3.3 Effect of Denatured Human Lactoferrin on Internalization in DE-
mediated Iron-limiting Conditions
The increase in internalization seen with the addition of hLf may
be attributable to the presence of Lf-bound iron in the assay.  To test this
hypothesis, the internalization assay was repeated under iron-limiting
condition (F12 medium + 10 % FBS + 20 µM DE) with or without the
addition of 1 mg/ml of denatured hLf.
As previously, internalization of H. pylori strain 60190 into AGS
cells was significantly reduced under iron-limiting conditions (p-
value<0.05)  (Table 3.5).  However, the addition of dhLf had the opposite
effect of hLf and instead significantly reduced H. pylori internalization of
AGS cells under iron-replete conditions (p-value<0.05).  In contrast, no
 *
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significant difference in the frequency of bacterial internalization was
observed under iron-limiting conditions, with or without the addition of
dhLf (Figure 3.3). Nor was the decrease seen with the addition of dhLf
significantly different than the increase seen with hLf.
Table 3.5: Effect of denatured human lactoferrin on internalization of
H. pylori into gastric epithelial cells under iron-limiting conditions.
Lf Medium1 % Internalization2 % of Positive
Control3
Control (none) Iron-replete 2.6  ± 1.1 100
none Iron-limited 0.99  ± 0.28 48  ± 17
Denatured hLf4 Iron-replete 1.4  ± 0.44 61  ± 13
Denatured hLf Iron-limited 0.66  ± 0.16 31 ± 7
(1) Iron-limited and iron-replete media defined as F12 nutrient medium with 10 % FBS,
with and without 20 µM DE respectively
(2) Mean internalization frequency, un-normalized.  Calculated as the percent of inoculum
recovered from AGS cells during a gentamycin protection assay.  Mean of three
experiments ± SE.
(3) Percent of internalization normalized to the iron-replete positive control for each
experiment.  Mean of three experiments ± SE
(4) Internalization measured in the presence of 1 mg/ml of partially iron-saturated human
lactoferrin
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Figure 3.3: Decreased internalization of H. pylori into gastric epithelial
cells with the addition of denatured human lactoferrin.  The ability of
H. pylori 690190 to invade AGS gastric epithelial cells was tested in iron-
replete and iron-limiting (with 20 µM DE) F12 medium, with and without
the addition of 1 mg/ml denatured hLf.  Internalization is expressed as
percent of positive control (iron-replete medium).  Results are the mean
±SE of three individual experiments. *, results are statistically significant
from iron-replete control (p < 0.05 by Student T-test).
It is interesting that internalization was significantly reduced in
iron-replete conditions with the addition of dhLf.  During the assay,
aggregations of dhLf were apparent on the AGS cells even after washing.
These large conglomerations of dhLf on the cell surface may have blocked
surface sites necessary for bacterial internalization. Alternatively, the
aggregates may be cytotoxic, as many aggregrates may be (Bucciantini et
al., 2002).
3.3.4 Effect of Lactoferrin on H. pylori Adhesion to AGS Cells under
Iron-Limiting Culture Conditions
 Internalization is often affected by the ability of the bacteria to
adhere to host cells. To see if a change in internalization correlated with a
 *
   *
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change in adhesion, an adhesion assay was performed with bLf and hLf in
DE-mediated iron-limiting conditions.  The adhesion assay was essentially
identical to the gentamcyin protection assay, where AGS cells were
infected with H. pylori for 4 hrs.  Instead of incubating with gentamycin to
kill extracellular bacteria, the AGS cells were gently washed before lysis to
recover cell-associated (internal or external) bacteria.
The frequency of adhesion to epithelial cells was found to be
higher than the frequency of internalization, ranging from 1 % to 13 %
across conditions (Table 3.6).
Table 3.6: The frequency at which H. pylori adheres to gastric
epithelial cells with the addition of lactoferrin.
Lf Medium1 % Adhesion 2 % of Positive
Control3
Control (none) Iron-replete 2.7 ± 2.1 100
none Iron-limited 1.0 ± 0.89 30 ± 5.7
bLf4 Iron-replete 6.4 ± 3.5 510 ± 370
bLf Iron-limited 13 ± 13 240 ± 160
hLf4 Iron-replete 9.1 ± 7.6 300 ± 46
hLf Iron-limited 6.3 ± 5.7 150 ± 51
(1) Iron-limited and iron-replete media defined as F12 nutrient medium with 10 % FBS,
with and without 20 µM DE respectively
(2) Mean internalization frequency, un-normalized.  Calculated as the percent of inoculum
recovered from AGS cells during a gentamycin protection assay.  Mean of three
experiments ± SE.
(3) Percent of internalization normalized to the iron-replete positive control for each
experiment.  Mean of three experiments ± SE
(4) Internalization measured in the presence of 1 mg/ml of partially iron-saturated human
lactoferrin.
The adhesion of H. pylori to AGS cells was observed to be
significantly higher in iron-replete medium (p-value<0.001), correlating
with the internalization assay results under these culture conditions.  The
addition of both bLf and hLf led to an appreciable increase in adhesion,
Chapter 3                                                             81
                                                                                  
irrespective of culture conditions, but again failed to reach significance at
p=0.05 (Figure 3.4).
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Figure 3.4: Adhesion of H. pylori to gastric epithelial cells: possible
increase with the addition of lactoferrin. The ability of H. pylori 690190
to adhere to AGS gastric epithelial cells was tested in iron-replete and iron-
limiting (with 20 µM DE) F12 medium, with and without the addition of 1
mg/ml partially saturated bLf and hLf.  Internalization is expressed as
percent of positive control (iron-replete medium).  Results are the mean
±SE of three individual experiments. *, results are statistically significant
from iron-replete control (p < 0.05 by Student T-test).
3.3.5 Analysis of the Statistical Power of the Internalization and
Adhesion Assays
A power analysis was used to determine how many additional
replicas would be needed to achieve significance in the internalization and
adhesion assays performed here.  Measured effect size (d) was calculated
between the different conditions, and used during a post-hoc power
analysis to determine the statistical power of each condition (Table 3.7).
Statistical power is the probability of rejecting a null hypothesis when it is
false and should be rejected.  A low power implies that there is a higher
likelihood that there actually is a difference between conditions, even when
the null hypothesis cannot be rejected.  Because a number of our
   *
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conditions did not reach significance, this tells us whether or not, given our
data, we may be able to reject our null hypothesis with additional trials.
The number of additional replicas needed to detect other effect sizes at the
p<0.05 level, given the degree of variation seen in the original data set, was
determined with an a-priori power analysis.
The effect size was calculated from the mean and standard
deviation of two populations, such that either a large difference in the
means of the two populations and/or a small standard deviation in the data
increase the effect size. If an experiment done four times, as was the
internalization assay, provides a large effect size but is not statistically
significant, it may mean the actual effect size between the two conditions is
smaller and needs more replicas before the data is at the significant level.
The number of additional replicas needed to detect effect sizes of 0.2, 0.5,
and 0.8 was calculated (Table 3.7). As previously defined by Cohen
(1977), a small effect size is 0.2, a medium effect size is 0.5, and a large
effect size is 0.8.
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Table 3.7: Additional replicas required for detecting specific effect
sizes at the p<0.05 level
small medium large
d1 Power2 0.23 0.53 0.83
Internalization Assay
IR, IR+bLf4 0.88 0.30 53 6 1
IR, IR+hLf 1.1 0.48 81 11 3
IL, IL+bLf 0.73 0.23 36 4 0
IL, IL+hLf 1.5 0.57 150 21 7
Adhesion Assay
IR, IR+bLf 0.91 0.24 36 5 1
IR, IR+hLf 3.6 0.97 520 81 31
IL, IL+bLf 4.8 0.99 55 8 2
IL, IL+hLf 2.0 0.63 170 25 9
(1) Effect size (d) was calculated from standard deviations and means of conditions.
(2) Power was calculated from effect size and number of replicas performed with a post-
hoc power analysis. Statistical power is defined as the probability of rejecting the null
hypothesis when it is false and should be rejected.
(3) Number of additional replicas required calculated from statistical power using an a-
priori power analysis, where 0.2 is a small effect, 0.5 is a medium effect, and 0.8 is a large
effect.
(4) Comparisons made between internalization and adhesion in iron-replete (IR) and iron-
limited (IL) conditions with or without the addition of 1 mg/ml of partially saturated bLf
or hLf
Thus, to detect a large effect size of 0.8 in the internalization assay,
additional replicas (up to 7) would be needed, depending on the conditions.
To detect a large effect size in the adhesion assay, additional replicas (1-
31) would be needed.   If the actual effect size between any two conditions
is greater than 0.8, even fewer replicas may suffice. For example, the
calculated effect size between internalization in iron-limiting conditions
with and without the addition of bLf is lower than 0.8, suggesting that the
actual effect size is medium (Table 3.7, row 3).  If it is as low as 0.5, four
additional replicas would be needed.  If it is between 0.73 and 0.5, then
fewer replicas should give significant data.
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The very high number of replicas (31) needed for an effect size of
0.8 between adhesion in iron-replete conditions with and without the
addition of hLf may suggest two things.  For one, the actual effect size is
quite a bit larger than 0.8.  Alternatively, the power for these conditions
was very high, suggesting there is not a large chance that there actually is a
difference between the conditions.  The degree of variability between
adhesion in those conditions may be too great to expect significant results
without a very large, possibly impractical, number of replicas.  Similarly, if
any of the actual effect sizes between the conditions were small (0.2), the
number of replicas needed to get significant results would be prohibitive,
up to 520.
Chapter 3                                                             85
                                                                                  
3.4 Discussion
Lactoferrin has been shown to have an inhibitory effect on the
internalization of a number of facultative intracellular bacteria.  Yet to
date, little work has been done on species that are adapted to high levels of
Lf and potentially express Lf binding proteins. Bacteria that can bind Lf,
such as H. pylori, may be able to adhere to and invade eukaryotic cells at
higher frequencies by directly binding Lf bound to epithelial cell surfaces.
Here, we tested the ability of H. pylori strain 60190 to invade AGS
cells, and looked at how iron-limitation, bLf and hLf affected this
internalization. The initial aim of this study was to see if Lf had a different
effect on H. pylori internalization than has been seen in other bacteria,
possibly via interactions with an LBP.  LBPs are typically induced by iron-
limiting conditions, so internalization assays were performed in both iron-
replete and iron-limiting conditions.
3.4.1 Frequency of Internalization and Adherence of H. pylori into AGS
cells
In this study, the overall frequency of internalization of strain
60190 into AGS cells was low but within levels reported elsewhere for
other H. pylori strains of the same type (Type 1).  From 0.0006-0.007 of
the initial 60190 inoculum was recovered from AGS cells grown in
medium containing 10 % FBS (iron-replete conditions).  In comparison the
literature values for internalization frequency for other Type 1 strains, in
conditions similar to those used here, range from 0.00006 to 0.03, with one
at 0.15 (Peterson et al. 2000, 2001, Kwok et al. 2002) (Table 1.3).
The frequency of adhesion of H. pylori strain 60190 to epithelial
cells in iron-replete conditions was 0.03, much higher than the
internalization frequency under the same conditions.   The adhesion assay
used here was based on similar assays designed to assess the role of Lf in
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bacterial adhesion and internalization (Di Biase et al. 2004, Longhi et al.
2004, Superti et al. 2005).  However, because this assay involves
quantifying bacteria after cell lysis, both adherent and intracellular bacteria
were detected. Thus it is more a measure of total cell-associated bacteria.
In preliminary experiments, where adhesion and internalization assays
were performed on the same day, numbers of adherent bacteria were found
to be greater than invasive bacteria by a factor of 10 or more (data not
shown).
With some facultative intracellular bacteria (e.g. Yersinia spp.), the
majority of bacteria that adhere become internalized, resulting in a lower
frequency of adherence than internalization (Superti et al. 2005) (see
Tables 1.1, 1.2).  In contrast, these results suggest that a larger number of
H. pylori are adhering to AGS cells and that only a small proportion of
these bacteria invade.  This is consistent with H. pylori reportedly having a
much lower propensity to invade epithelial cells (Peterson and Krogfelt
2003, Dubois and Boren 2007).
3.4.2 Effect of FBS on the Frequency of Internalization of H. pylori into
AGS Cells
 Iron-limiting conditions were initially created by not adding FBS
(which contains free iron) to F12 nutrient medium.  Removal of FBS from
the medium resulted in a 10-fold drop in internalization. Along with iron,
fetal bovine serum contains many factors necessary for growth of H. pylori
and cultured cells.  While AGS cells incubated for 4 hrs in medium without
FBS did not reveal morphological signs of stress, a decline in H. pylori
growth over this time period was observed, and may account for some of
the decrease in internalization seen here.
The effect of FBS on internalization, however, may be independent
of iron-limitation and/or AGS cell and bacteria viability.  While FBS is
iron-rich, this iron can be complexed to proteins such as transferrin, and
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thus be unavailable for bacterial use (Worst et al. 1995).  Furthermore,
FBS contains protein factors that are believed to aid adherence and
internalization by H. pylori (Peterson et al. 2000).  Similar to results
presented here, Peterson et al. reported a higher frequency of
internalization when 10 % FBS was present (Peterson et al. 2000).
Interestingly, the effect was eliminated when the FBS was treated with
proteinase K, suggesting that the active component was a protein (Peterson
et al. 2000).
FBS is also reported to modulated adhesion and internalization in
other species of invasive bacteria.  Two serum factors found within FBS,
vitronectin and fibrinogen have already been shown to mediate engulfment
of N. gonorrhoaea and S. pyogenes, respectively (Cue and Cleary 1997,
Duensing and van Putten 1997).  Vitronectin in particular facilitates αvβ5-
integrin-mediated uptake by direct binding with N. gonorrhoaea (Kwok et
al. 2002).  H. pylori also binds vitronectin, and is believed to exhibit
integrin-mediated internalization (Kwok et al. 2002).
Human Lf was added to F12 medium with FBS and without FBS.
There was an apparent increase in internalization with the addition of hLf
to medium without FBS, and an apparent decrease with the addition to
medium with FBS, though neither was statistically significant.  However,
the addition of hLf did seem to confound the large decrease in
internalization seen with the removal of FBS, with internalization in both
conditions being similar when hLf was present.  Thus, hLf may be able to
mediate the loss of protein factors that aid in H. pylori adhesion and
internalization, binding both the cell surfaces and H. pylori in a manner
similar to that reported for components of FBS.
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3.4.3 Reduction of Adherence and Internalization in Iron-Limiting
Conditions
In an attempt to clarify the effect of Lf on internalization, without
the possible confounding factors involved in removing FBS from the
medium, another system of iron-limitation was used.  Here, FBS was
added to F12 medium and iron-limitation was created by the addition of 20
µM DE.
Reducing the level of available iron in the medium significantly
reduced the frequency of bacterial adherence and internalization, to about
30 % of the iron-replete control.  Because adherence is a necessary step in
internalization, a similar reduction in the number of invading bacteria was
not unexpected.
Bacteria grown for 4 hrs in iron-limited F12 medium showed no
decrease in growth (measured by optical density), but did display a
different phenotype, with up-regulated expression of a 70 kDa band after 4
hrs of culture in iron-limiting medium (Chapter 2).  This raises the
possibility that iron-associated phenotypic changes may be modulating the
ability of H. pylori to adhere to the host cell.  Iron-limiting conditions, for
instance, have been shown to decrease expression of Lewis antigens
(Keenan et al. 2008), components of LPS that mediate adhesion and
internalization of H. pylori (Lozniewski et al. 2003).
3.4.4 Increase in Adhesion and Internalization in the Presence of Bovine
Lactoferrin
The addition of bLf resulted in an apparent increase in adhesion
and internalization, although these differences failed to reach statistical
significance.  Additional replications of this assay are likely to confirm that
these interesting trends are indeed significant.
As before, changes in the viability of bacteria can affect
internalization and adhesion rates.  Most work suggests that H. pylori is not
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able to use iron from bLf for growth (Husson et al. 1993, Dial et al.
1998), and may in fact be inhibited by it, suggesting that in increase in
adhesion and internalization is not likely to be due to an increase in
growth.
It is interesting that adhesion and internalization were increased to
a similar degree across conditions, irrespective of iron-limitation.  It has
been suggested that the putative H. pylori LBP has low affinity for bLf
(Dhaenens et al. 1997).  If the binding of bLf to an LBP were increasing
adhesion to AGS cells, we would expect to see even more bacterial
adherence in iron-limiting conditions when production of LBPs is
upregulated.
  Like hLf, bLf can bind elements of bacteria and mammalian cell
surfaces (Valenti et al. 2005), and this non-specific binding could lead to
an increase in adhesion and thus internalization that is independent of iron
levels or an iron-regulated H. pylori LBP.
3.4.5 Iron-related Increases in Adhesion and Internalization in the
Presence of Human Lactoferrin
The addition of hLf led to an apparent increase in both
internalization and adhesion, though these effects were not statistically
significant.  As with bLf, it is difficult to make robust statements about the
effect of hLf on adhesion and internalization without additional
quantitative data, but some trends can be identified.
The original hypothesis was that hLf might increase the ability of
H. pylori to adhere to and invade human epithelial cells, by binding both
epithelial cell surfaces and an H. pylori LBP.  The addition of hLf
increased adhesion to a similar degree in both iron-replete and iron-
limiting conditions, analogous to what was seen with the addition of bLf.
Internalization with hLf was likewise increased in iron-replete conditions.
A substantially larger increase in internalization, but not adhesion, was
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seen in iron-limiting conditions.  If internalization in iron-limiting
conditions were mediated solely by an increase in cell binding, we would
expect a more correlative increase in adherence and internalization.  This
raises the question of whether the altered bacterial phenotype observed
under iron-limiting conditions includes upregulation of a putative LBP.
It is possible then, that Lf slightly increases the number of bacteria
that adhere in iron-limiting conditions, but greatly increasing the likelihood
of those that adhere to be internalized.  This would normally be associated
with a decrease in the number of bacteria on the cell surface, as more are
being internalized, but would not be reflected with the adhesion assay used
here, which measured total cell-associated bacteria (Figure 3.5).
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Figure 3.5: Schematic of total cell-associated H. pylori, including
invasive and adherent bacteria.  The frequency of internalization and
adhesion has been generalized, to the total cell associated bacteria in iron-
replete (IR) conditions reported as 100 %.
The increased internalization seen in iron-limiting conditions could
be due to an increase in the production of cellular receptors for binding and
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internalizing Lf.  Acquiring iron is not considered a major purpose for
Lf-uptake outside of the neonate intestine (Scarino et al. 2007), though
there is evidence for iron-regulated Lf uptake in hepatocyte and myeloid
cell lines (Mikogami et al. 1995, McAbee and Ling 1997, Olakanmi et al.
2002).  A reduction in intracellular iron stores increases both binding and
iron-uptake from Lf in hepatocytes, probably due to upregulation of the Lf
receptor (Mikogami et al. 1995).
H. pylori may be binding the cell-bound Lf via an LBP, or through
non -specific binding via the bacterial outer membrane.  One way to test
the relative importance of Lf binding to cellular or bacterial surfaces would
be incubating both AGS cells and H. pylori with Lf before the infection
step of the internalization assay, as reported elsewhere (Duensing and
Putten 1997, Valenti and Antonini 2005).  It would further need to be
ascertained whether or not AGS cells exhibit iron-regulated uptake of hLf.
The internalization assay was repeated with denatured hLf (dhLf),
based on the hypothesis that denaturation is likely to interfere with
receptor-mediated binding, as well as releasing Lf-bound iron to the
medium, allowing H. pylori access to it independent of any LBP.
Internalization in the presence of dhLf in iron-limiting conditions
was not significantly different than internalization without dhLf in iron-
limiting conditions, with a slight (and non-significant) decrease apparent.
This suggests that an increase in iron in the medium is not sufficient to
account for the increase in internalization seen with hLf.  These data also
suggest that a natively folded hLf is necessary for the increase in
internalization seen here.
3.4.6 How these Data Compare to the Effect of Lactoferrin on
Internalization in other Species
 The majority of studies have found that both bLf and hLf reduced
the ability of bacteria to invade host cells, either through binding or
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degrading proteins necessary for internalization (Valenti and Antonini.
2005, Ward et al. 2005).  There is evidence of increased adhesion of
Yersinia spp. to epithelial cells in the presence of bLf, although no increase
was seen in internalization and no mechanism for the increase was
postulated (Di Biase et al. 2004).  In this study, the presence of either bLf
or hLf did not decrease either internalization or adhesion.  Instead, both
bLf and particularly hLf appeared to increase adhesion and internalization,
though not to the statistical level.
3.4.7 Implications for Lactoferrin-mediated Effects In vivo
The majority of information we have relating to H. pylori
internalization is from cell-based assays, which typically report a greater
frequency of internalization than is apparent in vivo (Peterson and Krogfelt
2003).  To better understand how H. pylori invades in vivo, and whether
this internalization is biologically relevant, future work that more precisely
replicates in vivo conditions is needed.  The increase in internalization seen
with hLf could be incidental, or could be relevant in vivo for bacterial
persistence and pathogenicity.  Internalization of H. pylori may, for
example, affect the ability of the bacteria to persist in the host despite
treatment with antibiotics.
A correlation has already been suggested between an FBS-
mediated increase in internalization in vitro, and internalization in vivo.  H.
pylori would be expected to be bathed in serum factors in areas such as
ulcerated epithelium, possibly explaining why larger numbers of
intracellular H. pylori are found in vivo at the edges of active duodenal
ulcers (Peterson et al. 2000).  The stomach is a high hLf environment and
both increasing quantities of Lf and increasing internalization of H. pylori
has been reported in cases of severe gastritis (Chan 1992, Wen et al. 2004).
 Many of the effects seen here did not reach statistical significance.
A power analysis was performed to determine how many additional
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replicas would be needed to achieve results statistically significant to the
p<0.05 level.  Assuming that Lf has a medium to large effect, the power
analysis suggested that significant results could be detected after one to
four additional replicas of the internalization assay with bLf, and seven
additional replicas with hLf.  However,  the actual effect size of adding Lf
may be higher than 0.8, and thus even fewer replicas may be needed to get
statistical confirmation.  These additional experiments would allow us to
establish if Lf is capable of significantly increasing internalization and
adhesion of H. pylori.
This work, then, provides preliminary data that will be used as a
platform for future research.  Should the increase in internalization by bLf
and especially hLf seen here hold through in future work, this would be
markedly different for what has been seen in other species.  Future
research could then be done on the mechanism by which hLf is acting on
internalization, from increased binding via H. pylori LBPs to increased Lf
cycling in AGS cells.  Eventually, this might lead to more insight into how
internalization occurs in vivo in high hLf conditions.
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Chapter 4
The Presence of Lactoferrin Binding Sites in Bacterial
Genomes: Potential Roles as DNA Vector and
Transcriptional Regulator
4.1 Experimental Justification
Lf has at least one DNA binding domain able to bind specific DNA
sequences (He and Furmanksi 1995). In eukaryotes, Lf is capable of
upregulating expression of genes downstream of these sequences, referred
to in the literature as lactoferrin response elements (LFREs) (He and
Furmanksi 1995, Son et al. 2002, Mariller et al. 2007). Lf is also able to
bind DNA outside of the nucleus, and has the potential to act as a vector,
bringing extracellular DNA into human cells as it is translocated across the
membrane (Sinogeeva et al. 2000).
A number of bacteria that live within mammals come into contact
with Lf extensively during their lifetimes, including the stomach pathogen
H. pylori.  The possibility of Lf binding sites in bacterial genomes suggests
that Lf could bind and possibly facilitate the movement of prokaryotic
DNA with and between species. The initial paper identifying Lf as a
transcription factor suggested it might work on targeted genes in bacteria
as well (He and Furmanksi 1995).
Here we use bioinformatics tools to see if bacteria have LFREs in
their genomes. Consensus sequences were made for each of the three
LFREs, and 100 bacterial genomes were searched for their presence. To
determine if these sequences were appearing at random, the observed
occurrence of these sequences was compared to the expected occurrence of
a random sequence of the same length and base composition. The presence
of Lf binding sites at a greater or lesser frequency than random sequences
may suggest that they have a function. The location of binding sites in
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relation to downstream elements was further investigated in H. pylori, to
determine their potential to regulate transcription.
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4.2 Materials and Methods
4.2.1 Searching the Literature for Known LFREs.
The literature was searched for reported, functional LFREs via the
databases Web of Science (www.isiknowledge.com) and PubMed
(www.ncbi.nlm.nih.gov/pubmed/) using the terms ‘Lf’, ‘DNA’, ‘DNA
binding’, ‘transcription activation’, and ‘gene expression’ individually or
in some combination.  Reported LFREs were chosen that were shown to be
specifically bound by Lf, and/or promote expression of reporter genes or
actual genes.
4.2.2 Generating Consensus Sequences
All LFREs known to drive gene expression, as determined above,
were put into an online WebLogo generator  (http://weblogo.berkeley.edu/;
Schneider TD et al. 1990, Crooks et al. 2004) to generate Sequence Logos.
The generated Sequence Logos were then used to derive consensus
sequences, written in the FASTA format (Table 4.1).
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Table 4.1: FASTA format abbreviations
A
C
G
T
U
R
Y
K
M
Adenine
Cytosine
Guanine
Thymidine
Uracil
G or A (puRine)
T or C (pYrimidine)
G or T (Ketone)
A or C (aMino group)
S
W
B
D
H
V
N
-
G or C (Strong interaction)
A or T (Weak interaction)
G, T or C (not A)
G, A, or T (not C)
A, C, or T (not G)
G, C, or A (not, T, not U)
A, G, C or T (aNy)
gap
4.2.3 Generating Scrambled Consensus Sequences.
Each consensus sequence was scrambled 10 times with the
ShuffleSeq program from EMBOSS (Rice et al. 2000), through the online
Mobyl portal (mobyle.pasteur.fr). Sequences and scrambled sequences
(scLFREs) were tested to see if they were known prokaryotic response
elements using the PRODORIC prokaryotic gene expression search
engine, searching the transcription factor binding site database
(prodoric.tu-bs.de; Münch et al. 2003).
4.2.4 Searching Bacterial Genomes for LFREs and Scrambled LFREs.
LFRE and scLFRE searches were performed on 100 prokaryotic
genomes using the DNA scan program from the National Microbial
Pathogen Data Resource website (www.nmpdr.org; McNeil et al. 2006).
Information on host, pathogenicity, genome size and GC content of each
species searched was obtained from Genomes Online
(www.genomesonline.org) using the GOLD search program (Liolios et al.
2008). The number of LFREs in each genome was normalized by genome
size to determine the number of LFREs per kilo-bp to compare across
species.  The number of hits from the 10 scLFREs was used to calculate a
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95 % confidence interval for each genome, which was then compared to
the number of actual LFREs found in that genome.
4.2.5 Location of Lactoferrin Binding Sites Relative to ORFs in H. pylori
The NMPDR website was used for analyzing functional elements
adjacent to reported LFRES in H. pylori.  Because Lf binds LFREs in
double stranded DNA, the nearest gene on either strand was recorded.
When the LFRE fell within the gene, the distance to the nearest
downstream element on either strand was also recorded.  A Chi-squared
test was used to analyze the frequency at which LFREs fell within genes.
The distribution of LFREs relative to the nearest downstream element was
analyzed in 200 bp intervals.  The distribution of LFRE1b was compared
to the distribution of 3 scrambles of the LFRE1b consensus sequence.
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 4.3 Results and Discussion
4.3.1 Searching the Literature for Known Lactoferrin Response Elements
Lactoferrin was initially reported to bind three response elements,
labeled LFRE1, LFRE2 and LFRE3 (He and Furmanski 1995). Lf was able
to increase transcription of a CAT reporter gene in eukaryotic cells with
upstream LFREs (See Table 4.2) (He and Furmanski 1995). Two versions
of LFRE1 with single base-pair mutations were also shown to drive
significant levels of CAT gene expression (above 50 % of original
LFRE1), and those sequences were included for further analysis.
Two genes in the human genome, IL-1β and Skp1, have functional
LFREs within their promoters. Two response elements were found before
the Skp1 gene, both capable of individually increasing gene expression
(Mariller et al. 2007).  They also appeared to act synergistically, with the
presence of both LFREs resulting in the highest level of gene expression.
Five response elements were found upstream of the IL-1β gene, and Lf
was shown to stimulate expression of an IL-1β-luciferase reporter plasmid
containing all five response elements in eukaryotic cell lines (Son et al.
2002).  It was not determined which combination was necessary for
transcription activation (though all were bound by Lf) and all variants were
included here.  One other possible response element was identified for the
Rb gene, with the sequence TGCACTTGTAT in the Rb promoter (Mariller
et al. 2007).  Further work is needed to determine if the sequence is a
functional lactoferrin response element, and as such was not included in
further analysis.
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Table 4.2: Functional lactoferrin response elements reported in the
literature1
LFRE Cell Type Gene Source
GGCACTT(G/A)C
GTCACTTGCGGCAATTGC
TAGA(A/G)GATCAAA
ACTACAGTCTACA
K562 CAT
reporter
gene
He and
Furmanski
1995
GGCACTTGC…(-23193)2
GGAACTTGC…(-23129) 2
GGAACTTGC… (-21043)2
GTCACGTGC…(-22376)2
GGCACTGTGC…(-21348)2
COS-1
K562
U947
IL-1β3 Son et al.
2002
GGCACTGTAC…(-1067bp)2
TAGAAGTCAA…(- 646 bp)2
HeLa
MDA-MB-
231
HEK 293
Skp14 Mariller et
al. 2007
(1) The databases Web of Science and PubMed were searched for literature reporting
LFREs known to bind DNA and increase transcription of downstream genes.
(2) Distance between the LFRE and the start codon of the downstream gene.
(3) IL-1β is released by macrophages, mediating tissue damage and activating a cascade of
cytokines, including TNF-α.
(4) S-phase kinase-associated protein, part of the Skp1/Cullin-1/F-box ubiquitin ligase
complex, responsible for the ubiquitination of cellular regulators preceding proteolysis.
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4.3.2 Generating Consensus sequences
The LFREs found in front of IL-1β and Skp1 were all similar to
those identified by He and Furmanski.  As such, all reported functional
response elements were grouped according to their similarity to LFRE1,
LFRE2, or LFRE3 (Table 4.3).  Each group of sequences was entered into
the online WebLogo program to generate sequence logos.  A sequence
logo represents the frequency at which certain bases occur in certain
positions graphically, by relative height (Figure 4.1).
Table 4.3:  Aligned input sequences for the WebLogo generator
Input
LFRE1 GGCACTGTAC
GGCACTGTGC
GTCAC-GTGC
GGAACT-TGC
GTCACT-TAC
GTCACT-TGC
GGCACT-TAC
GGCACT-TGC
GGCACT-TGC
GGAACT-TGC
LFRE2 TAGAAGATCAAA
TAGAGGATCAAA
TAGAAG-TCAA
LFRE3 ACTACAGTCTACA
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(A) LFRE1
Sequence Logo
Consensus Sequences: (1a) GKMACTGTRC
  (1b) GKMACTTRC
(B) LFRE2
Sequence Logo
Consensus Sequences: (2a) TAGARGATCAA
        (2b) TAGARGTCAA
(C) LFRE3
Sequence Logo
Consensus Sequence: ACTACAGTCTACA
Figure 4.1:  Sequence logos for lactoferrin response elements.  Known
functional LFREs were grouped into three similar sequences and entered
into a WebLogo program to generate sequence logos.  The prevalence of
each base in a given position is demonstrated by relative height.
Consensus sequences were derived using FASTA format, with multiple
consensus sequences for elements of variable length.
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Consensus sequences were built from the sequence logos for use in
an online genome search program that reads FASTA format.  FASTA
format allows one to specify multiple combinations of bases for each
position within the consensus sequence (Figure 4.1).  Both LFRE1 and
LFRE2 had an optional base in position 7. Because consensus sequences
do not allow for alternate spacing (a specific base or no base at all), two
consensus sequences were built for these LFREs, a short one for ‘no-
base’ in position 7 and a longer one for ‘this-base’ in position 7 (Figure
4.1).  The final base was not added to the LFRE2 consensus sequences
because the final base was “any base” and should not affect the
occurrence of the sequence within the genome. For convenience, the
consensus sequences were labeled after the sequences they were derived
from, as LFRE1a, LFRE1b, and LFRE2 etc.  These labels are not meant
to indicate that a given sequence occurring within a genome is necessarily
functional.
Consensus sequences do not account for the relative frequency of a
given base in each position, giving all possible bases in a position equal
weight. Because of this, an unusual binding site can have an unduly large
influence on the final consensus sequence (Wasserman and Sandelin
2004).  One way that the limitations of consensus sequences can be
overcome is with the use of position weight matrices (Wasserman and
Sandelin 2004, Stormo 2000).
Weight matrices are used to calculate the frequency at which a
specific base occurs in a specific position, a mathematical approach to the
visual weighting seen in the sequence logos. This weighting appears to
have biological significance, with the weight matrix ‘score’ of a particular
sequence found to correlate with activity as a promoter (Stormo 2000).
The benefit of weight matrices diminishes with small data sets,
such as the one for lactoferrin response elements.  Furthermore, the focus
here is more on the prevalence and location of Lf binding sites, not the
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relative ability of any given found sequence to drive transcription.  Were
Lf shown to activate transcription in prokaryotes, and a database of
functional prokaryotic Lf response elements tabulated, weight matrices
could become a more reasonable choice.
The use of consensus sequences maximizes the potential number of
Lf binding sites found in each genome.  In this analysis, all possible
lactoferrin response elements known to be bound by Lf and/or act as a
regulatory element were included, even when their individual ability to
drive transcription was not known, such as with the response elements
found before the human IL-1β gene.  This inclusivity may be biologically
justified, because functional binding sites for regulatory proteins in vivo are
often more diverse than those found in vitro (Shultzaberger and Schneider
1999).  Alternatively, there is the danger of false binding sites that can
increase the number of times a given consensus sequence occurs in a
genome, including non-functional ones, and obscure potential patterns in
where they fall in relation to genes.
4.3.3 Determining if and how Frequently Lactoferrin Binding Sites occur
within Bacterial Genomes
The genomes of 100 bacteria were searched for the presence of all
five consensus sequences with the National Microbial Pathogen Data
Resource (NMPDR) genome search program, DNA scan (McNeil et al.
2006). Species from numerous classes were chosen.  These include ones
that are thought to use Lf, ones that could potentially have come into
contact with Lf through pathogenesis or host colonization, and ones that
are unlikely to have regular contact with Lf.
All species had at least one Lf binding site in their genome (see
Appendix II for complete data tables).  The vast majority of the sequences
found across the genomes were LFRE1, making up 97.3 % of the total.
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Every species had at least one LFRE1a or LFRE1b.  The shorter LFRE1b
occurred at a greater frequency than the similar but longer LFRE1a.
LFRE2 made up 2.7 % of the total LFREs found across genomes.
Though a much smaller percentage of the total LFREs, all but 7 species of
100 had at least one LFRE2a or LFRE2b.  Again, the shorter LFRE2b
occurred at a greater frequency than LFRE2a.  LFRE3 did not occur once
in any of the genomes.
This is consistent with a priori calculations of how often a given
sequence is likely to occur within a genome, depending on its length and
the number of variable positions that occur. This calculation assumes an
equal composition of all four bases, which is unlikely to be strictly true for
any given genome, but it can provide a general idea of how often the
different consensus sequences would occur relative to each other (Table
4.4).
Table 4.4: Expected occurrence of a given sequence in a genome
assuming equal composition of all bases.
Consensus Sequence Expected Occurrence (per kbp)1
LFRE1a 0.0076
LFRE1b 0.030
LFRE2a 0.00048
LFRE2b 0.0018
LFRE3 0.000015
(1) Calculated from the number of positions in the sequence where one base can occur x,
and the number of positions where two bases can occur y, such that: 4x * 2y = Z, with the
sequence expected to occur once every Z bps. The inverse was taken to provide the
expected occurrence of the sequence per kbp.
The total number of Lf binding sites, the sum of all three consensus
sequences, varied greatly from species to species.  To compare across
species, the number of total Lf binding sites for each species was divided
by the genome size of that organism to provide the number of binding sites
per kbp.  These were then averaged within each phylogenetic class
represented (Figure 4.2).
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The number of Lf binding sites per kbp ranged from a low of 0.041
among the Epsilon proteobacteria, to a high of 0.122 among the
Actinobacteria-Actinomycetales class (Figure 4.2).
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Figure 4.2: Average number of lactoferrin binding sequences per kilo
base pair by kind of bacteria.  A hundred genomes were searched for the
presence of Lf binding sites.  For each species, the total found Lf binding
sites was divided by genome size to get the number of binding sites per
kbp. Standard error bars represent the variation between species within that
class. (1) Actinobacteria-Actinomycetales (2) Alpha Proteobacteria (3)
Aquificae (4) Bacteriodetes (5) Beta proteobacteria (6) Cyanobacteria (7)
Deinococcus-Thermus (8) Delta Proteobacteria (9) Epsilon Proteobacteria
(10) Firmicutes-Bacilli (11) Firmicutes-Clostridia (12) Gamma
Proteobacteria (13) Planctomycetes (14) Spirochaetes (15) Thermotogae
The Potential of Lactoferrin to act as a DNA Vector for Horizontal Gene
Transfer
This work has demonstrated the presence of the consensus
sequences and thus Lf binding sites in every prokaryotic genome searched.
Lf has already been shown to bind the CpG islands common in bacterial
DNA, and modulate the subsequent host immune response by inhibiting
the uptake of CpG-containing DNA into cells (Britigain et al. 2001,
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Mulligan et al. 2006).  Yet research using Lf as a DNA vector shows that it
can also facilitate the internalization of DNA with lactoferrin binding sites
(Elfinger et al. 2007), and in some cases, transport it to the nucleus
(Sinogeeva et al. 2000).  The presence of the lactoferrin response
consensus sequences in bacterial genomes may mean that Lf can bind
sections of bacterial DNA, other than CpG islands, and transport DNA of
bacterial origin into eukaryotic cells.
4.3.4 Analysis of Whether Sequences are Occurring at Random within
Genomes
The likelihood that the Lf binding sites are occurring at random
was investigated. Each consensus sequence was scrambled 10 times by the
program ShuffleSeq that shuffles both nucleotides and amino acid
sequences (Table 4.5). There is evidence that scrambling lactoferrin
response elements eliminates their function as a transcription factor, with
scrambling eradicating the ability of LFRE1 to activate gene expression
(He and Furmanski 1995).  All 100 species were searched for the
prevalence of the scrambled sequences using the NMPDR database.
Table 4.5: Sequences for shuffled lactoferrin response elements1
LFRE1a
GKMACKGTRC
LFRE1b
GKMACKTRC
LFRE2a
TAGARGATCAA
LFRE2b
TAGARGTCAA
LFRE3
ACTACAGTCTACA
KACTGMKRGC
CRCGKMAGTK
KKGRMTACGC
TGRGMCCAKK
GRAMKKCGTC
RKGCMGCTAK
MGKRKGCTAC
GGMTKRKCCA
CAKKRGGMTC
CTCKKGRAMG
AGTKRMCCK
GTRAKCKMC
CAKRGKCTM
MCARKCTKG
MGTCCKRAK
CMCTKRKAG
CMRGKKCTA
GKCATRCKM
CMAKCGKTR
TKCGMCAKR
AGATAACRAGT
TCAGARAGAAT
ARCGAATGAAT
AAATAGATCRG
TRTACGAAAAG
AGCTAARGAAT
ATAACATGAGR
AATTCAGRAGA
TATAAGCGRAA
AAGACGTTAAR
ARACTAAGTG
CGTAAATRGA
ACAGATTARG
ATGTCRAGAA
ATARAAGCTG
ATRAGGCTAA
GCAAGTARTA
ARGATAACTG
CGTAAAGTRA
CAGGARTAAT
AATACCTTCAACG
GCTCCTCAAAATA
ACCCCAAGTATAT
CACATTCAGTAAC
TACACGCACTATA
GAATCACCTCTAA
AACTACGATCTCA
CATGCACATCATA
TCTGTACCACAAA
GCATTATAAACCC
(1)The five LFRE consensus sequences were shuffled on the program ShuffleSeq to
generate 10 randomized sequences of same length and base composition as the original
LFRE
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Each of these scrambled LFREs (scLFREs), as well as the initial
consensus sequences, were checked against a database of known
prokaryotic transcription factor binding sites.  This was to ensure that the
consensus sequences were not being compared against functional
sequences that may occur at a non-random frequency within the genome.
None of these sequences were recorded as known transcription factor
binding sites, so all were used for determining the number of scLFREs
within the genomes.
However, this does not preclude unknown functions for the
scrambled sequences.  In fact, of the 2000-3000 transcription factors
believed to be encoded in the human genome, only 123 have
experimentally determined binding sites in the eukaryotic transcription
binding site database, JASPAR (Zeng et al. 2008). Though not performed
here, it would be possible to scramble the genomes of the bacteria, and
tabulate how often the non-scrambled consensus sequences appear in the
scrambled genome.  This would still account for genome length and GC
content, but would eliminate the potential problem with functional
scrambled consensus sequences.
The prevalence of the 10 scrambled sequences was used to
generate a 95 % confidence interval for the number of a times a given
sequences of that length and base composition would be expected to
appear. The confidence intervals were generated for individual genomes,
thus accounting for differences in genome length and GC content across
species.  The observed occurrence of each consensus sequence was then
compared to its confidence interval to see if they occurred outside of the
expected frequency for a random sequence. When an LFRE consensus
sequence appeared in a genome higher or lower than the confidence
interval, it was marked with a (+) or a (-), respectively (Table 4.6; see
Appendix II for complete data tables).
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Table 4.6: Comparison of observed occurrences of consensus
sequences within the H. pylori strain J99 genome to occurrence of
random sequences
Consensus
Sequence
Mean
Occurrence
of Random
Sequences
95 %
Confidence
Interval
Observed
Occurrence
of Consensus
Sequence
+/-
LFRE1a 21 ± 8.8 1 -
LFRE1b 120  ± 55 42 -
LFRE2a 2.8 ± 2.9 8 +
LFRE2b 7.8 ± 7.0 19 +
LFRE3 0 ± 0 0
The main observations are as follows:
• Most species (84) had at least one consensus sequence that
occurred at a frequency outside of the confidence interval, though
often by a small margin.
• No species was found to have all five consensus sequences at a
greater or lesser prevalence than expected from the confidence
interval.
• Only a few species (12) were found to have a greater or lower
prevalence of both consensus sequences for an individual LFRE
(e.g. both LFRE1a and LFRE1b or both LFRE2a and LFRE2b
outside of the confidence interval) as was seen in H. pylori strain
J99.
 Chapter 4                                                          111
                                                                                  
Bacterial species thought to use Lf as an iron-source were
examined to see if there were any patterns of Lf binding sites occurring at
a greater or lesser frequency than would be expected from the confidence
intervals (Table 4.7).  There were no apparent patterns across these
species.
Table 4.7 Occurrence of lactoferrin binding sites in comparison to
expected frequencies1 in species thought to use lactoferrin
LFREs
Disease Species 1a 1b 2a 2b 3
Respiratory
infection Bordetella pertussis Tohama I +
Ulcer, gastric
inflammation Helicobacter pylori 26695 - +
Ulcer, gastric
inflammation Helicobacter pylori J99 - - + +
Gonorrhea Neisseria gonorrhoeae FA 1090 +
Meningitis,
septicemia Neisseria meningitidis FAM18
Mastitis Streptococcus uberis 0140J +
Periodontal
infection
Treponema denticola ATCC
35405 -
Syphilis
Treponema pallidum subsp.
pallidum str. Nichols + + -
(1) The number of LFRE consensus sequences in each genome was compared to the
expected frequency (95 % confidence interval) of sequences of the same length and base
composition in a given genome.  LFREs that occurred at a greater or lower than expected
frequency were marked with a (+) or (-), respectively.
Many of the 100 bacteria examined here could potentially come
into contact with Lf, either long-term through host colonization, or more
briefly as in the case of soil and water bacteria, which may enter the host
via the food supply.  Some of these bacteria were examined together to see
if any patterns emerged (Table 4.8).  Again, there appeared to be no overall
pattern for an increase or decrease in LFREs from the 95 % confidence
intervals.  Bacteria not expected to come into regular, extended contact
with Lf, such as those that regularly inhabit thermal vents, had a similar,
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apparently random, occurrence of LFREs outside of the expected
frequency (data not shown; refer to Appendix II for complete data tables).
Table 4.8: Occurrence of lactoferrin binding sites in comparison to
expected frequencies1 in species likely to come into contact with
lactoferrin
(1) LFRE consensus sequences were scrambled 10 times to generate 95 % confidence
intervals for a sequence with the same length and base compositions in each genome.
LFREs that occurred at a higher frequency than predicted by the confidence interval
represented with a (+) and LFREs that occurred at a lower frequency than predicted
represented with a (-) (see Appendix II for complete data tables).
LFREs1
Disease Species 1a 1b 2a 2b 3
Anthrax Bacillus anthracis str. A1055 + + -
Food poisoning Bacillus cereus ATCC 10987 + + -
Food poisoning Bacillus licheniformis ATCC 14580 -
Brucellosis Brucella abortus biovar 1 str. 9-941 -
Brucellosis Brucella melitenus 16M - -
Pneumonia Burkholderia cenocepacia AU 1054 +
Bactaeremia
Campylobacter jejuni subsp. doylei
269.97 - -
Diarrhea,
septicemia
Chromobacterium violaceum ATCC
 12472 - + -
Botulism
Clostridium botulinum A str. ATCC
 19397 - +
Diphtheria,
respiratory
infection
Corynebacterium diphtheriae NCTC
13129 - +
Ehrlichiosis Ehrlichia chaffeensis str. Arkansas + +
Urinary infection,
bactaeremia Enterococcus faecalis V583
None Escherichia coli K12 + -
Diarrhea,
hemorrhagic colitis Escherichia coli O157:H7 + - -
Meningitis Haemophilus influenzae - +
None Lactobacillus acidophilus NCFM - - -
Opportunistic/
nocosomial
infection
Pseudomonas aeruginosa UCBPP
PA14 -
Food poisoning;
Salmonellosis Salmonella bongori 12149 -
Salmonellosis,
food poisoning Salmonella typhimurium LT2 - - -
Pneumonia Streptococcus pneumoniae 23F - +
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While Lf binding sites do occasionally occur at greater or lesser
frequency than would be expected for similar sequences of the same length
and base composition, they appeared to do so at random.  This may
indicate that Lf binding sites have not been recruited or culled by natural
selection. While no strong patterns emerged across these species, it is not
necessary for a particular sequence to be enriched in a genome to be
functional.  A role for Lf in individual species, then, cannot be precluded.
 Furthermore, a number of species that come into regular contact
with Lf, such as H. pylori and Neisseria sp, are naturally transformable,
that is they take up DNA readily from their environment (Saunders et al.
1999, Smeets and Kusters 2002, Hamilton and Dillard 2006).  By
interacting with Lf, they would also come into contact with Lf-bound
DNA.  Neisseria sp preferentially take up DNA containing a 10 bp uptake
sequence frequent within their own genome, which increases the likelihood
that the DNA is derived from related bacteria (Hamilton and Dillard 2006).
A similar uptake sequence has not been identified in H. pylori (Saunders et
al. 1999).  If Lf were regularly functioning in horizontal gene transfer,
areas of the genome with more Lf binding sites would more likely be
transferred, with Lf binding sites acting as de facto uptake sequences.
4.3.5 Location of Lactoferrin Binding Sequences in the H. pylori Genome
The genome of H. pylori strain J99 was examined to see if the Lf
binding sequences that occur in the genome (70 total) were in locations
that suggest they could have a function in the regulation of transcription.
An initial search was conducted on the location of the consensus
sequence in relation to the nearest functional element, as defined by the
NMPDR database.  Most (62) Lf binding sites fell within an open reading
frame (ORF) (see Appendix II for complete data tables).  The genome of
H. pylori strain J99 has been completely sequenced, and the predicted
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proportion of the genome believed to be outside of an ORF is 0.092 (Tomb
et al. 1997).
A chi-squared test was used to determine if the actual frequency of
a lactoferrin response element occurring outside of an ORF corresponded
to the expected frequency.  This resulted in a p-value of 0.50, such that the
null hypothesis that there is no difference between the expected frequency
and actual frequency of Lf binding sites occurring outside of ORFs cannot
be rejected.
While not at a frequency greater than expected, Lf binding sites
still exist mostly within ORFs.  This suggests that were Lf to bind
extracellular H. pylori DNA, it would likely be within an ORF.  This
would increase the chance that functional DNA is being transferred during
any possible Lf mediated horizontal gene transfer.
Lf binding sites that occur within ORFs are also often relatively
near to additional downstream ORFs.  The distance between every Lf
binding site and the nearest downstream ORF was calculated, to determine
if the sequences occurred more frequently in some positions, possibly
indicating functionality (see Appendix II).
Many binding sites for transcriptional activators and repressors are
found near the promoter, about –35 bp from the start codon (Madigan et al.
2003). Cis-acting sequences that regulate transcription tend to be near to
the initiation of transcription, with current data suggesting that sequences
near a transcription start are more likely to be important regulators than
more distant sequences (Wasserman and Sanderman 2004).  Only 2 of the
70 Lf binding sites fell within 100 bps of the nearest downstream ORF.
However, regulatory elements can also occur at hundreds of base
pairs away from the genes they modulate (Madigan et al. 2003), and
indeed LFREs in the human genome have been found up to 2300 bp
upstream. Most LFREs occurred within 1000 bp of the nearest downstream
element; those that did not were scattered thinly up to 6000 bp away. To
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see if any positions appeared to be enriched for Lf binding sites, the
proportion of sequences that occurred up to 1000 bps before a gene was
tabulated, in 200 bp intervals (Table 4.9).
The largest proportion of LFREs occurred between 200-400 bp
upstream of the nearest element (Table 4.9).  A similar pattern was seen for
the two consensus sequences with the greatest number of hits within the H.
pylori genome, LFRE1b and LFRE2b.  The distribution of LFRE1b was
compared to the distribution of three scrambles of the LFRE1b consensus
sequences  (Table 4.9, Figure 4.3).
Table 4.9: Distribution of lactoferrin binding sites at 200 bp intervals
upstream of functional elements1
0-2002 200-4002 400-6002 600-8002 800-10002 1000+2
Total LFREs 0.100 0.186 0.100 0.100 0.100 0.314
LFRE1b 0.119 0.214 0.048 0.095 0.095 0.381
scLFRE1b.i3 0.107 0.107 0.143 0.036 0.179 0.321
scLFRE1b.ii3 0.163 0.143 0.122 0.102 0.163 0.429
scLFRE1b.iii3 0.120 0.179 0.145 0.120 0.060 0.350
(1) Distribution of LFRE consensus sequences, reported as the proportion of total LFREs
that fell within that distance interval from the nearest downstream functional element.
(2) Number of base pairs between the Lf binding site and the nearest downstream
functional element.
(3) LFRE1b scrambled to provide sequences of the same length and base composition.
The distribution of the scrambled sequences varied widely, yet the
increase in Lf binding sites at the 200-400 bp interval in scLFRE1b.iii
suggests that the distribution of LFRE1b is not unlikely for a sequence of
that length and base composition.
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Figure 4.3: Distribution of lactoferrin binding sites at 200 bp intervals
upstream of functional elements. Distribution of Lf binding sites,
reported as the proportion of total binding sites within 200 bp intervals
from the nearest downstream ORF.
Regulatory proteins often have affinity for sequences of DNA
outside of their target sites, which can lead to false positive identifications
(Stormo 2000).  A large number of false positives is likely to obscure any
patterns seen in the distribution of Lf binding sites.  That said, the data
presented here does not provide compelling evidence for Lf binding sites
to act as transcriptional regulators in H. pylori strain J99.
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4.4 Conclusion
 This work showed the presence of potential Lf binding sites within
a broad range of bacterial genomes.  The presence of potential Lf binding
sites suggests that Lf can bind bacterial DNA. If so, then it is reasonable to
speculate that Lf could be a vector for uptake of this DNA just as it is for
DNA of eukaryotic origin.  Lf’s ability to act as a DNA vector, then, may
be exploited for drug and DNA vaccine delivery, but it could also increase
non-specific DNA transfer. H. pylori undergoes a particularly high rate of
natural transformation with DNA from the environment (Saunders et al.
1999, Smeets and Kusters 2002, Baltrus and Guillemin 2006); its ability to
use lactoferrin brings it into close proximity of any DNA that might be
bound to it.
Since Lf interacts with both bacterial cells and eukaryotic cells, it
may shuttle DNA back and forth from prokaryotes and eukaryotes in the
extracellular environment and possibly even bring the DNA into human
cells.  Furthermore, genes have been shown to transfer between Salmonella
enterica within epithelial cells (Ferguson et al. 2002).  By increasing the
uptake of H. pylori into epithelial cells, Lf could be increasing the chances
of gene transfer within the intracellular environment.
The frequency and location of Lf binding sites appear to be
random, with no patterns emerging of sequences being enriched across
species or of them occurring in similar positions relative to downstream
ORFs in H. pylori.  While this work provides no evidence that Lf has a role
in bacterial transcription, additional laboratory based research would be
needed to determine if this indeed were the case.
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Chapter 5
Summary and Future Work
The aim of this study was to increase knowledge of the Lf-bacterial
interface, especially at the interface of bacteria that might come into
regular contact with Lf.  Bacteria that are regularly exposed to large
quantities of Lf would need to adapt to its antimicrobial properties, and
those that adapt might even exploit it (Heinemann 2008).  This is
interesting as it applies both to the microbial ecology of the human body,
and to issues of biosafety.  Recombinant hLf is currently being produced in
plants and soon may also be produced in cows and harvested from the milk
(Heinemann 2008).  This will likely increase the range of bacteria that are
exposed, and potentially adapted, to Lf.
Our first thought was that the functions Lf is known to have in
eukaryotes, such as iron absorption and transcription activation, might
extend to prokaryotes and thus these are the functions most likely to be
exploited. H. pylori was chosen as a model organism to investigate these
speculations.  It lives in a high-Lf environment and has previously been
reported to use Lf as an iron-source. Here, the affects of Lf on H. pylori
growth and internalization were investigated.  Also, using bioinformatics
tools, a number of bacterial genomes were searched for the presence of Lf
binding sites, and these sites were examined in relation to Lf’s potential as
a DNA vector or transcriptional regulator in prokaryotes.
In this study, growth of H. pylori strains 60190, SS1 and Tx30a
decreased in the presence of partially iron-saturated hLf.  Growth of strain
60190 was also tested with fully iron-saturated hLf.  In iron-limited media,
growth increased to levels comparable to the iron-replete control when
holo-hLf was added as an iron source.  A slight increase in growth was
also seen in iron-replete medium when supplemented with holo-hLf.
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 The difference in growth recovery between partially and fully
saturated hLf could be due to an increase in the quantity of Lf-bound iron.
Insufficient iron, however, does not account for the decrease in growth
seen with partially saturated hLf.  It could be that H. pylori is able to access
the iron bound to holo-Lf more efficiently.  The mechanism by which H.
pylori acquires iron from Lf is unknown, but may include an LBP, flavin
reductases, or other mechanisms.
Previous work has suggested that H. pylori expresses an LBP that
specifically interacts with hLf (Dhaenens et al. 1997).  Lf binding proteins
are best characterized in the Neisseriaceae family.  Interestingly, while all
natural isolates of Neisseria meningitidis make functional Lf receptors,
only half of Neisseria gonorrhoeae do (Anderson et al. 2003).  Similarly,
though N. meningitidis invariably expresses Lf receptors, a number of
bacterial species that inhabit the same nasopharyngeal niche do not (Ling
and Schryvers 2006).  This suggests that while Lf can be an iron-source in
these conditions, it does not have to be.  Ling and Schryvers suggested that
there is evidence for opposing selective forces for LBP expression in
different niches that may be separate from iron-binding, and, while iron-
acquisition appears to be an important role of LBPs in some bacteria, this
does not preclude LBPs having additional functions in vivo.
The presence of an LBP may affect the ability of hLf to adhere to
and invade epithelial cells.  Lf is bound and internalized by receptors on
epithelial cell surfaces, and by binding hLf bound to cell surfaces, H. pylori
may be able to adhere to and invade at a higher frequency.
Here, H. pylori was found to adhere to epithelial cells at a higher
frequency with both bLf and hLf, irrespective of the level of iron in the
medium.  This may be due to the ability of bLf and hLf to non-specifically
bind components of bacterial and epithelial cell surfaces.  Internalization
was increased to a similar degree with bLf in both conditions, and hLf in
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iron-replete conditions, suggesting that an increase in adhesion is related
to an increase in internalization in these situations.
Interestingly, internalization with hLf in iron-limiting conditions
was 18-fold higher than the iron-limited control, far higher than any other
condition.  Adherence was not increased to the same degree as
internalization, suggesting that a larger proportion of total adherent
bacteria are being internalized under these conditions.  The increased
internalization seen in iron-limiting conditions could be due to an iron-
regulated increase in the production of cellular receptors for binding and
internalizing Lf, known to occur in some cell lines (Mikogami et al. 1995,
McAbee and Ling 1997, Olakanmi et al. 2002).  H. pylori could be binding
the Lf bound to cell receptors via an LBP, also believed to be upregulated
in iron-limiting conditions, or through non-specific binding of hLf to the
bacterial outer membrane. This could be confirmed with microscopy work,
to see if H. pylori and Lf co-localize on cell surfaces, possibly in relation to
cell or bacterial receptors for Lf.
Lf has been shown to affect the internalization of a number of
facultative intracellular bacteria, usually decreasing it by blocking binding
sites on cell surfaces or degrading necessary bacterial proteins (Ajello et al.
2002, Di Biase et al. 2004, Superti et al. 2004).  Should the increase in
internalization by bLf and especially hLf seen here be confirmed, the effect
of Lf would be markedly different from what has been seen using other
species.
Lf was also investigated in relationship to its role as a DNA vector
or transcription factor.  Lf has been shown to bind sequences of DNA with
a high affinity, and increase the transcription of downstream eukaryotic
genes both in vitro and in vivo (He and Furmanksi 1995, Son et al. 2002,
Mariller et al. 2007).  The possibility exists that Lf may also be able to act
as a transcription factor in prokaryotes.  Bioinformatics tools were used to
determine if Lf binding sites occur within 100 bacterial genomes, if they
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were more or less prevalent than expected, and, in the genome of H. pylori,
if they occur in locations that would suggest a function in transcriptional
regulation.
The number of Lf binding sites for each species was compared to
the likelihood that a random sequence of the same length and base
composition would occur in a particular genome. Though the majority of
species had at least one sequence that was more or less abundant than
expected, these incidences appeared to be randomly distributed across
species.
As sequences do not need to be enriched in a genome to be
functional, the location of individual binding sites in the genome of H.
pylori in relation to downstream ORFs was also investigated.  Only 2 of 70
Lf binding sites occurred near a promoter (within 100 bps upstream).
Though elements appeared to be enriched in the interval between 200-400
bp away from the nearest downstream ORF, similar distributions were seen
for random sequences of the same length and base composition.
 No patterns emerged from this study that suggested that Lf binding
sites were occurring in higher than expected numbers across species, or, in
the case of H. pylori, in locations likely to be relevant to a transcription
factor.  Yet this does not preclude their use in individual species.  Further
work in vitro and in vivo would be needed to confirm or negate Lf’s ability
to act as a transcription factor in prokaryotes. For one, it is not yet known if
bacteria regularly internalized Lf, which could be examined with labeled
Lf.  Additionally, bacteria could be transformed with Lf expression vectors
and plasmids containing Lf binding sequences upstream of reporter genes,
similar to the work first describing Lf-mediated upregulation of
transcription in eukaryotes.
This study confirmed the presence of high affinity Lf-binding sites
in all prokaryotic genomes surveyed.  Lf interacts with both bacterial cells
and mammalian cells, and could bind and shuttle DNA in the extracellular
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environment, possibly even bringing DNA into human cells.
Furthermore, Lf increases the chances of gene transfer within the
intracellular environment by increasing the uptake of H. pylori into
epithelial cells.
Future Work
Much of the work done here can be used to chart future
confirmatory experiments. One way to expand on this research would be to
determine if there are strain-specific effects of Lf, effects that might differ
between laboratory strains and clinical isolates. Previous work has shown
that strains react differently to iron-limitation, including storage of
intracellular iron, levels of growth in low-iron environments and changes
in outer membrane profiles (Bland et al. 2004, Lee et al. 2009).
 H. pylori exhibits a high degree of inter- and intra-strain
variability, and significant genomic changes can occur after a relatively
small number of laboratory passages as well as from strains within the
same host over time (Kuipers et al. 2000, Bourzac and Guillemin 2005,
Baltrus et al. 2007). All three strains, 60190, Tx30a, and SS1 are common
laboratory strains and extensive passaging may have changed their
interactions with hLf.  Testing clinical isolates associated with different
virulence phenotypes could shed light on how Lf interactions affect
bacterial pathogenesis.
 The ability to use hLf as an iron-source could give H. pylori strains
a selective advantage in the stomach, and may increase their pathogenicity.
Patients with H. pylori-related, iron-deficient anemia are colonized with
strains that produce more IROMPs and are more efficient users of iron
(Lee et al. 2009).  Some of these IROMPs may be involved in sequestering
iron from hLf.  Severe gastritis has been associated both with an increase
in intracellular H. pylori in vivo, and higher levels of hLf in the gut (Chan
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1992, Wen et al. 2004).  Furthermore, intracellular bacteria may be able to
evade antibiotic treatment, and thus persist for longer (Heinemann 1999,
Peterson and Krogfelt 2003).
A good deal of information on how H. pylori is interacting with Lf
would depend on isolation and characterization of the putative LBP.  While
the effects seen here are consistent with the presence of an LBP, they could
be mediated by other factors.  Isolation of an LBP and the LBP gene would
allow for investigation of the mechanisms by which H. pylori uses Lf-
bound iron and invades epithelial cells in the presence of Lf.  Similar
studies could also be performed with other species of bacteria known to
use hLf and invade epithelial cells, such as Neisseria sp.  The LBP of
Neisseria sp is well characterized, and work could be done on isogenic
strains to see if the affects on internalization were LBP mediated.  It would
also serve as a point of comparison to how other Lf-adapted bacteria
interact with Lf.
The bioinformatics work done here suggested that Lf binding sites
exist in a wide range of bacteria.  If time had permitted, Lf would have
been tested for its potential to act as a vector for DNA uptake by H. pylori
by measuring rates of transformation in the presence or absence of
plasmid-bound Lf.  Standard plasmids, with selective marker genes, would
be modified with putative Lf binding sequences and used to visualize and
select for the transfer of genetic material. During the course of this
investigation, an application was prepared and filed with ERMA NZ to
investigate the movement of plasmids containing Lf-binding sites from
bacteria to epithelial cells, yeast cells, phage, and between ten species of
gut and soil bacteria.  This will allow continuing work to be done on Lf’s
potential to act as a DNA vector for both prokaryotes and eukaryotes.
Interactions between bacteria and Lf are important in light of the
current interest in utilizing Lf’s wide range of anti-microbial activities for
commercial and therapeutic purposes. A number of plants and animals
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have been investigated as potential biofactories for the mass production
of recombinant hLf (Heinemann 2008).  The mass production of hLf in
non-human hosts will both increase the range of environments, numbers
and kinds of bacteria that will be exposed to Lf, and increase the quantity
of Lf they will be exposed to.
Bacteria that live in high Lf environments have adapted to its
presence, ranging from tolerance of the normally anti-microbial peptide to
use of it as a source of iron and possibly for other purposes (Ling and
Schryvers 2006).  While resistance to anti-microbial peptides is reportedly
rare, commercial use and the associated increase in bacterial exposure to Lf
could greatly amplify the selective pressure for resistance among bacteria
not already tolerant (Heinemann 2008).  Already, it has been found that
resistance to bovine Lfcin is rapidly induced in Staphylococcus aureus in
the laboratory, and has been reported in clinical isolates of S. aureus small
colony variants (Samuelson et al. 2005a,b).  Because hLf is part of the
human immune system, widespread resistance to its antimicrobial
properties could compromise our natural defense against infection (Bell
and Gouyon 2003).
Depending on how the bacteria became resistant to Lf, this
resistance could potentially spread to other species via horizontal gene
transfer.  Issues of horizontal gene transfer are especially pertinent for risk
assessment of genetically modified organisms, involving the spread of
resistance as well as the movement of transgenes into other, non-GMO
species.  Because Lf can act as DNA vector, the presence of Lf binding
sites within bacterial DNA suggests that it might increase horizontal gene
transfer not just within its natural host but also within new organisms and
new environments.  Lf could bind DNA in animals and possibly plants in
vivo, and shuttle it to microbes in and on transgenic plants and animals
used as biofactories (Heinemann 2008).
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Our ability to assess the risks of undertakings such as biopharming,
the use of GMOs to produce pharmaceuticals, first relies on a solid
understanding of Lf’s interactions with prokaryotes: those that are adapted
to its presence and those that might become adapted to it.
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Appendix I
Additional Material and Methods
Chapter 2
Media
Brucella Broth Solution
                (per liter)
Pancreatic digest of casein 10 g
Peptic digest of animal tissue 10 g
Dextrose 1.0 g
Yeast extract 2.0 g
Sodium Chloride 5.0 g
Sodium bisulfite 0.1 g
Columbia Blood Agar Plates
(per liter)
Special peptone 23.0 g
Starch 1.0 g
Sodium Chloride 5.0 g
Agar No. 1 39.0 g
Defibrinated sheep blood 50.0 ml
(Prepared by Fort Richard, NZ)
Protein Assay Solutions
Solution A (w/v)
Sodium carbonate 2 %
Sodium hydroxide 0.4 %
Potassium sodium-tartrate 0.16 %
Sodium dodecyl sulphate (SDS) 1 %
in dH20
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Solution B (w/v)
Copper sulphate crystals 0.5 %
in dH20
Solution C
Solution A     50 ml
Solution B   1 ml
SDS-PAGE Solutions
Resolving Gel (12.5 %)
40 % Acrylamide/Bis solution (BioRad)  3.13 ml
Resolving Gel Buffer (below)  2.5 ml
dH2O   4.37 ml
10 % Ammonia Persulphate (APS)         100 µl
NNN’N’-tetramethylethylene (TEMED)      20 µl
Stacking Gel (4.5 %)
40 % Acrylamide/Bis solution (BioRad)  450 µl
Stacking Gel Buffer (below)                     1 ml
dH2O                                                    2.55 ml
APS                                                  100 µl
TEMED                                                20 µl
Resolving Gel Buffer (w/v)
Tris 18.3 %
SDS 0.4 %
in dH20
Stacking Gel Buffer (w/v)
Tris 6.06 %
SDS 0.4 %
in dH20
Reservoir Buffer (1.8 liters)
Tris 5.4 g
Glycine 25.92 g
SDS 1.8 g
dH20 1.76 l
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Silver Staining Solutions
Farmers Reducer (w/v)
Potassium ferricyanide 0.15 g
Sodium thiosulphate 0.3 %
Sodium carbonate 0.05 %
in dH20
Chapter 3
N-P40 solutions
Tris-HCl (7.5 pH) 50mM
NaCl 100mM
nanodine P40 1 %
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Appendix II
Raw and Supplemental Data
Chapter 2
Table A2.1: Effect of increasing iron-limitation on the growth of H.
pylori strain 60190.
14-Aug 16-Aug 28-SepMean STDEV STERR
IR Control 100 100 100 100 0 0
10uM DE 43 14 105 54 47 27
20uM DE 4 15 4 8 6 4
35uM DE 4 21 2 9 11 6
50uM DE 2 29 2 11 15 9
Table A2.2:  Iron supplementation (10 µM) rescues growth of H. pylori
strain 60190 in iron-limiting conditions
14-Aug 16-Aug 28-SepMean STDEV STERR
IR Control 100 100 100 100 0 0
10uM DE 84 124 111 106 20 12
20uM DE 90 134 108 111 22 13
35uM DE 37 136 107 93 51 29
50uM DE 2 48 5 19 26 15
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Figure A2.1: Effect of increasing levels of iron-limitation on the growth
of H. pylori strains SS1 and Tx30a. Bacteria were grown in iron-replete
media (IR control) and iron-limited media (with10-50 µM DE) supplemented
with 10 µM FeCl3 to determine if it was sufficient iron for recovery of
growth. Growth was measured over 72 hrs from one representative trial
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Figure A2.2: Growth recovery of H. pylori strains SS1 and Tx30a with
iron supplementation in iron-limiting conditions. Bacteria were grown in
iron replete media (IR control) and iron-limited media (with10–50 µM DE)
supplemented with 10 µM FeCl3 to determine if it was sufficient iron for
recovery of growth. Growth was measured over 72 hrs in one representative
trial.
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Table A2.3: Growth of strain 60190 with 0.5 mg/ml of partially
saturated human lactoferrin.
24-Sep 4-Nov
7-Nov
(1)
7-Nov
(2) Mean STDEV STERR
IR Control 100 100 100 100 100.0 0.0 0.0
IL Control 6 4 29 11.4 10.7 4.8
IR + hLf 62 106 78 82.0 22.3 12.9
IL + hLf 8 0 3 3 3.5 3.3 1.7
IL + FeCl3 116 108 82 106.0 20.7 9.3
Table A2.4: Growth of strain SS1 with 0.5 mg/ml of partially iron-
saturated human lactoferrin, with growth inhibition in iron-replete
conditions.
28-Oct 4-Nov
7 Nov
(1)
7 Nov
(2) Mean STDEV STERR
IR Control 100 100 100 100 100.0 0.0 0.0
IL Control 3 25 2 10.0 13.0 7.5
IR + hLf 82 84 82 82.7 1.2 0.7
IL + hLf 1 2 2 1.7 0.6 0.3
IL + FeCl3 97 86 93 92.0 5.6 3.2
Table A2.5: Growth of strain Tx30a with 0.5 mg/ml of partially iron-
saturated human lactoferrin, with growth inhibition in iron-limiting
conditions
4 Nov (1) 4 Nov (2) 7 Nov (1) Mean STDEV STERR
IR control 100 100 100 100.0 0.0 0
IL control 40 41 95 58.7 31.5 18.2
IR+hLf 103 95 109 102.3 7.0 4.1
IL+hLf 1 1 45 15.7 25.4 14.7
IL+FeCl3 82 86 84.0 2.8 1.6
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Table A2.6: Possible growth inhibition of strain 60190 with 1 mg/ml of
partially iron-saturated human lactoferrin.
9-Dec 12-DecAVE STDEV STERR
IR Control 100 100 100.0 0.0 0.0
IL Control 1 1 1.3 0.0 0.0
IR+hLf 80 63 71.8 11.9 6.9
IL+hLf 1 1 1.3 0.1 0.1
IL+FeCl3 92 80 86.2 8.3 4.8
Table A2.7: Growth recovery of strain 60190 in iron-limiting
conditions with 0.5 mg/ml of fully iron-saturated human lactoferrin.
10-Feb 11-Feb 12-FebMean STDEV STERR
IR Control 100 100 100 99.9 0.1 0.0
IL Control 24 40 37 33.5 8.1 4.7
IR+hLf 142 131 107 126.5 18.1 10.4
IL+hLf 103 171 89 120.9 44.1 25.4
IL+FeCl3 85 89 78 84.1 6.0 3.5
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Table A3.1: Frequency of Internalization into Epithelial cells of H.
pylori strain 60190 with hLf in FBS-mediated iron-limiting conditions.
12-Sep 6-Oct 21-OctMean STDEV STERR
Total Bacteria Recovered
(-) FCS 1428 300 18500 6743 10198 5888
(+)FCS 15675 3050 149000 55908 80867 46688
(-)FCS(+)LF 16275 200 5300 7258 8214 4743
(+)FCS(+)LF 9925 3125 6350 6467 3402 1964
Percentage Internalization of Innoculum
(-) FCS 0.002 0.007 0.235 0.081 0.133 0.077
(+)FCS 0.021 0.067 1.900 0.662 1.072 0.619
(-)FCS(+)LF 0.022 0.004 0.068 0.031 0.033 0.019
(+)FCS(+)LF 0.013 0.068 0.081 0.054 0.036 0.021
Table A3.2: Frequency of Internalization into Epithelial cells of H.
pylori strain 60190 with Lf in DE-mediated iron-limiting conditions.
30-Oct 3-Nov 7-Nov 11-DecMean STDEV STERR
Total Recovered Bacteria
(-)DE 5800 3000 2325 16200 6831 6424 3212
(+)DE 550 300 775 9170 2699 4319 2159
(-)DE (+)bLF 16400 20600 1075 16700 13694 8627 4314
(+)DE (+)bLF 2330 4750 1500 16400 6245 6909 3454
(-)DE (+)hLF 12900 14500 825 36400 16156 14812 7406
(+)DE (+)hLF 4250 26500 19300 20300 17588 9445 4722
Percent Internalization of Innoculum
(-)DE 0.091 0.061 0.062 0.007 0.055 0.035 0.017
(+)DE 0.009 0.006 0.021 0.004 0.010 0.007 0.004
(-)DE (+)bLF 0.257 0.417 0.029 0.008 0.178 0.196 0.098
(+)DE (+)bLF 0.037 0.096 0.039 0.007 0.045 0.037 0.019
(-)DE (+)hLF 0.203 0.294 0.022 0.166 0.171 0.113 0.057
(+)DE (+)hLF 0.067 0.535 0.513 0.009 0.281 0.282 0.141
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Table A3.3: Frequency of Internalization into Epithelial cells of H.
pylori strain 60190 with denatured Lf in DE-mediated iron-limiting
conditions.
21-Jan 27-Jan 28-JanMean STDEV STERR
Total Bacteria Recovered
(-)DE 22600 10005 21300 17968 6927 3999
(+)DE 18500 2900 6900 9433 8103 4678
(-)DE(+)dhLf 12800 8500 8850 10050 2388 1379
(+)DE(+)dhLf 9950 2850 4300 5700 3751 2166
Percent Internalization of Inoculum
(-)DE 0.995 2.080 4.750 2.608 1.932 1.116
(+)DE 0.811 0.604 1.540 0.985 0.492 0.284
(-)DE(+)dhLf 0.561 1.770 1.975 1.435 0.764 0.441
(+)DE(+)dhLf 0.436 0.580 0.959 0.658 0.270 0.156
Table A3.4: Frequency of Adhesion onto Epithelial cells of H. pylori
strain 60190 with Lf in DE-mediated iron-limiting conditions.
28-Nov1 Dec (1) 1 Dec (2) Mean STDEV STERR
Total Bacteria Recovered
(-)DE 35200 49500 502000 100 0 0
(+)DE 10200 10500 205000 30 10 6
(-)DE(+)bLF 35000 620000 923000 512 643 371
(+)DE(+)bLF 22400 40100 2820000 235 283 163
(-)DE(+)hLF 122000 104000 1770000 303 81 47
(+)DE(+)hLF 42100 43300 1280000 154 89 51
Percent Adhesion of Innoculum
(-)DE 0.567 0.481 6.920 2.656 3.693 2.132
(+)DE 0.164 0.102 2.820 1.029 1.552 0.896
(-)DE(+)bLF 0.564 6.020 12.700 6.428 6.078 3.509
(+)DE(+)bLF 0.361 0.389 38.900 13.217 22.242 12.842
(-)DE(+)hLF 1.970 1.010 24.400 9.127 13.236 7.642
(+)DE(+)hLF 0.678 0.420 17.700 6.266 9.903 5.717
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Table A4.1: Occurance of LFREs Across Genomes.  Genomes were
searched for the presence of five LFREs.  The total number of LFREs
was calculated and divided by the genome size to get number of LFREs
per kilo-base-pair.
LFREs
Species 1a 1b 2a 2b 3 Total
per
kbp
Actinobacteria-Actinomycetales
Corynebacterium
diphtheriae NCTC 13129 72 217 0 12 0 301 0.121
Corynebacterium
efficiens YS-314 133 191 2 5 0 331 0.105
Mycobacterium bovis
AF2122/97 181 285 1 1 0 468 0.108
Mycobacterium
tuberculosis CDC1551 179 292 1 1 0 473 0.107
Streptomyces avermitilis
MA-4680 369 906 0 2 0 1277 0.141
Streptomyces coelicolor
A3(2) 410 863 0 0 0 1273 0.147
Alpha Proteobacteria
Agrobacterium
tumefaciens str. C58 320 352 5 18 0 695 0.141
Bradyrhizobium
japonicum USDA 110 247 558 3 5 0 813 0.089
Brucella abortus biovar 1
str. 9-941 84 217 0 4 0 305 0.093
Brucella melitenus 16M 83 216 0 4 0 303 0.092
Ehrlichia canis str. Jake 6 44 12 9 0 71 0.054
Ehrlichia chaffeensis str.
Arkansas 6 55 5 4 0 70 0.060
Ehrlichia ruminantium
str. Gardel 5 60 2 4 0 71 0.047
Nitrobacter
hamburgensis X14 133 273 0 1 0 407 0.092
Rhizobium
leguminosarum bv. viciae
3841 177 453 6 5 0 641 0.127
Rhodospirillum rubrum 91 67 2 1 0 161 0.037
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Rickettsia akari str.
Hartford 13 57 4 2 0 76 0.062
Rickettsia rickettsii 9 76 4 2 0 91 0.072
Aquificae
Aquifex  aeolicus VF5 10 137 2 4 0 153 0.099
Bacteriodetes
Bacteroides fragilis
NCTC 9343 95 523 6 20 0 644 0.124
Bacteroides fragilis
YCH46 97 530 5 25 0 657 0.125
Bacteroides
thetaiotaomicron VPI-
5482 143 701 4 18 0 866 0.138
Cytophaga hutchinsonii
ATCC 33406 89 330 2 7 0 428 0.097
Flavobacterium
psychrophilum JIP02/86 49 121 5 3 0 178 0.062
Bacteroides fragilis
NCTC 9343 95 523 6 20 0 644 0.124
Bacteroides fragilis
YCH46 97 530 5 25 0 657 0.125
Bacteroides
thetaiotaomicron VPI-
5482 143 701 4 18 0 866 0.138
Cytophaga hutchinsonii
ATCC 33406 89 330 2 7 0 428 0.097
Flavobacterium
psychrophilum JIP02/86 49 121 5 3 0 178 0.062
Beta Proteobacteria
Bordetella bronchiseptica
RB50 216 368 1 1 0 586 0.110
Bordetella parapertussis
12822 202 352 2 0 0 556 0.116
Bordetella pertussis
Tohama I 149 261 1 4 0 415 0.102
Burkholderia ambifaria
AMMD 260 945 1 1 0 1207 0.157
Burkholderia
cenocepacia AU 1054 259 910 2 3 0 1174 0.161
Chromobacterium
violaceum ATCC 12472 90 204 3 1 0 298 0.063
Neisseria gonorrhoeae
FA 1090 50 147 0 1 0 198 0.092
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Neisseria meningitidis
FAM18 53 162 0 2 0 217 0.099
Nitrosomonas europaea
ATCC 19718 67 300 0 2 0 369 0.131
Nitrosomonas eutropha
C71 63 251 3 8 0 325 0.122
Cyanobacteria
Nostoc sp. PCC 7120 141 386 11 36 0 574 0.070
Prochlorococcus marinus
str. MIT 9211 14 100 12 9 0 135 0.080
Synechococcus elongatus
PCC 6301 49 140 2 12 0 203 0.075
Synechococcus sp.
CC9605 79 116 1 8 0 204 0.078
Deinococcus-Thermus
Deinococcus
geothermalis DSM11300 162 263 0 6 0 431 0.175
Deinococcus radiodurans
R1 207 303 0 8 0 518 0.169
Thermus thermophilus
HB27 33 70 0 5 0 108 0.057
Thermus thermophilus
HB8 37 70 0 6 0 113 0.061
Delta Proteobacteria
Bdellovibrio
bacteriovorus HD100 87 286 0 3 0 376 0.099
Desulfovibrio
desulfuricans G20 0 280 0 0 0 280 0.075
Desulfovibrio vulgaris
subsp. vulgaris str.
Hildenborough 227 474 0 5 0 706 0.197
Desulfuromonas
acetoxidans 200 380 3 0 0 583 0.165
Geobacter
metallireducens GS-15 129 266 3 4 0 402 0.101
Pelobacter carbinolicus
DSM 2380 91 217 2 5 0 315 0.086
Syntrophobacter
fumaroxidans MPOB 131 359 1 5 0 496 0.099
Epsilon Proteobacteria
Campylobacter jejuni
subsp. doylei 269.97 3 32 8 15 0 58 0.031
Campylobacter jejuni
subsp. jejuni 260.94 4 34 7 9 0 54 0.033
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Campylobacter jejuni
subsp. jejuni 81-176 6 38 5 10 0 59 0.037
Helicobacter pylori
26656 27 37 8 2 0 74 0.044
Helicobacter pylori J99 1 42 8 19 0 70 0.043
Thiomicrospira
crunogena XCL-2 32 124 5 8 0 169 0.070
Wolinella succinogenes
DSM 1740 11 39 1 15 0 66 0.031
Firmicutes Bacilli
Bacillus anthracis str.
A1055 95 415 14 9 0 533 0.101
Bacillus anthracis str.
'Ames Ancestor' 95 424 14 9 0 542 0.104
Bacillus cereus ATCC
10987 81 439 18 8 0 546 0.105
Bacillus cereus ZK 83 412 12 10 0 517 0.098
Bacillus licheniformis
ATCC 14580 54 169 2 9 0 234 0.055
Bacillus thuringiensis
serovar konkukian str. 97-
27 87 408 14 6 0 515 0.098
Enterococcus faecalis
V583 38 193 3 19 0 253 0.079
Lactobacillus acidophilus
NCFM 0 152 0 0 0 152 0.076
Lactobacillus brevis
ATCC 367 0 266 0 0 0 266 0.116
Lactobacillus gasseri
ATCC 33323 0 126 0 0 0 126 0.066
Lactococcus lactis subsp.
lactis Il1403 17 136 2 11 0 166 0.070
Staphylococcus aureus
RF122 27 155 3 10 0 195 0.078
Staphylococcus
haemolyticus JCSC1435 24 137 8 11 0 180 0.067
Streptococcus
pneumoniae 23F 20 148 2 16 0 186 0.085
Streptococcus uberis
0140J 18 112 4 14 0 148 0.087
Firmicutes Clostridium/Mollicutes
Clostridium
acetobutylicum ATCC
824
28 174 2 15 0 219 0.056
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824
Clostridium botulinum A
str. ATCC 19397 14 99 24 12 0 149 0.039
Spiroplasma kunkelii
CR2-3x 1 96 2 3 0 102 0.064
Gamma Proteobacteria
Acinetobacter baumannii
ATCC 17978 68 330 6 17 0 421 0.106
Azotobacter vinelandii 143 277 0 4 0 424 0.094
Escherichia coli K12 140 349 2 3 0 494 0.106
Escherichia coli O157:H7 183 404 0 1 0 588 0.095
Francisella tularensis
subsp. holarctica FTA 6 72 4 6 0 88 0.047
Francisella tularensis
subsp. tularensis FSC198 6 71 4 6 0 87 0.046
Haemophilus influenzae
86-028NP 3 136 3 18 0 160 0.084
Legionella pneumophila
str. Lens 38 174 5 10 0 227 0.068
Methylococcus
capsulatus str. Bath 125 166 0 2 0 293 0.089
Photobacterium
profundum 3TCK 124 517 7 11 0 659 0.108
Pseudomonas aeruginosa
2192 181 354 1 3 0 539 0.079
Pseudomonas aeruginosa
PAO1 165 312 1 1 0 479 0.076
Pseudomonas aeruginosa
UCBPP-PA14 163 340 1 1 0 505 0.077
Salmonella bongori
12149 126 320 3 4 0 453 0.103
Salmonella enterica
subsp. enterica serovar
Choleraesuis str. SC-B67 125 308 0 3 0 436 0.092
Salmonella typhimurium
LT2 127 302 0 0 0 429 0.088
Vibrio alginolyticus
12G01 123 555 9 18 0 705 0.137
Vibrio cholerae AM-
19226 100 324 2 9 0 435 0.107
Vibrio splendidus 12B01 0 479 0 0 0 479 0.086
Vibrio vulnificus YJ016 139 477 2 10 0 628 0.121
Planctomycetes
Pirellula sp. 1 159 621 2 8 0 790 0.111
 Appendix II                                                          143
                                                                                  
Spirochaetes
Borrelia afzelii PKo 2 36 2 4 0 44 0.049
Borrelia burgdorferi B31 6 28 2 12 0 48 0.053
Leptospira interrogans
serovar Copenhageni str.
Fiocruz L1-130 19 212 11 20 0 262 0.061
Treponema denticola
ATCC 35405 29 124 1 5 0 159 0.056
Treponema pallidum
subsp. pallidum str.
Nichols 50 195 0 2 0 247 0.217
Thermotogae
Thermotoga maritima
MSB8 29 133 4 7 0 173 0.093
Thermotoga petrophila
RKU-1 27 120 3 5 0 155 0.083
Table A4.2: Occurrence of lactoferrin binding sites in comparison to
expected frequencies1 by LFRE consensus sequence
LFRE1a
Mean
Occ. of
Random
LFREs
95 %
CI
Obs.
Occ. of
Actual
LFREs
+/-
Actinobacteria-Actinomycetales
Corynebacterium diphtheriae
NCTC 13129 83.90 15.01 72
Corynebacterium efficiens YS-314 91.60 34.63 133 +
Mycobacterium bovis AF2122/97 127.80 45.85 181 +
Mycobacterium tuberculosis
CDC1551 130.00 46.75 179 +
Streptomyces avermitilis MA-4680 299.00 179.4 369
Streptomyces coelicolor A3(2) 299.60 186.1 410
Alpha Proteobacteria
Agrobacterium tumefaciens str.
C58 142.00 69.19 320 +
Bradyrhizobium japonicum USDA
110 271.20 169.4 247
Brucella abortus biovar 1 str. 9-941 62.80 26.76 84
Brucella melitenus 16M 63.50 27.05 83
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Ehrlichia canis str. Jake 9.10 3.94 6
Ehrlichia chaffeensis str. Arkansas 10.20 4.03 6
Ehrlichia ruminantium str. Gardel 10.50 3.91 5 -
Nitrobacter hamburgensis X14 143.20 78.53 133
Rhizobium leguminosarum bv.
viciae 3841 206.00 127.4 177
Rhodospirillum rubrum 116.40 63.67 91
Rickettsia akari str. Hartford 11.10 6.77 13
Rickettsia rickettsii 12.20 5.34 9
Aquificae
Aquifex  aeolicus VF5 41.60 30.43 10 -
Bacteriodetes
Bacteroides fragilis NCTC 9343 83.70 17.14 95
Bacteroides fragilis YCH46 85.90 16.29 97
Bacteroides thetaiotaomicron VPI-
5482 103.60 22.68 143 +
Cytophaga hutchinsonii ATCC
33406 52.70 13.67 89 +
Flavobacterium psychrophilum
JIP02/86 23.80 6.39 49 +
Beta Proteobacteria
Bordetella bronchiseptica RB50 141.90 69.69 216
Bordetella parapertussis 12822 127.40 59.44 202 +
Bordetella pertussis Tohama I 123.1 80.67 149
Burkholderia ambifaria AMMD 197.90 150.5 260
Burkholderia cenocepacia AU
1054 194.60 158.2 259
Chromobacterium violaceum
ATCC 12472 140.40 83.51 90
Neisseria gonorrhoeae FA 1090 33.20 15.69 50 +
Neisseria meningitidis FAM18 38.80 18.80 53
Nitrosomonas europaea ATCC
19718 64.50 20.39 67
Nitrosomonas eutropha C71 62.40 22.67 63
Cyanobacteria
Nostoc sp. PCC 7120 105.80 33.73 141 +
Prochlorococcus marinus str. MIT
9211 32.20 9.90 14 +
Synechococcus elongatus PCC
6301 90.80 25.22 49 -
Synechococcus sp. CC9605 84.90 32.11 79
Deinococcus-Thermus
Deinococcus geothermalis
DSM11300
92.70 30.47 162 +
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DSM11300
Deinococcus radiodurans R1 87.30 32.47 207 +
Thermus thermophilus HB27 111.80 78.68 33
Thermus thermophilus HB8 109.70 74.43 37
Delta Proteobacteria
Bdellovibrio bacteriovorus HD100 92.90 33.43 87
Desulfovibrio desulfuricans G20 89.10 29.38
Desulfovibrio vulgaris subsp.
vulgaris str. Hildenborough 114.10 43.67 227 +
Desulfuromonas acetoxidans 137.60 60.02 129
Geobacter metallireducens GS-15 81.00 22.28 91
Pelobacter carbinolicus DSM 2380 160.90 87.21 131
Syntrophobacter fumaroxidans
MPOB 92.90 33.43 87
Epsilon Proteobacteria
Campylobacter jejuni subsp. doylei
269.97 13.00 3.97 3 -
Campylobacter jejuni subsp. jejuni
260.94 12.30 5.82 4 -
Campylobacter jejuni subsp. jejuni
81-176 12.60 6.25 6 -
Helicobacter pylori 26656 19.4 9.04 27
Helicobacter pylori J99 20.80 8.77 1 -
Thiomicrospira crunogena XCL-2 39.80 14.32 32
Wolinella succinogenes DSM 1740 42.70 13.48 11 -
Firmicutes Bacilli
Bacillus anthracis str. A1055 57.00 7.80 95 +
Bacillus anthracis str. 'Ames
Ancestor' 58.20 8.13 95 +
Bacillus cereus ATCC 10987 61.80 7.56 81 +
Bacillus cereus ZK 57.70 8.09 83 +
Bacillus licheniformis ATCC
14580 80.40 35.56 54
Bacillus thuringiensis serovar
konkukian str. 97-27 60.10 11.21 87 +
Enterococcus faecalis V583 44.80 11.86 38
Lactobacillus acidophilus NCFM 30.80 8.24 0 -
Lactobacillus brevis ATCC 367 27.80 10.34 17
Lactobacillus gasseri ATCC 33323 23.60 5.15 27
Lactococcus lactis subsp. lactis
Il1403 25.60 6.24 24
Staphylococcus aureus RF122 39.00 10.04 20 -
Staphylococcus haemolyticus
JCSC1435
28.40 12.47 18
146                                                     Appendix I
JCSC1435
Streptococcus pneumoniae 23F 35.90 15.90 28
Streptococcus uberis 0140J 31.10 17.09 14 -
Firmicutes Clostridium/Mollicutes
Clostridium acetobutylicum ATCC
824 35.90 15.90 28
Clostridium botulinum A str.
ATCC 19397 31.10 17.09 14 -
Spiroplasma kunkelii CR2-3x 6.50 2.68 1 -
Gamma Proteobacteria
Acinetobacter baumannii ATCC
17978 54.20 12.61 68
Azotobacter vinelandii 165.30 69.78 143
Escherichia coli K12 97.30 36.84 140 +
Escherichia coli O157:H7 118.40 43.44 183 +
Francisella tularensis subsp.
holarctica FTA 18.00 6.95 6 +
Francisella tularensis subsp.
tularensis FSC198 23.80 12.52 6 +
Haemophilus influenzae 86-028NP 26.5 11.51 3 -
Legionella pneumophila str. Lens 54.20 18.88 38
Methylococcus capsulatus str. Bath 111.40 58.10 125
Photobacterium profundum 3TCK 106.30 22.35 124
Pseudomonas aeruginosa 2192 207.50 86.06 181
Pseudomonas aeruginosa PAO1 188.10 77.89 165
Pseudomonas aeruginosa UCBPP-
PA14 198.70 81.49 163
Salmonella bongori 12149 112.10 39.61 126
Salmonella enterica subsp. enterica
serovar Choleraesuis str. SC-B67 120.50 43.74 125
Salmonella typhimurium LT2 121.10 44.26 127
Vibrio alginolyticus 12G01 106.30 23.31 123
Vibrio cholerae AM-19226 91.30 26.70 100
Vibrio splendidus 12B01 104.60 22.10
Vibrio vulnificus YJ016 122.30 30.84 139
Planctomycetes
Pirellula sp. 1 205.50 84.00 159
Spirochaetes
Borrelia afzelii PKo 8.00 3.31 2 -
Borrelia burgdorferi B31 10.40 4.21 6 -
Leptospira interrogans serovar
Copenhageni str. Fiocruz L1-130 48.60 19.96 19 -
Treponema denticola ATCC 35405 33.10 11.12 29
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Treponema pallidum subsp.
pallidum str. Nichols 29.6 10.67 50 +
Thermotogae
Thermotoga maritima MSB8 47.60 32.27 29
Thermotoga petrophila RKU-1 48.30 31.64 27
LFRE1b
Mean
Occ. of
Random
LFREs
95 %
CI
Obs.
Occ. of
Actual
LFREs
+/-
Actinobacteria-Actinomycetales
Corynebacterium diphtheriae
NCTC 13129 259.00 58.90 217
Corynebacterium efficiens YS-314 374.67 87.02 191 -
Mycobacterium bovis AF2122/97 529.33 169.8 285 -
Mycobacterium tuberculosis
CDC1551 537.78 171.4 292 -
Streptomyces avermitilis MA-4680 797.33 113.6 906
Streptomyces coelicolor A3(2) 780.67 116.4 863
Alpha Proteobacteria
Agrobacterium tumefaciens str.
C58 611.67 173.9 352 -
Bradyrhizobium japonicum USDA
110 770.22 176.1 558 -
Brucella abortus biovar 1 str. 9-941 403.75 211.0 217
Brucella melitenus 16M 417.89 200.2 216 -
Ehrlichia canis str. Jake 44.00 10.83 44
Ehrlichia chaffeensis str. Arkansas 43.11 7.73 55 +
Ehrlichia ruminantium str. Gardel 45.22 11.99 60 +
Nitrobacter hamburgensis X14 560.44 171.5 273 -
Rhizobium leguminosarum bv.
viciae 3841 749.56 173.1 453 -
Rhodospirillum rubrum 513.11 213.5 67 -
Rickettsia akari str. Hartford 62.78 20.87 57
Rickettsia rickettsii 59.22 22.92 76
Aquificae
Aquifex  aeolicus VF5 117.22 33.09 137
Bacteriodetes
Bacteroides fragilis NCTC 9343 443.33 81.60 523
Bacteroides fragilis YCH46 449.22 76.85 530 +
Bacteroides thetaiotaomicron VPI-
5482 498.67 95.86 701 +
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Cytophaga hutchinsonii ATCC
33406 307.22 124.5 330
Flavobacterium psychrophilum
JIP02/86 144.11 46.93 121
Beta Proteobacteria
Bordetella bronchiseptica RB50 610.11 206.4 368 -
Bordetella parapertussis 12822 547.11 234.8 352
Bordetella pertussis Tohama I 483.8 202.8 261 +
Burkholderia ambifaria AMMD 604.33 207.1 945 +
Burkholderia cenocepacia AU
1054 577.89 214.0 910 +
Chromobacterium violaceum
ATCC 12472 592.11 211.2 204 -
Neisseria gonorrhoeae FA 1090 163.00 61.60 147
Neisseria meningitidis FAM18 168.67 63.14 162
Nitrosomonas europaea ATCC
19718 344.67 121.9 300
Nitrosomonas eutropha C71 318.67 131.4 251
Cyanobacteria
Nostoc sp. PCC 7120 576.44 127.9 386 -
Prochlorococcus marinus str. MIT
9211 140.67 36.29 100 -
Synechococcus elongatus PCC
6301 352.56 129.1 140 -
Synechococcus sp. CC9605 337.67 109.4 116 -
Deinococcus-Thermus
Deinococcus geothermalis
DSM11300 356.11 88.58 263 -
Deinococcus radiodurans R1 356.89 85.86 303
Thermus thermophilus HB27 224.78 85.40 70 -
Thermus thermophilus HB8 226.00 86.49 70 -
Delta Proteobacteria
Bdellovibrio bacteriovorus HD100 388.44 128.2 286
Desulfovibrio desulfuricans G20 449.00 157.0 280 -
Desulfovibrio vulgaris subsp.
vulgaris str. Hildenborough 463.11 157.5 474
Desulfuromonas acetoxidans 459.00 89.84 266 -
Geobacter metallireducens GS-15 443.89 138.9 217 -
Pelobacter carbinolicus DSM 2380 555.78 125.7 359 -
Syntrophobacter fumaroxidans
MPOB 388.44 128.6 286
Epsilon Proteobacteria
Campylobacter jejuni subsp. doylei
269.97
75.33 27.35 32 -
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269.97
Campylobacter jejuni subsp. jejuni
260.94 54.00 21.07 34
Campylobacter jejuni subsp. jejuni
81-176 58.63 18.93 38 -
Helicobacter pylori 26656 100.8 48.24 37 -
Helicobacter pylori J99 119.11 54.63 42 -
Thiomicrospira crunogena XCL-2 226.78 94.86 124 -
Wolinella succinogenes DSM 1740 199.44 56.20 39 -
Firmicutes Bacilli
Bacillus anthracis str. A1055 313.00 143.0 415
Bacillus anthracis str. 'Ames
Ancestor' 317.11 142.9 424
Bacillus cereus ATCC 10987 326.67 141.7 439
Bacillus cereus ZK 315.22 144.5 412
Bacillus licheniformis ATCC
14580 337.00 103.3 169 -
Bacillus thuringiensis serovar
konkukian str. 97-27 314.67 140.3 408
Enterococcus faecalis V583 244.67 114.1 193
Lactobacillus acidophilus NCFM 112.78 39.80 152
Lactobacillus brevis ATCC 367 142.00 38.39 136
Lactobacillus gasseri ATCC 33323 151.33 63.83 155
Lactococcus lactis subsp. lactis
Il1403 141.22 41.22 137
Staphylococcus aureus RF122 178.00 64.52 148
Staphylococcus haemolyticus
JCSC1435 114.67 23.39 112
Streptococcus pneumoniae 23F 313.00 143.0 415
Streptococcus uberis 0140J 317.11 142.9 424
Firmicutes Clostridium/Mollicutes
Clostridium acetobutylicum ATCC
824 166.11 50.11 174
Clostridium botulinum A str.
ATCC 19397 127.89 43.85 99
Spiroplasma kunkelii CR2-3x 35.44 11.61 96 +
Gamma Proteobacteria
Acinetobacter baumannii ATCC
17978 299.89 93.45 330
Azotobacter vinelandii 679.56 175.7 277 -
Escherichia coli K12 504.78 204.7 349
Escherichia coli O157:H7 559.89 191.5 404
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Francisella tularensis subsp.
holarctica FTA 101.67 24.12 72 -
Francisella tularensis subsp.
tularensis FSC198 103.44 23.58 71 -
Haemophilus influenzae 86-028NP 119.1 59.07 136
Legionella pneumophila str. Lens 253.33 71.84 174 -
Methylococcus capsulatus str. Bath 461.67 135.9 166 -
Photobacterium profundum 3TCK 518.22 173.5 517
Pseudomonas aeruginosa 2192 761.33 147.8 354 -
Pseudomonas aeruginosa PAO1 721.67 156.3 312 -
Pseudomonas aeruginosa UCBPP-
PA14 742.22 148.2 340 -
Salmonella bongori 12149 496.78 191.8 320
Salmonella enterica subsp. enterica
serovar Choleraesuis str. SC-B67 525.56 182.1 308 -
Salmonella typhimurium LT2 522.78 181.0 302 -
Vibrio alginolyticus 12G01 512.89 170.0 555
Vibrio cholerae AM-19226 447.00 165.2 324
Vibrio splendidus 12B01 459.67 175.6 479
Vibrio vulnificus YJ016 523.89 182.7 477
Planctomycetes
Pirellula sp. 1 720.89 199.3 621
Spirochaetes
Borrelia afzelii PKo 35.44 13.59 36
Borrelia burgdorferi B31 118.11 136.5 28
Leptospira interrogans serovar
Copenhageni str. Fiocruz L1-130 231.00 59.13 212
Treponema denticola ATCC 35405 154.88 30.97 124
Treponema pallidum subsp.
pallidum str. Nichols 100.9 22.29 195 +
Thermotogae
Thermotoga maritima MSB8 173.78 56.39 133
Thermotoga petrophila RKU-1 150.56 38.08 120
LFRE2a
Mean
Occ. of
Random
LFREs
95 %
CI
Obs.
Occ. of
Actual
LFREs
+/-
Actinobacteria-Actinomycetales
Corynebacterium diphtheriae
NCTC 13129 1.7 1.24 0 -
Corynebacterium efficiens YS-314 0.4 0.32 2 +
Mycobacterium bovis AF2122/97 0.6 0.67 1
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Mycobacterium tuberculosis
CDC1551 0.5 0.60 1
Streptomyces avermitilis MA-4680 0.1 0.20 0
Streptomyces coelicolor A3(2) 0 0.00 0
Alpha Proteobacteria
Agrobacterium tumefaciens str.
C58 2.7 2.73 5
Bradyrhizobium japonicum USDA
110 2.8 2.81 3
Brucella abortus biovar 1 str. 9-941 1.4 0.73 0 -
Brucella melitenus 16M 1.4 0.73 0 -
Ehrlichia canis str. Jake 0.7 0.78 12 +
Ehrlichia chaffeensis str. Arkansas 1.8 1.05 5 +
Ehrlichia ruminantium str. Gardel 2.4 1.90 2
Nitrobacter hamburgensis X14 1.4 1.10 0 -
Rhizobium leguminosarum bv.
viciae 3841 3.3 2.26 6 +
Rhodospirillum rubrum 1.1 1.19 2
Rickettsia akari str. Hartford 1.1 1.53 4 +
Rickettsia rickettsii 1.3 1.13 4 +
Aquificae
Aquifex  aeolicus VF5 2 1.87 2
Bacteriodetes
Bacteroides fragilis NCTC 9343 4 2.32 6
Bacteroides fragilis YCH46 4 2.00 5
Bacteroides thetaiotaomicron VPI-
5482 6.3 3.13 4
Cytophaga hutchinsonii ATCC
33406 7.1 6.17 2
Flavobacterium psychrophilum
JIP02/86 3.8 1.59 5
Beta Proteobacteria
Bordetella bronchiseptica RB50 0.5 0.60 1
Bordetella parapertussis 12822 0.3 0.30 2 +
Bordetella pertussis Tohama I 1 1.05 1
Burkholderia ambifaria AMMD 1.3 1.10 1
Burkholderia cenocepacia AU
1054 1.7 2.07 2
Chromobacterium violaceum
ATCC 12472 0.8 0.57 3 +
Neisseria gonorrhoeae FA 1090 0.2 0.26 0
Neisseria meningitidis FAM18 0.2 0.26 0
Nitrosomonas europaea ATCC
19718
1.1 1.41 0
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19718
Nitrosomonas eutropha C71 2.6 2.55 3
Cyanobacteria
Nostoc sp. PCC 7120 3.8 2.49 11 +
Prochlorococcus marinus str. MIT
9211 2.4 1.66 12 +
Synechococcus elongatus PCC
6301 0.9 1.07 2
Synechococcus sp. CC9605 0.7 0.59 1
Deinococcus-Thermus
Deinococcus geothermalis
DSM11300 0.1 0.20 0
Deinococcus radiodurans R1 0.7 0.83 0
Thermus thermophilus HB27 0.2 0.39 0
Thermus thermophilus HB8 0.1 0.20 0
Delta Proteobacteria
Bdellovibrio bacteriovorus HD100 2.8 1.96 0 -
Desulfovibrio desulfuricans G20 0.8 1.00 0
Desulfovibrio vulgaris subsp.
vulgaris str. Hildenborough 1.1 1.15 0
Desulfuromonas acetoxidans 1.3 1.40 3 +
Geobacter metallireducens GS-15 1.6 0.78 2
Pelobacter carbinolicus DSM 2380 2.6 2.11 1
Syntrophobacter fumaroxidans
MPOB 2.8 1.96 0 -
Epsilon Proteobacteria
Campylobacter jejuni subsp. doylei
269.97 4.3 6.31 8
Campylobacter jejuni subsp. jejuni
260.94 3.9 5.95 7
Campylobacter jejuni subsp. jejuni
81-176 3.3 4.97 5
Helicobacter pylori 26656 3 3.20 8 +
Helicobacter pylori J99 2.8 2.99 8 +
Thiomicrospira crunogena XCL-2 3 2.77 5
Wolinella succinogenes DSM 1740 2.6 2.57 1
Firmicutes Bacilli
Bacillus anthracis str. A1055 9.3 4.32 14 +
Bacillus anthracis str. 'Ames
Ancestor' 10 4.77 14
Bacillus cereus ATCC 10987 8.7 4.79 18 +
Bacillus cereus ZK 8.4 4.05 12
Bacillus licheniformis ATCC
14580
5.5 2.71 2
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14580
Bacillus thuringiensis serovar
konkukian str. 97-27 8.7 4.22 14 +
Enterococcus faecalis V583 5.6 3.22 3
Lactobacillus acidophilus NCFM 3.8 2.98 0 -
Lactobacillus brevis ATCC 367 3.7 3.42 2
Lactobacillus gasseri ATCC 33323 5.1 3.54 3
Lactococcus lactis subsp. lactis
Il1403 5 3.61 8
Staphylococcus aureus RF122 3 2.17 2
Staphylococcus haemolyticus
JCSC1435 1.3 0.88 4 +
Streptococcus pneumoniae 23F 9.3 4.32 14 +
Streptococcus uberis 0140J 10 4.77 14
Firmicutes Clostridium/Mollicutes
Clostridium acetobutylicum ATCC
824 8 6.14 2
Clostridium botulinum A str.
ATCC 19397 9.2 10.95 24 +
Spiroplasma kunkelii CR2-3x 2.3 1.83 2
Gamma Proteobacteria
Acinetobacter baumannii ATCC
17978 4.8 2.86 6
Azotobacter vinelandii 0.7 0.78 0
Escherichia coli K12 3.2 1.67 2
Escherichia coli O157:H7 4.2 1.80 0 -
Francisella tularensis subsp.
holarctica FTA 2.4 2.41 4
Francisella tularensis subsp.
tularensis FSC198 2.3 2.23 4
Haemophilus influenzae 86-028NP 2.7 1.65 3
Legionella pneumophila str. Lens 3.7 2.61 5
Methylococcus capsulatus str. Bath 1.4 0.98 0 -
Photobacterium profundum 3TCK 7.9 3.68 7
Pseudomonas aeruginosa 2192 1.5 1.71 1
Pseudomonas aeruginosa PAO1 1.6 1.88 1
Pseudomonas aeruginosa UCBPP-
PA14 1.3 1.52 1
Salmonella bongori 12149 2.3 1.31 3
Salmonella enterica subsp. enterica
serovar Choleraesuis str. SC-B67 3.3 1.98 0 -
Salmonella typhimurium LT2 3.8 2.08 0 -
Vibrio alginolyticus 12G01 5.1 2.60 9 +
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Vibrio cholerae AM-19226 3.2 1.65 2
Vibrio splendidus 12B01 5.7 3.80 0 -
Vibrio vulnificus YJ016 4.4 2.65 2
Planctomycetes
Pirellula sp. 1 2.5 2.27 2
Spirochaetes
Borrelia afzelii PKo 1.5 1.35 2
Borrelia burgdorferi B31 1.7 1.55 2
Leptospira interrogans serovar
Copenhageni str. Fiocruz L1-130 6.3 4.12 11 +
Treponema denticola ATCC 35405 5.7 3.91 1 -
Treponema pallidum subsp.
pallidum str. Nichols 1.4 0.78 0 -
Thermotogae
Thermotoga maritima MSB8 1.8 1.23 4 +
Thermotoga petrophila RKU-1 1.6 1.35 3 +
LFRE2b
Mean
Occ. of
Random
LFREs
95 %
CI
Obs.
Occ. of
Actual
LFREs
+/-
Actinobacteria-Actinomycetales
Corynebacterium diphtheriae
NCTC 13129 7.3 3.68 12 +
Corynebacterium efficiens YS-314 1.9 1.00 5 +
Mycobacterium bovis AF2122/97 3.1 2.45 1
Mycobacterium tuberculosis
CDC1551 2.9 2.38 1
Streptomyces avermitilis MA-4680 3.2 3.32 2
Streptomyces coelicolor A3(2) 1.3 1.28 0 -
Alpha Proteobacteria
Agrobacterium tumefaciens str.
C58 23.2 24.34 18
Bradyrhizobium japonicum USDA
110 8.4 8.05 5
Brucella abortus biovar 1 str. 9-941 7.3 6.17 4
Brucella melitenus 16M 7.6 6.24 4
Ehrlichia canis str. Jake 7.0 4.95 9
Ehrlichia chaffeensis str. Arkansas 13.9 11.04 4
Ehrlichia ruminantium str. Gardel 8.1 4.36 4
Nitrobacter hamburgensis X14 6.8 7.93 1
Rhizobium leguminosarum bv.
viciae 3841 15.4 16.39 5
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Rhodospirillum rubrum 5.5 5.98 1
Rickettsia akari str. Hartford 6.7 5.01 2
Rickettsia rickettsii 10.0 5.35 2 -
Aquificae
Aquifex  aeolicus VF5 7.6 2.81 4
Bacteriodetes
Bacteroides fragilis NCTC 9343 20.6 6.02 20
Bacteroides fragilis YCH46 16.5 5.67 25 +
Bacteroides thetaiotaomicron VPI-
5482 34.2 18.55 18
Cytophaga hutchinsonii ATCC
33406 15.5 7.16 7 -
Flavobacterium psychrophilum
JIP02/86 16.7 6.85 3 -
Beta Proteobacteria
Bordetella bronchiseptica RB50 3.8 3.38 1
Bordetella parapertussis 12822 3.6 3.11 0 -
Bordetella pertussis Tohama I 2.3 1.92 4
Burkholderia ambifaria AMMD 3.8 3.59 1
Burkholderia cenocepacia AU
1054 3.6 3.35 3
Chromobacterium violaceum
ATCC 12472 4.1 2.72 1 -
Neisseria gonorrhoeae FA 1090 3.3 2.63 1
Neisseria meningitidis FAM18 3.9 2.96 2
Nitrosomonas europaea ATCC
19718 10.5 5.07 2 -
Nitrosomonas eutropha C71 10.2 4.70 8
Cyanobacteria
Nostoc sp. PCC 7120 43.6 22.22 36
Prochlorococcus marinus str. MIT
9211 12.6 4.92 9
Synechococcus elongatus PCC
6301 4.2 1.80 12 +
Synechococcus sp. CC9605 3.1 2.33 8 +
Deinococcus-Thermus
Deinococcus geothermalis
DSM11300 1.2 0.91 6 +
Deinococcus radiodurans R1 2.5 2.34 8 +
Thermus thermophilus HB27 0.4 0.55 5 +
Thermus thermophilus HB8 0.2 0.28 6 +
Delta Proteobacteria
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Bdellovibrio bacteriovorus HD100 5.1 2.21 3
Desulfovibrio desulfuricans G20 5.6 1.79 0 -
Desulfovibrio vulgaris subsp.
vulgaris str. Hildenborough 4.3 5.22 5
Desulfuromonas acetoxidans 3.9 4.04 4
Geobacter metallireducens GS-15 5.8 3.26 5
Pelobacter carbinolicus DSM 2380 5.4 5.41 5
Syntrophobacter fumaroxidans
MPOB 5.1 2.21 3
Epsilon Proteobacteria
Campylobacter jejuni subsp. doylei
269.97 11.0 7.67 15
Campylobacter jejuni subsp. jejuni
260.94 13.8 14.29 9
Campylobacter jejuni subsp. jejuni
81-176 15.0 14.33 10
Helicobacter pylori 26656 7.0 6.27 2
Helicobacter pylori J99 7.8 7.03 19 +
Thiomicrospira crunogena XCL-2 11.5 9.81 8
Wolinella succinogenes DSM 1740 2.8 2.26 15 +
Firmicutes Bacilli
Bacillus anthracis str. A1055 23.9 10.99 9 -
Bacillus anthracis str. 'Ames
Ancestor' 25.4 10.99 9 -
Bacillus cereus ATCC 10987 37.7 22.43 8 -
Bacillus cereus ZK 23.5 11.32 10 -
Bacillus licheniformis ATCC
14580 8.8 5.20 9
Bacillus thuringiensis serovar
konkukian str. 97-27 29.5 10.72 6 -
Enterococcus faecalis V583 15.6 4.86 19
Lactobacillus acidophilus NCFM 15.8 1.72 0 -
Lactobacillus brevis ATCC 367 9.4 4.54 11
Lactobacillus gasseri ATCC 33323 13.7 8.14 10
Lactococcus lactis subsp. lactis
Il1403 14.2 6.79 11
Staphylococcus aureus RF122 9.5 4.79 16 +
Staphylococcus haemolyticus
JCSC1435 11.7 6.37 14
Streptococcus pneumoniae 23F 23.9 10.99 9 -
Streptococcus uberis 0140J 25.4 10.99 9 -
Firmicutes Clostridium/Mollicutes
Clostridium acetobutylicum ATCC
824
21.9 12.12 15
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824
Clostridium botulinum A str.
ATCC 19397 27.5 17.09 12
Spiroplasma kunkelii CR2-3x 5.4 4.58 3
Gamma Proteobacteria
Acinetobacter baumannii ATCC
17978 21.2 7.73 17
Azotobacter vinelandii 4.6 4.72 4
Escherichia coli K12 12.2 3.87 3 -
Escherichia coli O157:H7 14.5 4.19 1 -
Francisella tularensis subsp.
holarctica FTA 12.7 5.46 6 -
Francisella tularensis subsp.
tularensis FSC198 12.9 5.98 6 -
Haemophilus influenzae 86-028NP 11.8 3.65 18 +
Legionella pneumophila str. Lens 16.7 10.17 10
Methylococcus capsulatus str. Bath 4.1 3.61 2
Photobacterium profundum 3TCK 26.5 10.66 11 -
Pseudomonas aeruginosa 2192 4.1 2.91 3
Pseudomonas aeruginosa PAO1 4.1 3.88 1
Pseudomonas aeruginosa UCBPP-
PA14 5.3 5.18 1
Salmonella bongori 12149 14.1 5.85 4 -
Salmonella enterica subsp. enterica
serovar Choleraesuis str. SC-B67 14.6 5.69 3 -
Salmonella typhimurium LT2 13.6 5.41 0 -
Vibrio alginolyticus 12G01 25.2 8.47 18
Vibrio cholerae AM-19226 12.7 6.34 9
Vibrio splendidus 12B01 29.6 4.57 0 -
Vibrio vulnificus YJ016 15.0 4.07 10 -
Planctomycetes
Pirellula sp. 1 11.4 8.37 8
Spirochaetes
Borrelia afzelii PKo 7.4 4.86 4
Borrelia burgdorferi B31 10.0 5.73 12
Leptospira interrogans serovar
Copenhageni str. Fiocruz L1-130 23.6 13.82 20
Treponema denticola ATCC 35405 17.2 13.40 5
Treponema pallidum subsp.
pallidum str. Nichols 2.5 1.71 2
Thermotogae
Thermotoga maritima MSB8 5.3 5.19 7
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Thermotoga petrophila RKU-1 4.4 3.77 5
LFRE3
Mean
Occ. of
Random
LFREs
95 %
CI
Obs.
Occ. of
Actual
LFREs
+/-
Actinobacteria-Actinomycetales
Corynebacterium diphtheriae
NCTC 13129 0.3 0.30 0
Corynebacterium efficiens YS-314 0 0.00 0
Mycobacterium bovis AF2122/97 0.1 0.20 0
Mycobacterium tuberculosis
CDC1551 0.1 0.20 0
Streptomyces avermitilis MA-4680 0 0.00 0
Streptomyces coelicolor A3(2) 0 0.00 0
Alpha Proteobacteria
Agrobacterium tumefaciens str.
C58 0 0.00 0
Bradyrhizobium japonicum USDA
110 0 0.00 0
Brucella abortus biovar 1 str. 9-941 0 0.00 0
Brucella melitenus 16M 0 0.00 0
Ehrlichia canis str. Jake 0 0.00 0
Ehrlichia chaffeensis str. Arkansas 0 0.00 0
Ehrlichia ruminantium str. Gardel 0 0.00 0
Nitrobacter hamburgensis X14 0 0.00 0
Rhizobium leguminosarum bv.
viciae 3841 0.1 0.20 0
Rhodospirillum rubrum 0 0.00 0
Rickettsia akari str. Hartford 0 0.00 0
Rickettsia rickettsii 0.3 0.30 0
Aquificae
Aquifex  aeolicus VF5 0.1 0.20 0
Bacteriodetes
Bacteroides fragilis NCTC 9343 0 0.00 0
Bacteroides fragilis YCH46 0.1 0.20 0
Bacteroides thetaiotaomicron VPI-
5482 0.1 0.20 0
Cytophaga hutchinsonii ATCC
33406 0.2 0.26 0
Flavobacterium psychrophilum
JIP02/86 0.2 0.26 0
Beta Proteobacteria
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Bordetella bronchiseptica RB50 0 0.00 0
Bordetella parapertussis 12822 0 0.00 0
Bordetella pertussis Tohama I 0 0.00 0
Burkholderia ambifaria AMMD 0.1 0.20 0
Burkholderia cenocepacia AU
1054 0 0.00 0
Chromobacterium violaceum
ATCC 12472 0.1 0.20 0
Neisseria gonorrhoeae FA 1090 0 0.00 0
Neisseria meningitidis FAM18 0 0.00 0
Nitrosomonas europaea ATCC
19718 0 0.00 0
Nitrosomonas eutropha C71 0 0.00 0
Cyanobacteria
Nostoc sp. PCC 7120 0.4 0.43 0
Prochlorococcus marinus str. MIT
9211 0 0.00 0
Synechococcus elongatus PCC
6301 0 0.00 0
Synechococcus sp. CC9605 0.1 0.20 0
Deinococcus-Thermus
Deinococcus geothermalis
DSM11300 0 0.00 0
Deinococcus radiodurans R1 0 0.00 0
Thermus thermophilus HB27 0.1 0.20 0
Thermus thermophilus HB8 0.1 0.20 0
Delta Proteobacteria
Bdellovibrio bacteriovorus HD100 0 0.00 0
Desulfovibrio desulfuricans G20 0 0.00 0
Desulfovibrio vulgaris subsp.
vulgaris str. Hildenborough 0 0.00 0
Desulfuromonas acetoxidans 0 0.00 0
Geobacter metallireducens GS-15 0 0.00 0
Pelobacter carbinolicus DSM 2380 0.2 0.26 0
Syntrophobacter fumaroxidans
MPOB 0 0.00 0
Epsilon Proteobacteria
Campylobacter jejuni subsp. doylei
269.97 0 0.00 0
Campylobacter jejuni subsp. jejuni
260.94 0.1 0.20 0
Campylobacter jejuni subsp. jejuni
81-176 0.1 0.20 0
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Helicobacter pylori 26656 0.1 0.20 0
Helicobacter pylori J99 0 0.00 0
Thiomicrospira crunogena XCL-2 0.1 0.20 0
Wolinella succinogenes DSM 1740 0.1 0.20 0 -
Firmicutes Bacilli
Bacillus anthracis str. A1055 0.2 0.26 0
Bacillus anthracis str. 'Ames
Ancestor' 0.1 0.20 0
Bacillus cereus ATCC 10987 0.1 0.20 0
Bacillus cereus ZK 0.1 0.20 0
Bacillus licheniformis ATCC
14580 0 0.00 0
Bacillus thuringiensis serovar
konkukian str. 97-27 0 0.00 0
Enterococcus faecalis V583 0.1 0.20 0
Lactobacillus acidophilus NCFM 0.1 0.20 0
Lactobacillus brevis ATCC 367 0.2 0.26 0
Lactobacillus gasseri ATCC 33323 0 0.00 0
Lactococcus lactis subsp. lactis
Il1403 0.2 0.26 0
Staphylococcus aureus RF122 0 0.00 0
Staphylococcus haemolyticus
JCSC1435 0 0.00 0
Streptococcus pneumoniae 23F 0.2 0.26 0
Streptococcus uberis 0140J 0.1 0.20 0
Firmicutes Clostridium/Mollicutes
Clostridium acetobutylicum ATCC
824 0.3 0.30 0
Clostridium botulinum A str.
ATCC 19397 0 0.00 0
Spiroplasma kunkelii CR2-3x 0 0.00 0
Gamma Proteobacteria
Acinetobacter baumannii ATCC
17978 0.1 0.20 0
Azotobacter vinelandii 0.1 0.20 0
Escherichia coli K12 0.3 0.30 0
Escherichia coli O157:H7 0.2 0.26 0
Francisella tularensis subsp.
holarctica FTA 0 0.00 0
Francisella tularensis subsp.
tularensis FSC198 0 0.00 0
Haemophilus influenzae 86-028NP 0.1 0.20 0
Legionella pneumophila str. Lens 0.2 0.26 0
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Methylococcus capsulatus str. Bath 0.1 0.20 0
Photobacterium profundum 3TCK 0.7 0.59 0 -
Pseudomonas aeruginosa 2192 0.1 0.20 0
Pseudomonas aeruginosa PAO1 0.2 0.26 0
Pseudomonas aeruginosa UCBPP-
PA14 0 0.00 0
Salmonella bongori 12149 0.2 0.39 0
Salmonella enterica subsp. enterica
serovar Choleraesuis str. SC-B67 0 0.00 0
Salmonella typhimurium LT2 0.1 0.20 0
Vibrio alginolyticus 12G01 0.3 0.30 0
Vibrio cholerae AM-19226 0.1 0.20 0
Vibrio splendidus 12B01 0.3 0.42 0
Vibrio vulnificus YJ016 0.5 0.33 0
Planctomycetes
Pirellula sp. 1 0 0.00 0
Spirochaetes
Borrelia afzelii PKo 0 0.00 0
Borrelia burgdorferi B31 0.1 0.20 0
Leptospira interrogans serovar
Copenhageni str. Fiocruz L1-130 0.2 0.26 0
Treponema denticola ATCC 35405 0.1 0.20 0
Treponema pallidum subsp.
pallidum str. Nichols 0.1 0.20 0
Thermotogae
Thermotoga maritima MSB8 0 0.00 0
Thermotoga petrophila RKU-1 0 0.00 0
(1) The number of LFRE consensus sequences in each genome was compared to the
expected frequency (95 % confidence interval) of sequences of the same length and base
composition in a given genome.  LFREs that occurred at a greater or lower than
expected frequency were marked with a (+) or (-), respectively.
Table A4.3: Summary of the occurrence of lactoferrin binding sites in
comparison to expected frequencies1 by species
LFREs
Species 1a 1b 2a 2b 3
Actinobacteria- Actinomycetales
Corynebacterium diphtheriae
NCTC 13129 - +
Corynebacterium efficiens YS-314 + - + +
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Mycobacterium bovis AF2122/97 + -
Mycobacterium tuberculosis
CDC1551 + -
Streptomyces avermitilis MA-4680
Streptomyces coelicolor A3(2) -
Alpha Proteobacteria
Agrobacterium tumefaciens str.
C58 + -
Bradyrhizobium japonicum USDA
110 -
Brucella abortus biovar 1 str. 9-941 -
Brucella melitenus 16M - -
Ehrlichia canis str. Jake +
Ehrlichia chaffeensis str. Arkansas + +
Ehrlichia ruminantium str. Gardel - +
Nitrobacter hamburgensis X14 - -
Rhizobium leguminosarum bv.
viciae 3841 - +
Rhodospirillum rubrum -
Rickettsia akari str. Hartford +
Rickettsia rickettsii + -
Aquificae
Aquifex  aeolicus VF5
Bacteriodetes
Bacteroides fragilis NCTC 9343
Bacteroides fragilis YCH46 + +
Bacteroides thetaiotaomicron VPI-
5482 + +
Cytophaga hutchinsonii ATCC
33406 + -
Flavobacterium psychrophilum
JIP02/86 + -
Beta Proteobacteria
Bordetella bronchiseptica RB50 -
Bordetella parapertussis 12822 + + -
Bordetella pertussis Tohama I +
Burkholderia ambifaria AMMD +
Burkholderia cenocepacia AU
1054 +
Chromobacterium violaceum
ATCC 12472 - + -
Neisseria gonorrhoeae FA 1090 +
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Neisseria meningitidis FAM18
Nitrosomonas europaea ATCC
19718 -
Nitrosomonas eutropha C71
Cyanobacteria
Nostoc sp. PCC 7120 + - +
Prochlorococcus marinus str. MIT
9211 + - +
Synechococcus elongatus PCC
6301 - - +
Synechococcus sp. CC9605 - +
Deinococcus-Thermus
Deinococcus geothermalis
DSM11300 + - +
Deinococcus radiodurans R1 + +
Thermus thermophilus HB27 - +
Thermus thermophilus HB8 - +
Delta Proteobacteria
Bdellovibrio bacteriovorus HD100 -
Desulfovibrio desulfuricans G20 - -
Desulfovibrio vulgaris subsp.
vulgaris str. Hildenborough +
Desulfuromonas acetoxidans - +
Geobacter metallireducens GS-15 -
Pelobacter carbinolicus DSM 2380 -
Syntrophobacter fumaroxidans
MPOB -
Epsilon Proteobacteria
Campylobacter jejuni subsp. doylei
269.97 - -
Campylobacter jejuni subsp. jejuni
260.94 -
Campylobacter jejuni subsp. jejuni
81-176 - -
Helicobacter pylori 26656 - +
Helicobacter pylori J99 - - + +
Thiomicrospira crunogena XCL-2 -
Wolinella succinogenes DSM 1740 - - + -
Firmicutes Bacilli
Bacillus anthracis str. A1055 + + -
Bacillus anthracis str. 'Ames
Ancestor' + -
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Bacillus cereus ATCC 10987 + + -
Bacillus cereus ZK + -
Bacillus licheniformis ATCC
14580 -
Bacillus thuringiensis serovar
konkukian str. 97-27 + + -
Enterococcus faecalis V583
Lactobacillus acidophilus NCFM - - -
Lactobacillus brevis ATCC 367
Lactobacillus gasseri ATCC 33323
Lactococcus lactis subsp. lactis
Il1403
Staphylococcus aureus RF122 - +
Staphylococcus haemolyticus
JCSC1435 +
Streptococcus pneumoniae 23F + + -
Streptococcus uberis 0140J + -
Firmicutes Clostridium/Mollicutes
Clostridium acetobutylicum ATCC
824
Clostridium botulinum A str.
ATCC 19397 - +
Spiroplasma kunkelii CR2-3x - +
Gamma Proteobacteria
Acinetobacter baumannii ATCC
17978
Azotobacter vinelandii -
Escherichia coli K12 + -
Escherichia coli O157:H7 + - -
Francisella tularensis subsp.
holarctica FTA + - -
Francisella tularensis subsp.
tularensis FSC198 + - -
Haemophilus influenzae 86-028NP - +
Legionella pneumophila str. Lens -
Methylococcus capsulatus str. Bath - -
Photobacterium profundum 3TCK - -
Pseudomonas aeruginosa 2192 -
Pseudomonas aeruginosa PAO1 -
Pseudomonas aeruginosa UCBPP-
PA14 -
Salmonella bongori 12149 -
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Salmonella enterica subsp. enterica
serovar Choleraesuis str. SC-B67 - - -
Salmonella typhimurium LT2 - - -
Vibrio alginolyticus 12G01 +
Vibrio cholerae AM-19226
Vibrio splendidus 12B01 - -
Vibrio vulnificus YJ016 -
Planctomycetes
Pirellula sp. 1
Spirochaetes
Borrelia afzelii PKo -
Borrelia burgdorferi B31 -
Leptospira interrogans serovar
Copenhageni str. Fiocruz L1-130 - +
Treponema denticola ATCC 35405 -
Treponema pallidum subsp.
pallidum str. Nichols + + -
Thermotogae
Thermotoga maritima MSB8 +
Thermotoga petrophila RKU-1 +
(1) The number of LFRE consensus sequences in each genome was compared to the
expected frequency (95 % confidence interval) of sequences of the same length and base
composition in a given genome.  LFREs that occurred at a greater or lower than expected
frequency were marked with a (+) or (-), respectively.
Table A4.4: Distance between features near and downstream of
lactoferrin binding sites in the H. pylori strain J99 genome
Nearest Feature Distance to
Nearest
Feature
(bp)1
Distance to
Nearest
Downstream
Feature
(bp) 1
LFRE1a
outer membrane protein - adhesin 1312 -1998
LFRE1b
putative vacuolating cytotoxin (VacA)
paralog 3213 -4039
DNA-directed RNA polymerase beta subunit
(EC 2.7.7.6) / DNA-directed RNA
polymerase beta' subunit (EC 2.7.7.6) 2649 -6111
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putative 2046 NA
putative Outer membrane protein 1996 -1731
Flagellar hook-associated protein flgL 1779 -2022
putative Outer membrane protein 1509 -258
Multi antimicrobial extrusion protein
(Na(+)/drug antiporter), MATE family of
MDR efflux pumps 1257 -148
[NiFe] hydrogenase metallocenter assembly
protein HypF 833 -1443
Leucyl-tRNA synthetase (EC 6.1.1.4) 777 -1640
INTEGRASE/RECOMBINASE (XERCD
FAMILY) 718 -4755
UDP-glucose 4-epimerase (EC 5.1.3.2) 699 -1614
Excinuclease ABC subunit C 658 -1136
Phosphogluconate dehydratase (EC 4.2.1.12) 654 -720
Membrane-fusion protein 652 -349
Polyphosphate kinase (EC 2.7.4.1) 648 -1418
tRNA uridine 5-carboxymethylaminomethyl
modification enzyme gidA 591 -687
Ribonuclease BN (EC 3.1.-.-) 558 -4466
Type III restriction-modification system
DNA endonuclease res (EC 3.1.21.5) 546 -955
Translation elongation factor P @
Translation initiation factor 5A 490 -620
putative 484 -152
Flagellar P-ring protein flgI 433 -619
putative oxidoreductase 411 -4031
putative transporter 382 -478
Aspartate aminotransferase (EC 2.6.1.1) 372 -967
outer membrane protein - adhesin 349 -3078
Dipeptide transport system permease protein
dppC (TC 3.A.1.5.2) 346 -244
putative 346 -404
putative periplasmic protein 336 -989
Exodeoxyribonuclease III (EC 3.1.11.2) 273 -1539
Purine nucleoside phosphorylase (EC
2.4.2.1) 264 -900
Acetone carboxylase, beta subunit (EC
6.4.1.6) / N-methylhydantoinase A (EC
3.5.2.14) 201 -1949
putative 192 -265
Two-component system response regulator 169 -278
putative TRANSCRIPTIONAL
REGULATOR 169 -2450
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2-keto-3-deoxy-D-arabino-heptulosonate-7-
phosphate synthase II (EC 2.5.1.54) # AroA
II 142 -323
Acyl carrier protein 67 -272
putative -43
Acetone carboxylase, gamma subunit (EC
6.4.1.6) -151
Lipoprotein releasing system transmembrane
protein LolC -154
Polysaccharide biosynthesis protein WlaX -295
putative -427
Diaminopimelate decarboxylase (EC
4.1.1.20) -1586
LFRE2a
Transcription-repair coupling factor 2392 -738
Flagellar M-ring protein fliF 1537 -183
Phospholipid-lipopolysaccharide ABC
transporter 1033 -616
putative 943 -79
probable chlorohydrolase 502 -974
putative 226 -591
Flagellar basal-body rod protein flgG -169
Putative predicted metal-dependent
hydrolase -523
LFRE2b
Flagellar M-ring protein fliF 1423 -1063
Phospholipid-lipopolysaccharide ABC
transporter 1315 NA
DNA gyrase subunit A (EC 5.99.1.3) 1132 -321
cyclopocyclopropane fatty acid synthase 1080 NA
Mannose-6-phosphate isomerase (EC
5.3.1.8) / Mannose-1-phosphate
guanylyltransferase (GDP) (EC 2.7.7.22) 973 -1047
ADP-L-glycero-D-manno-heptose-6-
epimerase (EC 5.1.3.20) 895 -978
Predicted D-lactate dehydrogenase, Fe-S
protein, FAD/FMN-containing 763 -536
3-polyprenyl-4-hydroxybenzoate carboxy-
lyase (EC 4.1.1.-) 625 -322
putative periplasmic protein 538 -4598
S-adenosyl-methyltransferase mraW (EC
2.1.1.-) 502 -797
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TETRATRICOPEPTIDE REPEAT
FAMILY PROTEIN 430 NA
putative periplasmic protein 354 -591
Methylated-DNA--protein-cysteine
methyltransferase (EC 2.1.1.63) 276 -2045
Fructose-bisphosphate aldolase class II (EC
4.1.2.13) 271 -344
Acetone carboxylase, alpha subunit (EC
6.4.1.6) / N-methylhydantoinase B 259 -291
putative keto-acid dehydrogenase 241 -992
LSU ribosomal protein L6p (L9e) 222 -2997
MOLYBDOPTERIN BIOSYNTHESIS
PROTEIN 145 -422
Potassium efflux system kefA / Small-
conductance mechanosensitive channel -237
CDP-diacylglycerol pyrophosphatase (EC
3.6.1.26) 1423 -1063
putative 1315 NA
(1) Position of lactoferrin in relationship to ORFs in bp, either downstream
the nearest ORF or upstream (-).
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